Synthesis of betulin derivatives against intracellular pathogens by Alakurtti, Sami
•V
IS
IO
N
S•
SC
IENCE•TEC
H
N
O
L
O
G
Y
•RESEARCHHIG
HL
IG
H
T
S
Dissertation 
39
Synthesis of betulin 
derivatives against 
intracellular pathogens
Sami Alakurtti
OH
HO

VTT SCIENCE 39
Synthesis of betulin derivatives
against intracellular pathogens
Sami Alakurtti
VTT Technical Research Centre of Finland
Division of Pharmaceutical Chemistry, Faculty of Pharmacy,
University of Helsinki, Finland
ACADEMIC DISSERTATION
Thesis for the degree of Doctor of Philosophy to be presented with the
permission of Faculty of Pharmacy of the University of Helsinki for public
examination and criticism in Auditorium 1041 at University of Helsinki,
Biokeskus 2, Viikinkaari 5, Helsinki, on September 6, 2013 at 12 noon.
ISBN 978-951-38-8013-2 (Soft back ed.)
ISBN 978-951-38-8014-9 (URL: http://www.vtt.fi/publications/index.jsp)
VTT Science 39
ISSN-L 2242-119X
ISSN 2242-119X (Print)
ISSN 2242-1203 (Online)
Copyright © VTT 2013
JULKAISIJA – UTGIVARE – PUBLISHER
VTT
PL 1000 (Tekniikantie 4 A, Espoo)
02044 VTT
Puh. 020 722 111, faksi 020 722 7001
VTT
PB 1000 (Teknikvägen 4 A, Esbo)
FI-02044 VTT
Tfn +358 20 722 111, telefax +358 20 722 7001
VTT Technical Research Centre of Finland
P.O. Box 1000 (Tekniikantie 4 A, Espoo)
FI-02044 VTT, Finland
Tel. +358 20 722 111, fax +358 20 722 7001
Kopijyvä Oy, Kuopio 2013
3Synthesis of betulin derivatives against intracellular pathogens
Betuliinijohdannaisten syntetisointi solunsisäisiä patogeenejä vastaan. Sami Alakurtti.
Espoo 2013. VTT Science 39. 99 p. + app. 43 p.
Abstract
Birch (Betula spp.) is utilized in huge quantities in the forest industry throughout
the Northern Hemisphere, and low-value side-stream birch bark is burnt for energy.
Outer birch bark is rich in (up to 30% dry weight) triterpene betulin, which is readily
isolable by solvent extraction. Betulin can be used both in its raw form and as a
starting material for more valuable products and fine chemicals.
The increasing drug resistance of numerous microbes and viruses is an issue
of global concern, and new inexpensive therapeutic agents are urgently needed.
In this study two sets of betulin derivatives were synthesized and screened as
antiviral, antileishmanial and antibacterial agents. The first set includes relatively
easily synthesizable betulin derivatives, such as esters and various oxidation
products. The second set includes novel heterocyclic betulin derivatives, where
the triazole ring is fused by the Diels-Alder reaction to the lupane skeleton of betulin.
Alphavirus Semliki Forest virus (SFV) is distributed by mosquitoes and infects
avian and mammalian hosts. Some alphaviruses may cause fatal encephalitis in
humans, although the number of cases is small. On the other hand, some alpha-
viruses have caused millions of cases of serious illnesses characterized by fever,
rash and painful arthralgia. There is currently no efficient medical treatment
against alphaviruses. In the antiviral assay, 18 betulin-derived compounds dis-
played good activity against SFV with low-micromolar 50% inhibitory concentration
values combined with low cytotoxicity. In addition, three assayed potent and rep-
resentative compounds displayed synergistic effect with modified nucleoside ana-
logue against SFV, and similar good antiviral efficacy against another alphavirus,
Sindbis virus.
The neglected tropical disease leishmaniasis is caused by protozoan parasites
belonging to the genus Leishmania, and is transmitted to mammalian hosts by
sandflies. It is estimated that around 12 million people are currently infected, mostly
in developing countries. The most severe form, visceral leishmaniasis, is fatal if
not treated. There are currently several drugs marketed for the treatment of leish-
maniasis. However, none of these are fully effective against Leishmania, and
severe side effects, often requiring hospitalization, are common. In addition, para-
site resistance to drugs is a serious growing problem. In the present study, the
most potent betulin derivatives displayed low-micromolar 50% growth inhibition
values against L. donovani amastigotes. Good inhibition activity was well retained
against L. donovani amastigotes growing inside macrophages. However, in some
cases betulin derivatives also showed cytotoxicity to host macrophage cell line.
Chlamydia pneumoniae is a common Gram-negative human pathogen mainly
causing mild respiratory infections, which can lead to pneumonia or bronchitis.
There is also strong evidence that associates C. pneumoniae with other severe
diseases, such as atherosclerotic cardiovascular diseases as well as some neuro-
degenerative diseases, such as Alzheimer’s disease and multiple sclerosis.
C. pneumoniae is susceptible to antibiotics that interfere with DNA and protein
synthesis. However, its complex life cycle and its chlamydial persistence, which
can last for years, as well as, importantly, the lack of specific diagnostic tests for
detection of the organism in clinical samples, make the current treatment regimens
unsatisfactory. Out of 32 betulin derivatives, five betulin derivatives showed high
(>70% growth inhibition) antichlamydial activity against C. pneumoniae at 1 µM
concentration. The most potent derivative displayed a remarkable 50% inhibition
at nanomolar concentration.
Keywords Betulin, betulinic acid, terpene, organic synthesis, derivative, bioactivity,
Semliki Forest virus, Leishmania sp., Chlamydia pneumoniae
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Tiivistelmä
Metsäteollisuus käyttää koivua raaka-aineenaan suunnattomia määriä. Sivuottee-
na syntyvä koivunkuori poltetaan energian tuotantoon. Koivun ulkokuori sisältää
runsaasti betuliini-nimistä triterpeeniä jopa 30 % kuivapainostaan. Betuliini voi-
daan helposti eristää kuoresta liuotinuutolla. Betuliinia voidaan käyttää sellaise-
naan tai lähtöaineena muille tuotteille ja hienokemikaaleille.
Useiden pieneliöiden ja virusten kasvava lääkeresistenssi on maailmanlaajuinen
ongelma, minkä takia on ilmennyt suuri tarve kehittää uusia lääkeaineita niitä vastaan.
Tässä väitöskirjatyössä syntetisoitiin kaksi betuliinijohdannaisryhmää ja yhdistei-
den tehokkuutta testattiin alfavirusten, Leishmania-suvun alkueläinten ja keuhko-
klamydiabakteerin vastaisina yhdisteinä. Ensimmäinen ryhmä sisältää melko hel-
posti valmistettavissa olevia johdannaisia, kuten betuliinin estereitä ja erilaisia
hapetustuotteita. Toinen ryhmä sisältää uusia heterosyklisiä betuliinijohdannaisia,
joissa triatsoli-rengas on fuusioitu betuliinin lupaanirakenteiseen hiilivetyrankaan.
Alfaviruksiin kuuluva Semliki Forest virus (SFV) leviää moskiittojen välityksellä,
ja se infektoi lintuja ja nisäkkäitä. Jotkin alfavirukset voivat aiheuttaa tappavaa
aivotulehdusta, mutta nämä tapaukset ovat hyvin harvinaisia. Useimmiten alfavi-
rukset aiheuttavat sairauskohtauksia, joiden oireet ilmenevät usein kuumeena,
allergisena ihottumana ja kivuliaana niveltulehduksena. Tällä hetkellä alfaviruksia
vastaan ei ole tehokasta ja turvallista lääkitystä. Kaikkiaan 18 betuliinijohdannaista
osoitti alfavirusten vastaista aktiivisuutta mikromolaarisella konsentraatiolla. Lisäk-
si kolmella potentiaalisella ja kemialliselta rakenteeltaan erilaisella betuliinijohdan-
naisella oli synergistisiä alfaviruksen vastaisia vaikutuksia muokatun nukleosidi-
johdannaisen kanssa. Lisäksi valitut kolme johdannaista olivat aktiivisia myös
toista alfavirusta, Sinbis virusta, vastaan.
Leishmaniaasi-tautia aiheuttavat Leishmania-sukuun kuuluvat alkueläimet. Tau-
ti esiintyy nisäkkäissä etenkin tropiikissa, ja sitä levittävät perhossääsket. Arvioi-
den mukaan 12 miljoonaa ihmistä sairastaa tällä hetkellä leishmaniaasia. Taudin
vakavin muoto on sisäelinleishmaniaasi, joka on hoitamattomana tappava. Leish-
maniaasia vastaan on käytössä useita lääkeaineita, mutta niiden tehokkuudessa
ja turvallisuudessa on toivomisen varaa. Ne aiheuttavat usein vakavia sivuvaiku-
tuksia, ja niiden käyttö edellyttää sairaalahoitoa. Lisäksi lääkeresistenssi on vaka-
va ja kasvava ongelma. Tässä tutkimuksessa lupaavimmat betuliinijohdannaiset
osoittivat Leishmania donovanin vastaisia vaikutuksia mikromolaarisilla konsent-
raatioilla. Johdannaisten estovaikutus pysyi hyvänä myös selvitettäessä niiden
vaikutuksia syöjäsolujen sisällä kasvavia L. donovani -alkueläimiä vastaan. Valitet-
6tavasti osa betuliinijohdannaisista osoitti sytotoksisuutta myös itse syöjäsoluja
vastaan.
Keuhkoklamydia (Chlamydia pneumoniae) on yleinen Gram-negatiivinen bak-
teeri, joka aiheuttaa lieviä hengitystieinfektioita. Ne voivat pahimmillaan johtaa
keuhkokuumeeseen tai keuhkoputkentulehdukseen. C. pneumoniaen aiheuttamilla
infektiolla on myös osoitettu olevan yhteys useisiin muihin vakaviin sairauksiin,
kuten sydän- ja verisuonisairauksiin, ja hermostoperäisiin sairauksiin, kuten Al-
zheimerin tautiin ja MS-tautiin. C. pneumoniaen aiheuttamia infektioita voidaan
hoitaa antibiooteilla, jotka vaikuttavat bakteerin DNA- tai proteiinisynteesiin. Vali-
tettavasti bakteerin monimutkainen elämänkierto, taudin vaikea diagnosointi ja
bakteerille tyypillinen oireeton, jopa vuosia kestävä piilevänä sairautena pysyminen
tekevät taudin hoidosta ongelmallista. Testisarjasta viisi betuliinijohdannaista esti
huomattavasti C. pneumoniae -bakteerin kasvua 1 µM konsentraatiolla. Parhaalla
johdannaisella 50 %:n inhibitioarvo saavutettiin nanomolaarisella konsentraatiolla.
Avainsanat Betulin, betulinic acid, terpene, organic synthesis, derivative, bioactivity,
Semliki Forest virus, Leishmania sp., Chlamydia pneumoniae
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13C NMR Carbon-13 nuclear magnetic resonance
1H NMR Hydrogen-1 nuclear magnetic resonance
AB Aberrant body
AIDS Acquired immunodeficiency syndrome
AT Adenine, thymine
ATP Adenosine triphosphate
AV Antiviral effect
BALB/c Bagg albino, laboratory-bred, genotype c/c
BHK Baby hamster kidney fibroblast cell line
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DHP 3,4-Dihydro-2H-pyran
DMAP 4-(Dimethylamino)pyridine
DMC 2’,6’-dihydroxy-4’-methoxychalcone
DMSO-d6 Deuterated dimethyl sulfoxide
DNA Deoxyribonucleic acid
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EC50 Half maximal effective concentration
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FTIR Fourier transform infrared spectroscopy
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WEEV Western equine encephalitis virus
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1. Introduction
1.1 Birch bark
Birch is  (Betula spp.) widespread throughout the Northern Hemisphere and har-
vested in huge volumes. Birch bark is produced in considerable quantities as a by-
product of the forest industry and its upgrading is almost totally neglected. Cur-
rently, this low-value side stream is burnt for combined heat and power production.
Birch bark could, however, find more valuable uses, for example as an additive in
plastic composite materials.1 Birch bark consists of brown inner bark ~75% and
white outer bark ~25%.2 The inner bark consists mainly of wood-like material such
as lignin, pentosans and hexosans. The outer bark contains, by dry weight, up to
40% fats, fatty acids, resins and triterpenes, in particular betulin, at up to 30%. In
addition, the outer bark contains up to 35% suberin. Valorization and upgrading of
these compounds by using modern chemical technology opens up entirely new
opportunities to produce new speciality chemicals from this low-value biomass
stream. It has been estimated theoretically that a pulp mill with an annual produc-
tion capacity of 200,000 tonnes of birch kraft pulp produces enough bark to pro-
duce around 2,500 tonnes of betulin of around 95% purity and 4,000 tonnes of
suberin acids per annum.3,4 Suberin polyester can be hydrolyzed by base treat-
ment to multifunctional suberin acids, which are potential raw materials for paints,
adhesives, lubricants and surface-active agents.5 New potential applications for
betulin or betulin derivatives include pharmaceuticals and cosmetic products as
well as agrochemicals.6
1.2  Alphaviruses
The Semliki Forest virus (SFV) belongs to the alphaviruses, which are small en-
veloped viruses containing a single-stranded positive-sense RNA genome.7 Virus-
es belonging to this genus are predominantly arthropod-borne viruses using mos-
quitoes as vectors and have a very wide geographic distribution, with isolates
having been reported from all continents except Antarctica and from many is-
lands.8 Alphaviruses infect avian and mammalian hosts and are a serious or po-
tential threat to human health. In North and South America some alphaviruses are
known to cause fatal encephalitis in humans, although the number of recorded
1. Introduction
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fatalities is small.9 Alphaviruses have, however, caused millions of cases of seri-
ous illness characterized by fever, rash and painful arthralgia.10 There is currently
no efficient pharmacotherapy for alphavirus-borne diseases.
1.3 Leishmania spp.
Leishmaniasis is a disease caused by protozoan parasites belonging to the genus
Leishmania. The disease is transmitted by sandflies and is present in all inhabited
continents.11 It is estimated that around 12 million people are currently infected.
More than 350 million people live in risk areas for the disease, and 2 million new
cases occur every year, especially in the developing countries. Leishmaniasis has
been designated as a neglected tropical disease by the World Health Organiza-
tion. The most severe form, visceral leishmaniasis, in which parasites invade the
liver, spleen and bone marrow, is fatal if not treated.12 Current treatment includes
pentavalent antimony compounds, pentamidine and amphotericin B.13 However,
there are risks of severe side effects and all of these current drugs are adminis-
tered by intravenous injection. Parasite resistance to pentavalent antimony drugs
has become a serious problem and is present in approximately 65% of patients
with visceral leishmaniasis in India.14 New drugs, such as primaquine, allopurinol,
imipramine, are being developed, however none of them are fully effective against
Leishmania.12 Recently, orally administrable miltefosine has shown promising
antileishmanial activity.15
1.4 Chlamydia pneumoniae
Chlamydia (Chlamydophila) pneumoniae is an important Gram-negative human
pathogen, mainly causing respiratory infections. It has been proposed that almost all
humans will become infected with C. pneumoniae during their life.16 C. pneumoniae
frequently causes community-acquired pneumonia in adults and children. Often
infections are asymptomatic and frequently of long duration, up to several years.
There is also strong evidence that associates C. pneumoniae with other severe
diseases, such as atherosclerotic cardiovascular diseases,17 as well as some
neurodegenerative diseases, such as Alzheimer’s disease and multiple sclerosis.18
Interestingly, C. pneumoniae infection has also been reported in a wide range of
animals, including other mammals such as horses and koalas, and frogs and other
reptiles.19 All chlamydial species are intracellular bacteria that infect and replicate
inside a variety of human cells, including epithelial, endothelial, macrophages, and
smooth muscle cells.20 C. pneumoniae is classified as an obligate intracellular
pathogen, as it has to infect another cell to reproduce. C. pneumoniae is suscepti-
ble to antibiotics that interfere with DNA and protein synthesis, including tetracy-
clines, macrolides and quinolones.16 However, its complex life cycle and its chla-
mydial persistence, which can last for years, as well as, importantly, the lack of
specific diagnostic tests for detection of the organism in clinical samples, make the
current treatment regimens unsatisfactory.
1. Introduction
18
1.5 Origin of drugs during the last 25 years
A total of 1,184 new chemical entities were approved for the market between 1981
and 2006 for treatment of various infective diseases caused by bacterial, fungal,
viral and parasitic infections and for the treatment of cancer.21 The new drugs can
be classified according to their source into six major categories and one subcate-
gory (Table 1).
Table 1. Classification of new drugs according to source.21
Category Source
B Biological; usually large peptide or protein
N Natural product
ND Derived from a natural product, usually semisynthetic
S Totally synthetic
S* Made by total synthesis, but the pharmacophore is from a natural product
V Vaccine
Subcategory NM Natural product mimic
A breakdown of the 1,184 new drugs based on the above categories is illustrated
in Figure 1. Only 30% of the drugs are completely synthetic; the rest have their
origins in the natural products.
Figure 1. New chemical entities during 1981–2006, according to source (N = 1,184)
(original from ref. 21).
2. Review of the literature
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2. Review of the literature
2.1 Betulin
Betulin 1, lup-20(29)-ene-3ȕ,28-diol, also known as betulinol, betuline and betulin-
ic alcohol (Figure 2), is a pentacyclic triterpene alcohol with a lupane skeleton.
Common structural features of the lupane skeleton are its five-membered ring E
and isopropylidene group. Betulin 1 can be isolated (up to 30% dry weight) from
the outer birch bark by extraction with high boiling hydrocarbon solvents or with
water azeotropes of alcohols.4
Betulin 1 can be used as a starting compound for other useful compounds that
possess various interesting pharmacological properties. Betulin 1 has three posi-
tions in its structure, namely a secondary hydroxy group at position C-3, a primary
hydroxy group at position C-28, and an alkene moiety at position C-20, where
chemical modifications can be easily performed to yield derivatives for structure–
activity relationship (SAR) studies. It is clear from the chemical structure of betulin
that most of the derivatives presented in the experimental part of this thesis are
lipophilic compounds and thus poorly soluble in water if no organic co-solvent is
used. This may have important implications for the interpretation of the results of
the bioactivity assays, which have been carried out predominantly in cell cultures.
Observed differences in bioactivity between different modified betulin derivatives
may be explained, at least partly, by different water/lipid distribution constants between
these analogues.
2.1.1 Pharmacological properties of betulin derivatives
Betulin 1 is biologically a relatively inactive compound. However, betulin 1 can be
oxidized to pharmacologically more active betulinic acid 2.22 Betulinic acid 2 and its
derivatives possess a wide spectrum of biological and pharmacological activity.6
Most notably, betulinic acid 2 and its derivatives have shown activity against human
immunodeficiency virus (HIV) as well as cytotoxicity against a variety of tumour cell
lines comparable to some clinically used drugs.
A new mechanism of action has been confirmed for some of the most promis-
ing anti-HIV derivatives, which makes them potentially useful additives to current
anti-HIV therapy. A43D23 3 and statine-derived IC956424 4 act as entry inhibitors
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and block HIV adsorption or membrane fusion. Furthermore, the dimethylsuccinyl
derivative of betulin, bevirimat 5 (DSB, BVM), acts as a virus maturation inhibitor.25
Bevirimat 5 was demonstrated to have dose-dependent anti-HIV potency in phase
I and phase II clinical studies.26 However, mutations in HIV cause resistance to
BVM 5, in addition to which some patients have this polymorphism present, result-
ing in lower BVM 5 anti-HIV efficacy.27 Development of BVM 5 has thus been
recently halted.
Betulinic acid 2 is specifically cytotoxic to several tumour cell lines by directly
triggering mitochondrial membrane permeabilization and inducing apoptosis in
cells.28,29 Moreover, it is non-toxic up to 500 mg/kg body weight in mice.28 Currently,
betulinic acid 2 is undergoing anti-cancer development with assistance from the
Rapid Access to Intervention Development Program of the National Cancer Insti-
tute.30
Figure 2. Betulin 1 and potential anticancer agent betulinic acid 2, as well as po-
tential anti-HIV agents A43D 3, IC9564 4 and bevirimat 5.
2.2 Alphaviruses
2.2.1 Species, taxonomy and lifecycle
Currently there are two main schemes used for the classification of viruses: the
International Committee on Taxonomy of Viruses (ICTV) system and the Baltimore
classification system. A universal system for classifying viruses, and a unified
taxonomy, is being established by the International Committee on Taxonomy of
Viruses (ICTV). 31 The system makes use of a series of ranked taxons:
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Table 2. Taxonomy of Semliki Forest virus.
Order (-virales) Virus
Family (-viridae) Togaviridae
Subfamily (-virinae) -
Genus (-virus) Alphavirus
Species Semliki Forest virus
In the ICTV 2012 taxonomy classification, the Semliki Forest virus (SFV) (which
was used as a target pathogen for betulin inhibition activity in publication I) spe-
cies is classified under the family Togaviridae and the genus Alphavirus, which
contains a total of 30 viruses, including human pathogens such as Rubella, Sind-
bis and Chikungunya viruses (Table 2).31
In the Baltimore classification system, viruses are divided into one of seven
groups depending on a combination of their nucleic acid (DNA or RNA), stranded-
ness (single- or double-stranded), sense, and method of replication (Table 3).32
Table 3. Virus groups according to the Baltimore classification system.
Group Classification
I Double-stranded DNA (dsDNA) viruses
II Single-stranded DNA (ssDNA) viruses (+)sense DNA
III Double-stranded RNA (dsRNA) viruses
IV Single-stranded RNA [(+)ssRNA] viruses (+)sense RNA
V Single-stranded RNA [(-)ssRNA] viruses (í)sense RNA
VI Single-stranded RNA (ssRNA-RT) viruses (+)sense RNA with replication
through a DNA intermediate
VII Double-stranded DNA (dsDNA-RT) viruses with replication through a
single-stranded RNA intermediate
Alphaviruses have a single-stranded, positive-sense RNA genome and are classi-
fied under group IV according to the Baltimore classification.8 Group IV includes
viruses from several ICTV orders: 1. Nidovirales including significant pathogens
such as Coronavirus and Severe acute respiratory syndrome virus (SARS); 2.
Picornavirales including significant pathogens such as Norwalk, Polio, the com-
mon cold and Hepatitis A viruses; 3. Tymovirales; and unassigned virus families
including significant human pathogens such as Yellow fever, West Nile, Hepatitis C
and Dengue fever.33
Entry of alphavirus into cells is initiated by receptor-binding, followed by endo-
cytosis (Figure 3).7 Fusion to endosomal membranes transports nucleocapsid
(NC) into the cytoplasm, where ribonucleic acid (RNA) is released after disassembly.
Genomic RNA is used for transcription of nascent (+)RNA via a (í)RNA template
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and translation of proteins from genomic and subgenomic (26S) RNA. The struc-
tural proteins translated from 26S RNA encapsidate nascent genomic RNA before
budding from cells, and eventual release.
Figure 3. Life cycle of alphavirus (original from ref. 7).
2.2.2 Chemotherapy against infections caused by alphaviruses
This section focuses on small-molecule antiviral inhibitors found to be effective
against viruses in the genus Alphavirus. The alphaviral species discussed in this
section include the Chikungunya virus (CHIKV), Eastern equine encephalitis virus
(EEEV), Getah virus (GETV), Semliki Forest virus (SFV), Sindbis virus (SINV),
Venezuelan equine encephalitis virus (VEEV) and Western equine encephalitis
virus (WEEV). As there are only very few reported in vivo alphavirus experiments,
in vitro experiments are also discussed here.
Nucleoside or nucleotide analogues
Synthetic nucleoside or nucleotide analogues are prodrugs that are phosphory-
lated to active triphosphate drugs by viral enzymes and used as normal building
blocks for the DNA polymerase-catalyzed replication of viral DNA.34 However, as a
consequence of the modifications in the nucleobase or in the sugar moiety, viral
DNA polymerase enzyme is deactivated or DNA chain formation is terminated.
In an early study by Huffman and co-workers, the synthetic nucleoside guano-
sine analogue ribavirin 6 (Figure 4) was screened against a wide panel of viruses,
including SFV.35 Ribavirin 6 showed broad antiviral activity, with moderate anti-
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alphaviral activity and a minimum inhibitory concentration (MIC) value of 131 µM.
Ribavirin 6 has since been used as a positive control in several assays.
Nucleotide analogue ribavirin 5’-sulphamate 7 displayed several-fold improved
antiviral activity against SFV with an IC50 value of 10 µM. The IC50 value repre-
sents the concentration of drug required for 50% inhibition in vitro (50% inhibitory
concentration). Ribavirin 6 displayed an IC50 value of <1 mm.36 In in vivo testing
with lethally SFV infected mice, ribavirin 5’-sulphamate 7 showed a clear protec-
tive effect with survival rates of 92% and 83% when intraperitoneally administered
at doses of 20 and 40 mg/kg/day for seven days.
Selenazofurin 8 and tiazofurin were assayed alone or in combination with rib-
avirin 6 against several viruses, including VEEV. Selenazofurin 8 displayed good
activity against VEEV with a 50% effective dose (ED50) value of 0.5 µg/mL, whereas
tiazofurin was inactive.37 Combination of ribavirin and 6 selenazofurin 8 displayed
synergistic efficacy with an ED50 value of 0.1 µg/mL.
Figure 4. Nucleoside guanosine analogues with antiviral activity against alphavirus.
Nucleoside adenosine-derived neplanocins A 9 and  C 10 (Figure 5) displayed
broad antiviral activity and significant anti-alphaviral activities against SFV with
IC50 values of 4 and 7 µM, respectively.38
Five 3’-fluorinated ribonucleosides were synthesized and screened against a
panel of viruses, including SFV and SINV.39 3'-Fluoro-3'-deoxyadenosine 11 dis-
played the best activity against several viruses, with IC50 values of 7 µM and
15 µM against SINV and SFV, respectively. General cytotoxic effects were ob-
served at 150 µM concentration.
Figure 5. Nucleoside adenosine analogues with antiviral activity against alphavirus.
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In a study by de Clercq et al., antiviral activity of racemic cytidine analogue car-
bodine 12 and 13 (Figure 6) was compared to known antiviral agents such as
carbocyclic 3-deazaadenosine (C-c3 Ado) and ribavirin 6.40 The racemic mixture of
carbodine enantiomers 12 and 13 showed broad activity against most of the viral
species tested by inhibition of cellular cytidine triphosphate (CTP) synthetase.
Especially against SINV, carbodine showed an IC50 value of 3 µM, which was
almost 60 times more potent than C-c3 Ado and over 200 times more potent than
ribavirin 6. In addition, the carbodine racemate displayed good inhibition against
SFV with an IC50 value of 12 µM.
In a study by Julander et al., activity of the D-()- and L-(+)-enantiomers of car-
bodine was determined against VEEV in cell culture and in an in vivo mouse model.
()-Carbodine 13 showed good inhibition activity with an EC50 value of 0.8 µM,
while (+)-carbodine 12 was  not  active  (EC50 > 100 µM). Post-virus exposure
treatment with ()-carbodine 13 was effective in significantly improving disease
parameters in mice infected with VEEV when treatment was initiated as late as 4
days post-virus installation, with a mouse survival rate of 90% (placebo 0%).
In another study by De Clercq et al., cyclopentenylcytosine (Ce-Cyd) 14 dis-
played broad-spectrum antiviral activity against several viruses, including SFV and
SINV with IC50 values of 0.4 and 0.2 µg/mL, respectively.41
Antiviral activity of eight commercially available compounds was estimated
against CHIKV and SFV.42 When comparing antiviral activities against CHIKV,
positive control ribavirin 6 had an EC50 value of 83 µM and a selectivity index (SI)
of 24. The two best test compounds, 6-azauridine 15 and sulfated polysaccharide
iota-carrageenan, displayed significantly better EC50 values of 0.2 and 3.8 µM and
SI values of 204 and >133, respectively. Against SFV, these compounds showed
similar activities: 6-azauridine 15 and iota-carrageenan EC50 values of 0.4 and
0.7 µM and SI values of 85 and >714, respectively, while ribavirin 6 showed a
moderate EC50 value of 47 µM and an SI value of 109.
Figure 6. Nucleoside cytidine analogues with antiviral activity against alphavirus.
Non-nucleoside analogues
In  a  study by  Pohjala  et  al.,43 a library of 356 compounds was screened in vitro
against CHIKV and SFV. The library consisted of natural compounds (mainly
flavonoids, coumarins and other phenolic compounds) as well as clinically ap-
proved drugs and their metabolites. Four natural 5,7-dihydroxyflavones, 16–19,
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were found to be effective against CHIKV with IC50 values of around 20–70 µM
(Figure 7). In the assay against SFV, in addition to the same four flavones
(naringenin 18 as the most potent compound with an IC50 value of 2.2 µM, SI 43),
several other natural compounds such as a synthetic coumarin derivative, couma-
rin-30 20, (IC50 value of 0.4 µM, SI 231) was found to be effective.
In addition, several pharmaceutical compounds were found to be effective as
SFV entry inhibitors. A phenothiazine core was identified in six out of twelve
pharmaceutical compound hits, with antipsychotic prothipendyl 21 and antihista-
mine methdilazine 22 (Figure 8) showing the best IC50 values of 8 and 11 µM,
respectively. The reference compounds 3’-amino-3’-deoxyadenosine 23 and chlo-
roquine 24 showed good activity with IC50 values of 13.4 and 16.2 µM and SI val-
ues of 14.9 and 10.7, respectively. Mycophenolic acid 25 was relatively inactive
(IC50 = 121 µM).
Figure 7. Natural compounds or their derivatives with good SFV inhibition activity.
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Figure 8. Pharmaceutical and selected reference compounds with good SFV inhibition
activity.
In a study by Peng at al., a library of over 50,000 compounds was assayed in a
high-throughput screening against WEEV RNA replication.44 The most promising
lead compound, CCG-32091 26 (Figure 9), displayed an IC50 value of 24 µM with
low cytotoxicity against BSR-T7/5 cells, which are BHK cells that constitutively
express bacteriophage T7 RNA polymerase. Several derivatives of CCG-32091 26
were synthesized for SAR studies, and in a follow up study45 the most promising
compound, 27 (IC50 value of 6.5 µM), was subjected to in vivo NSV (neuroadapted
Sindbis virus) infected mouse testing. After 12 h post treatment, 27 (30 mg/kg
twice a day) displayed a clear protective effect with a mouse survival rate of 80%,
compared to the control group with a survival rate of 20%.
Arbidol 28, an antiviral drug originally licensed in Russia for treatment of influ-
enza, showed potent CHIKV inhibition activity with an IC50 value of 12.2 µM.46
However, a single amino acid substitution in a mutant CHIKV envelope protein
caused resistance to arbidol 28.
In another HTS study, 61,600 commercial small molecular weight compounds
were screened against influenza virus.47 The most promising lead compound, 29,
was further evaluated against a broad spectrum of viruses representing several
different families, including alphavirus SINV. Compound 29 showed a broad spec-
trum of viral inhibition and a degree of inhibition of 2 logs against SINV.
VX-497 30 is a potent, reversible uncompetitive inosine-5ƍ-monophosphate de-
hydrogenase (IMPDH) inhibitor, which was investigated in a comparison study
with ribavirin 6 in terms of their cytotoxicities and their efficacies against a variety
of viruses including alphavirus VEEV.48 VX-497 30 displayed superior anti-
alphaviral activity (IC50 = 19.2 µM) compared to non-active ribavirin 6 (IC50 > 500).
The effect of four lysosomotropic weak bases (chloroquine 24, amantadine,
tributylamine and methylamine) and NH4Cl against SFV infection has been studied
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in BHK cells.49 All substances prevent the transfer of the virus nucleocapsid into
the cytoplasm by increasing the lysosomal pH from 4–5 to approximately 6, which
is above the critical value needed to trigger a low pH-dependent fusion reaction
between the membranes of the lysosome and the virus. Antimalarial drug chloro-
quine 24 displayed the best IC50 value of 50 µM. However, in a double-blind pla-
cebo-controlled randomized human trial with chloroquine 24 doses of 600 mg at
days 1–3 and 300 mg at days 4–5, no significant difference between the treated
and placebo groups could be identified.50
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Figure 9. N-heterocyclic compounds possessing anti-alphaviral activity.
Molecular modelling of the hydrophobic binding pocket of SINV capsid protein was
used to design 1,4-dioxane-based antiviral agents.51 Surprisingly, the best target
compound according to the model with a three-carbon linker chain connecting two
1,4-dioxane 31 (Figure 10) moieties was significantly less active (EC50 =  40 µM)
than the synthetic intermediate 32 (EC50 = 1 µM). Both compounds were not cyto-
toxic in uninfected BHK cells at concentrations of 1 mm.
Seco-pregnane steroid glaucogenin C 33 and its glycosides isolated from Stro-
bilanthes cusia (Nees) Kuntze and Cynanchum paniculatum (Bunge) Kitagawa
displayed selective inhibitory activity against several members of the alphavirus
genus.52 The EC50 value of the most potent glaucogenin C derivative, pentasugar-
glycoside paniculatumoside C 34, was remarkable. Paniculatumoside C 34 showed
EC50 values of 1.5, 1 and 2 nM against SINV, GETV and EEEV, respectively. In
addition, it proved effective in reducing the mortality rate (18%, 54%, and 100%) of
SINV infected mice when administered at a dose of 5, 50, or 100 mg/kg body
weight before inoculation. However, when paniculatumoside C 34 was adminis-
tered 1 or 4 h after SINV infection, no mice survived, although delayed mortality
was observed.
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Figure 10. 1,4-Dioxane-based compounds 31 and 32, and seco-pregnane-derived
compounds 33 and 34, R = [(O-ȕ-D-glucopyranosyl-(1ĺ4)-O-ȕ-D-glucopyranosyl-
(1ĺ4)-O-2,6-dideoxy-3-O-methyl-Į-D-arabino-hexopyranosyl-(1ĺ4)-O-2,6-
dideoxy-ȕ-D-ribo-hexopyranosyl-(1ĺ4)-2,6-dideoxy-3-O-methyl-ȕ-D-arabino-
hexopyranosyl)oxy] with anti-alphaviral activity.
Betulin-derived compounds
Bevirimat 5 (Figure 2), a semisynthetic dimethylsuccinic acid derivative of natural
product betulinic acid53, blocks HIV maturation by inhibiting the final stage of HIV
Gag protein processing.54 It was initially considered as a possible first member of
the HIV maturation inhibitors, and it successfully demonstrated potency in phase I
and phase II clinical studies.26 However, mutations in HIV cause resistance to
BVM 5, in addition to which some patients also have this polymorphism present,
resulting in lower anti-HIV efficacy.27 Thus, development of BVM 5 has been cur-
rently halted. Bevirimat 5 was found to be inactive against herpes simplex type 1
(HSV-1) and influenza virus.25
The antiviral activity of betulin 1 and betulinic acid 2 and their derivatives have also
been studied against influenza A, herpes simplex type 1 (HSV-1), influenza FPV/Rostock
and ECHO-6 enterovirus, however their antiviral activities were weak. 55,56,57
2.3 Leishmania spp.
2.3.1 Species, taxonomy and lifecycle
Protozoan parasites belonging to the genus Leishmania are transmitted to mam-
malian hosts by female sandflies of the genera Phlebotomus and Lutzomyia in the
Old and New World, respectively.58 The life cycle of the leishmanial parasite con-
sists of a flagellated promastigote phase in the sandfly gut and a non-flagellated
intracellular amastigote phase in mammalian macrophages (Figure 11).59 After  a
blood meal from the infected host, amastigotes are released from the macrophages
into the sandfly gut; these then transform through a multiplying non-infectious
procyclic promastigote phase to infectious metacyclic promastigotes and migrate
to the pharyngeal valve of the sandfly.60 The metacyclic promastigotes are trans-
mitted during feeding to the mammalian host, where the promastigotes successfully
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infect and invade the host macrophages. Inside the macrophages, the parasites
transform into amastigotes and start to multiply. The amastigotes are released into
the blood stream from the infected macrophages to infect new macrophages,
which are finally transferred during feeding back to the vector sandfly.
Figure 11. Life cycle of leishmania parasite.59
In taxonomy, the species Leishmania donovani (used as a target microbe for betu-
lin inhibition activities in publications II and III), is classified under the subkingdom
Protozoa, order Kinetoplastida, family Trypanosomatidae, genus Leishmania, sub-
genus Leishmania and complex L. donovani (Table 4). Other complexes under the
subgenus Leishmania are L. tropica, L. major, L. aethiopica and L. mexicana. In
addition, the genus Leishmania also contains the subgenus Viannia, which includes
the complexes L. braziliensis, L. guyanensis, L. naiffi and L. lainsoni. These com-
plexes include a total of 30 species, of which 20 are infectious to humans.61,62
Table 4. Taxonomy of L. donovani.
Subkingdom Protozoa
Order Kinetoplastida
Family Trypanosomatidae
Genus Leishmania
Subgenus Leishmania
Complex L. donovani
Species L. donovani
2. Review of the literature
30
Leishmaniasis is a disease caused by leishmania parasites and it has been divided
into three major clinical manifestations:12
1) Cutaneous leishmaniasis (CL): produces skin lesions.
2) Mucocutaneous leishmaniasis (MCL): ulcerates oro-naso-pharyngeal region.
3) Visceral leishmaniasis (VL): devastates internal organs, especially liver, spleen
and bone marrow and the untreated disease is usually fatal.
2.3.2 Leishmania and HIV co-infection
Interaction between leishmaniasis (VL) and HIV has been well established, mak-
ing VL-HIV co-infection a serious worldwide concern.63 HIV-infected people are
particularly vulnerable to VL infection and the risk of developing active VL is in-
creased dramatically. VL accelerates HIV replication and progression to AIDS. In
areas endemic for VL, many people have asymptomatic infection and patients
should be considered as potential reservoirs of infection. In addition, all antileish-
manial therapies are less effective with HIV-positive patients and the risk of treat-
ment failure or relapse of VL is increased. There is a high mortality rate due to
concurrent illness, complications, and drug toxicity. VL-HIV co-infection decreases
host humoral and cellular responses (specific antibodies), which limits the diag-
nostic value of simple serological tests for co-infected patients.
2.3.3 Chemotherapy against infections caused by Leishmania spp.
This section focuses on small molecule antileishmanial drugs currently in use as
well as on compounds in clinical or preclinical trials, and experimental inhibitors
found promising in in vivo activity in mouse trials. The results of preclinical human
trials are collected in Table 5.
Vaccines
The ideal antileishmanial treatment would be an effective vaccine. The Leishmania
parasite has a relatively uncomplicated life cycle and patients that recover from
infection have resistance to subsequent infection. This indicates that a successful
vaccine could be produced. For example, vaccines comprising killed parasites,
subunits such as parasite proteins, DNA, poly-protein, and peptides derived from
leishmanial antigens have shown promising results on animal models. However,
these vaccines have been disappointing when tested in field trials and currently
there is no effective vaccine available.64,65
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Currently approved drugs
The first-line drugs for treatment of leishmaniasis include pentavalent antimony
compounds such as stibogluconate (Pentostam®) 35 and meglumine antimonate
(Glucantime®) 36 (Figure 12),66 which have been in use for over 70 years. How-
ever, there are several drawbacks with these drugs. As pentavalent antimony
drugs are highly water soluble, they are not absorbed through the lipophilic intesti-
nal barrier and must be administered by intravenous injection.67 In addition, drugs
have severe toxic side effects, such as cardiotoxicity and hepatotoxicity, and their
use requires clinical supervision or hospitalization. Moreover, resistance to anti-
mony-based drugs is increasing, for example in India.68 Although antimonials have
been used for decades for the treatment of leishmaniasis, their mode of action is
not fully known. Pentavalent antimony compounds are accumulated to pro-
mastigotes and amastigotes and, in the most accepted model for the mechanism
of action, Sb(V) acts as a prodrug and is reduced to the more biologically active
and toxic Sb(III).69 There is evidence that Sb(III) inhibits trypanothione reductase
and glutathione reductase70 or induces apoptosis71 of the parasite.
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Figure 12. Traditional antimony-based drugs stibogluconate 35 and meglumine
antimonate 36 used for treatment of leishmaniasis.
The second-line drugs for treatment of leishmaniasis include aromatic diamine
pentamidine 37 and amphotericin B 38 (Figure 13). Pentamidine 37 binds to the
adenine and thymine (AT) sequences of leishmanial kinetoplast DNA, leading to
mitochondrial destruction and parasite death.72 Pentamidine 37 has severe toxic
side effects leading to renal toxicity73 and cardiotoxicity74, in addition to which
resistance to pentamidine 37 has developed.75 The polyene macrolide compound
amphotericin B 38 increases parasite membrane permeability by acting with mem-
brane sterols.76 This leads to release of cellular components, mainly potassium, thus
killing the parasite. Using relatively expensive lipid-based formulations of the drug,77
the occurrence of severe side effects, such as nephrotoxicity, is reduced.78
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Figure 13. Second-line drugs, pentamidine 37 and amphotericin B 38, used for
treatment of leishmaniasis.
The aminoglycoside antibiotic paromomycin 39 (Figure 14) was approved in 2006
for treatment of leishmaniasis in India. Paromomycin administered intramuscularly
for 21 days showed an initial cure rate of 96% of patients and a definitive cure rate
of 92% after 6 months.79 It has a reasonable safety profile with only a minimal
proportion of patients suffering possible side effects such as ototoxicity.80 However,
the drug must be administered by injection. Paromomycin 39 affects mitochondrial
activity81 and ribosomes.82
8-Aminoquinoline sitamaquine 4083 has been approved for treatment of leish-
maniasis in India. This orally administered drug has shown good cure rates of up
to 87%, and side effects seem to be relatively mild, such as vomiting, dyspepsia
and methemoglobinemia.84 The drug induces collapse of mitochondrial membrane
potential85 as well as alkalization of acidocalcisomes, specific organelles present
only in parasites.86
Alkylphosphocholine miltefosine 4187 was the first approved orally administered
antileishmanial drug on the market. Miltefosine has displayed an initial cure rate of
up to 97% and a final cure rate of 82% after 6 months.88 It has a generally safe
toxicology profile, the main side effects being related to toxicity to the gastrointes-
tinal tract. However, due to possible teratogenic effects of miltefosine 41,89 it is not
suitable for treatment of pregnant women. Suggested targets for miltefosine 41
include inhibition of glycosomal acyltransferase,90 mitochondrial enzyme cyto-
chrome c oxidase91 and effects on lipid metabolism.92
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Figure 14. New drugs for treatment of leishmanial infections.
Lead compounds in clinical and preclinical trials
In this section antileishmanial agents showing promising in vivo inhibition activities
in human clinical or preclinical studies are presented. Some of the following lead
compounds are currently in further development.
Antifungal heterocyclic imidazole and 1,2,4-triazole-derived compounds have
been tested in several clinical trials for the treatment of leishmaniasis. The effec-
tiveness of itraconazole 42, ketoconazole 43 and fluconazole 44 (Figure 15) in in
vivo human studies are promising but still inconclusive. The performance of itra-
conazole 42 (400 mg dosage for a minimum of 3 months) was studied in an un-
controlled study with 13 Ecuadorian patients with mucocutaneous leishmaniasis.93
All 13 subjects responded to itraconazole 42 during the first month of treatment,
but by 12 months after treatment complete resolution of mucocutaneous leishman-
iasis lesions was observed in only three (23%) patients. No adverse effects of
treatment were reported.
The efficacy of ketoconazole 43 (600 mg/day for 28 days) was compared to
reference drug pentostam 35 (20 mg antimony/kg for 20 days) against Panamani-
an cutaneous leishmaniasis due to L. braziliensis panamensis.94 Ketoconazole 43
clinically cured 16 out of 21 (76%) patients. Side effects were limited to a 27%
incidence of mild, reversible hepatocellular enzyme elevation and an asymptomat-
ic, reversible, approximately 70% decrease in serum testosterone in all patients.
Pentostam 35 cured 13 of 19 (68%) patients and a placebo group of 11 patients
had a 0% cure rate. The authors conclude that oral ketoconazole 43 is compara-
ble in efficacy to this parenteral pentostam regimen and can be recommended as
initial treatment for this disease.
Fluconazole 44 (200 mg daily for six weeks) was studied for the treatment of
cutaneous leishmaniasis caused by L. major.95 A total of 106 patients received
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fluconazole 44 and 103 patients received a placebo. 79% of patients in the flucon-
azole 44 group and 34% of the placebo group showed complete recovery during
the trial. Side effects were mild, and oral fluconazole 44 thus seems to be a safe
and useful treatment for cutaneous leishmaniasis caused by L. major.
Figure 15. Antifungal heterocyclic imidazole and 1,2,4-triazole drugs displaying
antileishmanial activity.
Purine analogue allopurinol 45 (drug used to treat hyperuricaemia, including
chronic gout; see Figure 16) has been tested in a clinical trial (20 mg/kg for 15
days) for treatment of American cutaneous leishmaniasis in an area where L. b.
panamensis is endemic.96 Reference treatment with meglumine antimonate 36
(20 mg antimony/kg for 15 days) showed a moderate 36% cure rate, a combina-
tion treatment of allopurinol 45 and meglumine antimonate 36 displayed a 74%
cure rate, and allopurinol 45 alone showed a good, 80%, cure rate. There were no
complete recoveries among the untreated patients. In addition, no major toxic
effects were observed. However, in another study contradictory results were ob-
served.97 A group of 187 patients with cutaneous leishmaniasis caused by
L. panamensis (84% of patients) or L. braziliensis (16% of patients) were treated
with allopurinol 45 (20 mg/kg of body weight per day for 28 days), a placebo, or
meglumine antimonate 36 (20 mg of intramuscular antimony/kg per day for 20
days). After the treatment period, the allopurinol 45 group showed 33%, the place-
bo group 37% and the meglumine antimonate 36 group 93% cure rates. The au-
thors of that study concluded that allopurinol 45 monotherapy has no effect on
Colombian cutaneous disease primarily caused by L. panamensis and therefore is
unlikely to be effective against cutaneous leishmaniasis in other endemic regions.
Topical treatment with antiviral drug imiquimod 46 (immune response modifier)
in combination with meglumine antimonate 36 has shown very good efficacy
against meglumine antimonate 36 resistant cutaneous leishmaniasis.98 The study
2. Review of the literature
35
was performed in Peru, where L. peruviana is endemic. All of the patients re-
sponded well to this combination therapy, and 90% of the patients were found to
be cured after a 6-month follow up period.
The affectivity of the antibiotic/anti-leprosy drug dapsone 47 was studied with
120 patients infected with cutaneous leishmaniasis.99 Two patient groups were
treated with tablets of dapsone 47 (100 mg) or placebo tablets every 12 h for 6
weeks. 82% of the dapsone treated group were cured. In addition, dapsone 47 is
economical, widely available and well-tolerated.
Azalide antibiotic azithromycin 48 has demonstrated very good efficacy (85%)
for the treatment of patients infected with cutaneous leishmaniasis caused by
L. (Viannia) braziliensis.100 However, unsatisfactory results were obtained from
trials conducted against L. major in Iran, with only 10% of patients displaying fully
cured lesions.101 A reference group treated with meglumine antimonate 36 showed
a better, though still moderate, cure rate of 34%.
Figure 16. N-heterocyclic drugs 45 and 46 and antibiotics 47 and 48 showing
potency as antileishmanial drugs in humans.
Table 5. Antileishmanial cure rates in human preclinical trials.
Compound Regimen Species Cure % Ref.
42 400 mg/day/3 months L. viannia
braziliensis /
L. viannia
23 93
43 600 mg/day/28 days L. b. panamensis 76 94
44 200 mg/day/6 weeks L. major 79 95
45 20 mg/kg/15 days L. b. panamensis 80 96
20 mg/kg/28 days L. panamensis 33 97
45 + 36 20 mg/kg/15 days + 20 mg antimo-
ny/kg/15 days
L. b. panamensis 74 96
46 + 36 topically 250 mg/every other day/20
days + 20 mg antimony/kg/20 days
L. peruviana 90 98
47 100 mg tablets/every 12 h/6 weeks L. major /
L. tropica
82 99
48 500 mg/3 days, 500 mg/5 days,
500 mg/10 days and 1000 mg/2 days
L. viannia
braziliensis
85 100
500 mg/day/5 days/month L. major 10 101
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Controls
35 20 mg antimony/kg/20 days L. b. panamensis 68 94
36 20 mg antimony/kg/15 days L. b. panamensis 36 96
20 mg of antimony/kg/20 days L. panamensis 93 97
60 mg/kg meglumine antimonate/20 days L. major 34 101
Placebo L. b. panamensis 0 94
L. major 34 95
L. b. panamensis 0 96
L. panamensis 37 97
L. major /
L. tropica
0 99
Hit compounds in in vivo animal testing
In this section, antileishmanial agents showing promising in vivo inhibition activi-
ties in animal studies are presented. Some of these early lead compounds are
currently in further development.
Investigational triazole antifungal agent posaconazole (SCH 56592) 49 (Figure 17)
showed very good in vivo activity with BALB/c mice against cutaneous leishmani-
asis due to L. amazonensis infection.102 At a dose of 60 mg/kg/day posaconazole
49 was superior to amphotericin B 38 at a dose of 1 mg/kg/day. However, activity
against visceral leishmaniasis due to L. donovani infection was clearly lower when
compared to positive control amphotericin B.
In a mouse model of L. major leishmaniasis, administration of indole-based im-
idazole antifungal agent 50 led to a clear parasite burden reduction: 99% in the
spleen, 79% in the liver and 50% in the cutaneous lesion.103 Compound 50 de-
creases ergosterol biosynthesis, leading to membrane fungal cell alterations. In
addition, 50 induces a parasite burden-correlated decrease in interleukine-4 pro-
duction both in the splenocyte and the popliteal node of the mouse.
Based on in vitro studies of 16 synthetic oximino benzocycloalkyl azoles
against L. donovani, five compounds showing best activity profile (SI) were tested
further in vivo in a hamster model.104 Of these derivatives, imidazole 51 showed
significant 70% reduction of parasite burden in spleen. However, 51 was still clear-
ly less active than the reference drug miltefosine 41 (96% inhibition) in vivo.
A library of 19 synthetic aryloxy alkyl/aryl alkyl imidazoles displayed very good
94–100% inhibition at 10 µg/mL in vitro against L. donovani promastigotes.105 In
addition, 12 compounds exhibited high inhibition with IC50 values in the range of
0.47–4.85 µg/mL against amastigotes (compound 52 had the best IC50 activity at
0.47 µg/mL). However, in vivo assays with the most promising four compounds
showed only moderate activities with 58–60% inhibition.
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Figure 17. Triazole and imidazole-based antileishmanial compounds.
Pyrazinamide 53 (Figure 18), which is used in tuberculosis chemotherapy, showed
good efficacy in the treatment of L. major-infected mice with a 100-fold reduction
in parasite burden, when compared to the control.106 In addition, mechanistic stud-
ies suggest that pyrazinamide 53 enhances effective immune responses against
the parasite and has an immunostimulatory effect. Treatment was non-toxic and
did not affect the growth of the experimental animals.
Two novel arylimidamide class antileishmanial drug candidates, DB745 and DB766
54 showed exceptional activity against intracellular L. donovani, L. amazonensis, and
L. major in vitro.107 In vivo orally given, DB766 54 produced a dose-dependent
inhibition of liver parasitemia in two efficacy models, L. donovani-infected mice
and hamsters, (71% and 89%, respectively). A marked reduction in parasitemia in
the spleen (79%) and bone marrow (92%) of hamsters was also observed. Fur-
thermore, the compounds were well distributed in the liver and spleen target tis-
sues, showed moderate oral bioavailability (up to 25%), and had a suitable elimi-
nation half-life ranging from 1 to 2 days in mice. No toxic side effects to liver or
kidney were observed, although mild hepatic cell eosinophilia, hypertrophy, and
fatty changes were noted. The results demonstrated that arylimidamides are a
promising class of compounds for preclinical development as an orally adminis-
tered drug.
The conventional dihydropyridine antihypertensive drugs amlodipine 55 and la-
cidipine 56 inhibited L. donovani infection in vitro and in mice when administered
orally.108 Amlodipine 55 and lacidipine 56 therapies led to significant reductions in
splenic (85% and 75%) and liver (86% and 72%) parasite burdens, when com-
pared to controls. The compounds functioned through dose-dependent inhibition
of oxygen consumption, triggering caspase 3-like activation-mediated programmed
cell death of the parasites.
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A series of 2,4,6-trisubstituted pyrimidines and 1,3,5-triazines were synthesized
and screened for in vitro and in vivo antileishmanial activity against L. donovani.109
Three compounds, 57, 58 and 59, showed a good selectivity index (SI) in vitro,
and these were screened for in vivo activity in golden hamsters infected with
L. donovani. The compounds showed decent in vivo inhibition of 48–56% at a
dose of 50 mg/kg when administered intraperitoneally.
Figure 18. Six-membered nitrogen-containing heterocycles with in vivo antileish-
manial activity.
A sitamaquine derivative of 8-aminoquinoline (±)NPC1161B 60 (Figure 19) and pure
()- and (+)-enantiomers were studied in vivo with L. donovani-infected mice.110 All
three components (dose 10 mg/kg/day) showed very good and comparable activity
to the parent compound sitamaquine, and cleared the parasites after a 5-day course
of treatment. ()-Enantiomer was better tolerated and had an increased therapeutic
window when compared to the racemate or (+)-enantiomer of the compound.
Oral administration of natural quinoline-based compound chimanine B 61 (twice
a day 50 mg/kg) to mice infected with L. amazonensis or L. venezuelensis resulted
in a decrease in lesion weight by 70% and parasite loads by 95% when compared
to the group of untreated mice.111 Injections of chimanine B 61 (five injections at
four-day intervals) and subcutaneous administration or intralesional injections of
reference drug meglumine antimonate 36 displayed similar and very good efficacy.
In the follow up study, the efficacy of nine chimanine B derivatives was determined
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in a murine model.112 Activity was further improved by the hydroxy derivative 62,
showing antileishmanial activity up to 90% in in vivo rat models.
A series of synthetic bis-quinolines showed excellent antileishmanial efficacy
against L. donovani in both in vitro and in vivo studies.113 Compound 63 exhibited the
most significant activity against visceral leishmaniasis in a mouse model without show-
ing any toxic manifestation. Intraperitoneal treatment with compound 63 at 12.5 mg/kg
body weight led to significant reduction of parasite burden in spleen (95%) and liver
(98%) compared to untreated controls. Ultrastructural studies of treated promastigotes
demonstrated membrane blebbing, chromatin condensation and vacuolization in the
parasites, and flagellated parasites became round-shaped after treatment.
The quinazoline derivative peganine hydrochloride dihydrate 64 isolated from
Peganum harmala L. seeds showed only moderate in vitro activity against both
extracellular promastigotes as well as intracellular L. donovani amastigotes grow-
ing inside macrophages.114 However, the alkaloid 64 administered by oral route
exhibited good in vivo activity with 80% reduction of L. donovani parasites in ham-
ster spleen at a dose of 100 mg/kg. The reference drug miltefosine 41 resulted in
96% inhibition of parasites at a dose of 40 mg/kg.
The quaternary isoquinoline alkaloid berberine 65 and several of its derivatives
were tested for efficacy against L. donovani and L. braziliensis panamensis in golden
hamsters.115 Tetrahydroberberine 66 was the most potent derivative against L. donovani
with 50% suppression of parasite burden, but was not as potent as the reference drug
meglumine antimonate 36. Only berberine 65 and 8-cyanodihydroberberine 67 showed
significant activity (>50% suppression of lesion size) against L. braziliensis pana-
mensis.
Figure 19. Quinoline-derived compounds showing antileishmanial activity in vivo.
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Various synthetic rhodacyanine derivatives were studied for their antileishmanial in
vitro and in vivo activities.116 Among the derivatives, the fluorinated variant SJL-01
68 (Figure 20) showed an excellent in vitro selectivity index of >15,000 and an IC50
value of 0.011 ȝM against L. donovani. The fluorinated compound 68 displayed an
exceptional 95% inhibition against L. donovani parasites in female mice by
1.3 mg/kg intravenous administrations. Preliminary studies showed that no bioa-
vailability was obtained by subcutaneous administration.
In vitro and in vivo (mice) activities of antiarrhythmic amiodarone 69 and
miltefosine 41 were investigated alone or in combination on L. mexicana.117 It was
found that whereas both drugs given individually failed to cure lesions, a combina-
tion of amiodarone 69 and miltefosine 41 had synergistic effects on the prolifera-
tion of intracellular amastigotes growing inside macrophages and led to 90% para-
sitological cures in a murine model. Amiodarone 69 disrupts intracellular Ca2+
homeostasis and inhibits the de novo sterol biosynthesis of the parasite.
Figure 20. Structures of potential antileishmanial compounds rhodacyanine deriv-
atives 68 and 69.
The common flavonoids luteolin 70 and quercetin 71 (Figure 21) were assayed in
vivo for visceral leishmaniasis against L. donovani-infected golden hamsters.118
Luteolin 70 showed good activity by an over 80% reduction in splenic parasites.
Quercetin 71 reduced the splenic parasite load by 90% at four times higher con-
centration. In vitro studies suggested that leishmanicidal activity was related to
inhibition of promastigotes DNA synthesis and promotion of topoisomerase II-
mediated linearization of kDNA minicircles. Quercetin 71 was almost equally po-
tent to the standard antileishmanial drug sodium stibogluconate 35 in lowering the
parasite load in the spleen of L. donovani-infected hamsters (reductions 77% and
82%, respectively).119 Combination therapy with quercetin 71 and stibogluconate
35 showed improved synergistic activity with a 93% reduction of parasites in ham-
ster spleen.
Hydroxynaphthoquinone-based buparvaquone 72 showed moderate antileish-
manial activity in L. donovani infected mice at very high concentration.120 Potency
of buparvaquone 72 was increased several-fold with the formulation containing
buparvaquone 72 (BPQ) and phosphatidylserine (PS) entrapped in liposomes
(BPQ–PS-LP).121 BPQ–PS-LP was evaluated in vivo against L. infantum (syn.
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L. chagasi) infected hamsters. BPQ–PS-LP reduced the number of amastigotes by
89% in the spleen and by 67% in the liver, compared to 84% and 99.7%, respec-
tively, with meglumine antimonate 36. Buparvaquone 72 alone failed to treat the
hamsters when compared to the untreated group.
Natural compound 2’,6’-dihydroxy-4’-methoxychalcone (DMC) 73 induced only
23% reduction in parasites in L. amazonensis-infected mice. When chalcone 73
was formulated with polylactide to form DMC-PLA nanoparticles, activity was
improved to 53% parasite reduction. Moreover, lesion size was reduced by about
60%. Thirty days after the initiation of treatment, the parasite load in the lesions
was reduced by 90% and the effect was comparable to equivalent doses of the
antileishmanial drug meglumine antimonate 36.122 In the follow up study, it was
demonstrated that DMC 73 alters the sterol composition of L. amazonensis, sug-
gesting that the target is different from other known sterol inhibitors.123
A treatment of hamsters infected with L. donovani with intraperitoneal admin-
istration of natural chalcone derivative, licochalcone A 74, resulted in a 96% re-
duction of parasite load in the liver and the spleen.124 Oral administration resulted
in 65% and 85% reductions of L. donovani parasite loads in the liver and the
spleen, respectively. In a subsequent study by the same authors, activity of the
oxygenated chalcones was studied.125 The best derivative, ‘35m4ac’ 75, showed
very good in vivo activity. L. donovani parasite load in hamster liver was reduced
by 97% after intraperitoneal administration. The chalcone derivative 75 inhibits
parasite respiration and activity of mitochondrial dehydrogenases.
Figure 21. Flavonoids 70 and 71, naphthoquinone 72 and chalcones 73–75 dis-
playing antileishmanial activity in vivo.
The seco-iridoid glycoside amarogentin 76 (Figure 22) was investigated in an in
vivo hamster model against visceral leishmaniasis caused by L. donovani.126 The
free form of amarogentin 76 displayed a 34% reduction in parasite load in the
spleen. When amarogentin 76 was applied with liposomal or niosomal non-ionic
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surfactant vesicles, its activity was improved considerably with a parasite load
reduction in the spleen of 90% and 69%, respectively.
Argentilactone 77 showed very good in vivo antileishmanial activity when ad-
ministered to L. amazonensis-infected mice by oral or subcutaneous routes.127
Argentilactone showed the same efficacy as the reference drug meglumine anti-
monate 36, reducing parasite load in lesions by 96% and in the spleen by 50%.
Figure 22. Lactone derivatives having antileishmanial activity in vivo.
Four potential anticancer alkyl-lysophopholipids were assayed by oral administra-
tion against two strains of L. donovani in a mouse model.128 The currently ap-
proved antileishmanial drug miltefosine 41 displayed the best parasitic reduction in
liver (97% and 99% inhibition against strain LV9 and Patna I) at a 30 mg/kg dose.
Ilmofosine 78 (Figure 23) displayed good activity with 67% and 92% inhibition.
Edelfosine 79 was moderately active. In a study by Cabrera-Serra et al., miltefo-
sine-related derivatives edelfosine 79 and perifosine 80 were orally administered
to L. amazonensis-infected mice.129 The edelfosine-treated mouse group showed
49% and perifosine 80 38% inhibition in footpad lesions. Biopsies obtained from
mice treated with edelfosine 79 showed a 19% parasitic burden when compared to
the non-treated control. In perifosine-treated mice, the parasitic burden was only
7% when compared to the control. The researchers concluded that perifosine 80
should be studied further in preclinical studies.
In vivo intraperitoneal administration of the osteoporosis bisphosphonate drug
pamidronate 81 to mice infected with cutaneous leishmaniasis caused by
L. mexicana amazonensis resulted in long-term disappearance of lesions.130 In
another study, pamidronate 81 and related bisphosphonate risedronate 82 were
studied against L. donovani.131 Intravenous administration of pamidronate 81 and
risedronate 82 was found to inhibit L. donovani amastigotes parasite burden in
mouse liver by 92% and 99%, respectively. However, at high doses of risedronate
82 toxicity was also observed.
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Figure 23. Phosphorus-containing antileishmanial compounds.
Hydroxybibenzyl 14-hydroxylunularin 83 (Figure 24) was highly active in an in vitro
assay against culture and intracellular forms of Leishmania spp., without cytotoxi-
city to mammalian cells.132 In addition, 14-hydroxylunularin 83 showed high anti-
protozoal activity in Leishmania spp.-infected mice by subcutaneous and oral
administration routes. Treatment caused the lesion weight to decrease by 96%
and the parasite load by 93% with the subcutaneous route, and 90% and 69% with
oral administration. The authors of that study suggest that 83 could be chosen as
a new candidate in the development of leishmanicidal therapy.
Antiestrogen drug tamoxifen 84, which is used as a chemotherapeutic and
chemopreventive agent against breast cancer, showed excellent antileishmanial
activity in mice infected with L. amazonensis promastigotes.133 Parasite burden in
tamoxifen-treated animal lesions was reduced by 99.7% in treated groups, as
compared to untreated animals. In addition, the reduction in parasite burden was
sustained for 6 weeks after the end of treatment. Thus, the results support the
proposal for further testing of this drug in other models of leishmaniasis.
2. Review of the literature
44
Figure 24. Antileishmanial compounds 14-hyroxylunularin 83 and antiestrogen
agent tamoxifen 84.
Natural oleane triterpene saponin maesabalide III 85 (MB-III, PX-6518, Figure 25)
demonstrated in vivo activity against L. donovani in golden hamsters.134 It  was
concluded that administration of a single dose of MB-III has efficacy comparable to
that of a single dose of liposomal amphotericin B 38. However, severe toxicity was
observed as several animals died during the experiment series and further devel-
opment is required. Activity of MB-III 85 was further evaluated in vivo with mice
infected with L. mexicana, L. panamensis or L. major.135 MP-III 85 completely
healed L. mexicana and L. panamensis lesions, whereas L. major lesions were
reduced by 50%, thus demonstrating broad-spectrum curative efficacy. In the
follow up study, the same authors synthesized several semisynthetic MB-III de-
rivatives to study the structure-activity relationships, but in in vitro studies none of
the derivatives showed increased activity compared to 85.136
Monoterpenoid cantharidin 86 is a natural poisonous terpenoid secreted by
male blister beetles (Lytta vesicatoria). The effect of different doses of cantharidin
86 on L. major were investigated both in vitro (promastigote and amastigote viability)
and in infected mice (skin lesions) using ointment or soluble cantharidin. Two
weeks of topical treatment with 0.1% cantharidin ointment was an effective method
for treating cutaneous leishmaniasis in infected mice and skin lesions were totally
healed. However, in the follow up study, after two months a relapse of lesions was
observed for two mice out of eight.
The widely used antimalarial drug sesquiterpene lactone, which contains an
unusual peroxide bridge, artemisinin 87, demonstrated only moderate antileish-
manial activity against promastigotes of a wide range of Leishmania species,
including strains responsible for visceral leishmaniasis (L. donovani, L. infantum),
cutaneous leishmaniasis (L. tropica, L. mexicana) and mucocutaneous leishmani-
asis (L. amazonensis, L. braziliensis) promastigotes, the IC50 value being approx.
100 µM.137 However, in a mouse model of visceral leishmaniasis, orally adminis-
tered artemisinin 87 (10 mg/kg and 25 mg/kg body weight) effectively reduced
both splenic weight and parasite burden by 83% and 86%, respectively. The refer-
ence drug sodium stibogluconate 35 demonstrated a similar significant 85% de-
crease in parasite burden.
2. Review of the literature
45
O
O
O
O
O
OH
O
O
O
O
O
O
O
O
O
O
HO
HO
HO
HOOC
OHHO
HO
OH
HO
HO
HO
HO OH
OH
OH
85
O
O
O O
87
O
O
O
O
86
Figure 25. Terpenes and terpenoids possessing antileishmanial activity in vivo.
Betulin-derived compounds
In a study by Sauvain et al., betulinic aldehyde 88 (Figure 26), obtained from Doli-
ocarpus dentatus (Aubl.) Stand. showed weak in vitro activity against
L. amazonensis amastigotes with a survival index of 12% at 136 µM and 42% at
68 µM.138 However, at these doses 88 also showed toxicity against peritoneal
macrophages with survival indices of 70% and 80%, respectively. At a concentra-
tion of 34 µM, aldehyde 88 was ineffective against L. amazonensis as well as non-
toxic to macrophages.
In another study, in which a library of natural compounds was screened for an-
tileishmanial activity, betulinic acid 2 was found to be weakly active against
L. major with an IC50 value of 88 µM.139 It was also noted that in triterpenes having
a ursane, oleanane or lupane skeleton, a carboxy substituent was required for
antileishmanial activity.
In a study by Chowdhury et al., dihydrobetulinic acid 89 was found to inhibit
growth of L. donovani promastigotes and amastigotes with an IC50 value of 2.6
and 4.1 µM, respectively.140 It acts by targeting DNA topoisomerase I and II, pre-
venting DNA cleavage and formation of the enzyme-DNA complex, ultimately
inducing apoptosis. Leishmanial parasitic burden in golden hamsters was reduced
by 92% after 6-week treatment with dihydrobetulinic acid 89 (10 mg/kg body
weight). In a subsequent study by the same authors, six betulin and six dihydrobetu-
lin esters were assayed against sodium stibogluconate sensitive and resistant
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L. donovani strains in vitro.141 Derivatives having small ester groups were active against
both L. donovani strains. 3,28-Disuccinoylbetulin 90, 3,28-disuccinoyldihydrobetulin 91
and 3,28-diglutaroylbetulin 92 showed the best inhibition activity against amastigote
growth inside macrophages, with EC50 values between 6.1 and 10.5 µM. The
suggested biochemical mechanism of these betulin esters was similar to dihy-
drobetulinic acid 89, as they inhibited in a reversible manner the relaxation activity
of enzyme type IB topoisomerase of the parasite as well as topoisomerase I–DNA
complex formation.
Figure 26. Betulin derivatives with antileishmanial activity.
2.4 Chlamydia pneumoniae
2.4.1 Species, taxonomy and life cycle
The order Chlamydiales comprises four families and 13 species, with the
C. pneumoniae species belonging to Family I: Chlamydiaceae and Genus I:
Chlamydia (Table 6).142 In addition to C. pneumoniae, C. trachomatis is the only
other bacterial species in the order Chlamydiales that infects humans. C. tracho-
matis causes urogenital infections and also trachoma, which causes roughening of
the inner eyelids and can lead to blindness. The remaining species are infectious
to animals only, including insects, birds and other mammals.
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Table 6. Taxonomy of Chlamydia pneumoniae.
Order Chlamydiales
Family Chlamydiaceae
Genus I Chlamydia
Species Chlamydia pneumoniae
The chlamydial life cycle consists of two distinct morphological forms: the elemen-
tary body (EB) and reticulate body (RB). EB is the metabolically inactive, infective
extracellular stage, and RB the metabolically active, replicating, intracellular form.
In the C. pneumoniae life cycle (Figure 27):143
1) EB attaches to the host cell (yet unknown receptors).
2) Entry of EB to host cell via phagocytosis144 or receptor-mediated endocytosis.145
3) Inside the host cell EB is surrounded by double-membrane inclusion. EB is
converted to RB.
4) Inclusion is enlarged and filled with new replicates of RB.
5) RBs are converted back to infectious EBs and exit of the EBs can occur via
lysis of the host cell or via extrusion of the EB packed inclusion.
Figure 27. Life  cycle  of C. pneumoniae. A = C. pneumoniae elementary body
(EB). B = Host cell, usually lung cell.146
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2.4.2 Chlamydial persistence
Chlamydial persistence can last for years and it is defined as a viable but non-
cultivable growth stage inside the infected host cell.142 In the persistence stage,
C. pneumoniae is not metabolically active and not replicating. Persistence is
caused by several stress factors that are unfavourable for bacterial growth, such
as insufficient nutrients (e.g. amino acids), iron depletion, non-lethal antibiotics,
heat and growth in monocytes.147 In all cases, the developmental cycle is halted
and the RBs are not converted back to the infective extracellular EB stage. Instead
of the normal round shape of EBs, enlarged aberrant bodies (AB) are formed. This
is clinically highly relevant, since a persistent culture cannot be subcultured for
diagnostic purposes. However, chlamydial persistence can be detected from
chlamydial DNA or marker proteins in the absence of viable Chlamydiae.148 It has
been suggested that C. pneumoniae can persist for many years after initial respir-
atory infection.149
2.4.3 Chemotherapy against infections caused by C. pneumoniae
C. pneumoniae is susceptible to antibiotics that interfere with DNA and protein
synthesis, including tetracyclines, macrolides, quinolones and rifamycins.16 These
classes of antibiotics are most widely studied and used for treatment of human
infections. However, C. pneumoniae is resistant to some common antibiotic classes,
such as trimethoprim, sulphonamides, aminoglycosides and glycopeptides.150
Clinical manifestation and treatment
Asymptomatic infection or unrecognized, mildly symptomatic illnesses, such as
prolonged cough and mild fever, are very common symptoms of C. pneumoniae
infection.151 Severe systemic infections with C. pneumoniae alone are not common.
Even in mild cases, complete recovery is slow, despite appropriate antibiotic therapy,
and cough and malaise may persist for many weeks after the acute illness. It has
been estimated that 10% of cases of pneumonia and approximately 5% of bron-
chitis and sinusitis cases in adults have been attributed to this organism.152 In
addition, there is strong evidence that C. pneumoniae is associated with other
severe diseases, such as atherosclerotic cardiovascular diseases as well as some
neurodegenerative diseases, such as Alzheimer’s disease and multiple sclerosis.17,18
The intracellular location of C. pneumoniae limits and hampers the efficacy of
some antibiotics. The antichlamydial agent must penetrate several biological
membranes in therapeutic concentrations: the host cell membrane, the inclusion
membrane, and, finally, the inner and outer membrane of the Gram-negative bac-
terium itself. Thus, antimicrobial agents need good intracellular penetration proper-
ties to be effective. The following regimen guidelines (Table 7) for adults can be
followed in clinical treatment of C. pneumoniae infection.16 However, some patients
may need re-treatment.
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Table 7. Current treatment guidelines for the treatment of respiratory infection due
to C. pneumoniae.16
Antibiotic class Drug Dosing Regimen
Fluoroquinolone Levofloxacin 101 500 mg once a day Orally or intravenously
7–14 days
Moxifloxacin 103 400 mg once a day Orally 10 days
Tetracycline Doxycycline 112 100 mg twice a day Orally 14–21 days
Tetracycline 114 250 mg four times a day Orally 14–21 days
Macrolide Azithromycin 115 1.5 g once a day Orally 5 days
Clarithromycin 116 500 mg twice a day Orally 10 days
Fluoroquinolones
Many of the commonly used fluoroquinolone antibiotics show very good in vitro
antichlamydial activity with low micromolar MIC values. The fluoroquinolone class
of antibiotics share a quinoline ring system with a fluorine atom at C-6. Piperazine
or another ring system is attached to C-7. Fluoroquinolones block DNA replication
and repair by inhibiting topoisomerase II function.153
The chemical structures of fluoroquinolone antibiotics and some experimental
fluoroquinolones (and a few quinolones) screened in vitro against C. pneumoniae
are presented in Figure 28 and their in vitro MIC values in Table 8. In most of the
cases, susceptibility of C. pneumoniae to antibiotics is tested using a HEp-2 cell
line or, in some cases, a HeLa 229 cell line, as a host. Several antibiotics, such as
garenoxacin 97 (MIC 0.015–0.03 µg/mL), sitafloxacin 107 (MIC 0.031–0.0125 µg/mL)
and experimental BMS-284756 94 (MIC 0.015–0.03 µg/mL) show very good in
vitro activities (Table 8). The MIC values from different studies are very consistent,
and usually only small variations can be seen between HEp-2 or HeLa 229 host
cell lines. The current recommendation for human treatment is to use levofloxacin
101 (MIC 0.25–1 µg/mL) or moxifloxacin 103 (MIC 0.06–1 µg/mL) as the first-
choice antibiotic of this class.16
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Figure 28. Chemical structures of the fluoroquinolone and quinolone classes of
antibiotics with antichlamydial activity.
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Table 8. In vitro efficacy of fluoroquinolones and some quinolones against
C. pneumoniae.
Quinolone or fluoroquinolone MIC range µg/mL Cell line Ref.
BAY 12-8039 93 0.5–1 HEp-2 154
BMS-284756 94 0.015–0.03 HEp-2 155
0.004–0.008 HEp-2 156
Ciprofloxacin 95 1.0–4.0 HEp-2 157
0.25–4 HeLa 229, HEp-2 158
Fleroxacin 96 2–8 HeLa 229, HEp-2 158
Garenoxacin 97 0.008 HEp-2 159
0.015–0.03 HEp-2 160
Gatifloxacin (AM-1155) 98 0.125 HEp-2 159
0.125–0.25 HEp-2 161
0.063–0.125 HeLa 229 162
Gemifloxacin 99 0.125–0.25 HEp-2 163
Grepafloxacin 100 0.063–0.125 HeLa 229 162
Levofloxacin 101 0.5–1.0 HEp-2 155
0.25 HEp-2 159
0.5 HEp-2 156
Lomefloxacin 102 2 * 164
Moxifloxacin 103 0.125–1.0 HEp-2 155
0.06–0.12 HEp-2 156
0.063 HEp-2 159
Norfloxacin 104 16 * 164
Ofloxacin 105 0.5–2.0 HEp-2 157
0.5–2.0 HEp-2 165
0.5–1 HEp-2 156
L-Ofloxacin 0.125–0.5 HeLa 229, HEp-2 166
OPC-17116 106 0.25–0.5 HEp-2 165
Sitafloxacin (DU-6859a) 107 0.031–0.125 HEp-2 157
0.031–0.063 HeLa 229 162
Sparfloxacin 108 0.031–0.125 HEp-2 157
0.016 HEp-2 159
0.06–0.25 HEp-2 165
0.06–0.25 HeLa 229, HEp-2 158
Temafloxacin 109 0.125–1 HeLa 229, HEp-2 158
Tosulfloxacin 110 0.063–0.25 HEp-2 157
0.125 * 164
Trovafloxacin 111 0.5–1 HEp-2 167
* Cell line not mentioned in publication.
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Tetracyclines
The first tetracycline antibiotics, chlortetracycline and oxytetracycline, were dis-
covered in the late 1940s and they are produced by the bacteria Streptomyces
aureofaciens and S. rimosus, respectively.168 Tetracycline antibiotic molecules
consist of four linearly fused rings, to which a variety of functional groups are at-
tached. Tetracyclines inhibit bacterial protein synthesis by preventing the associa-
tion of aminoacyl-tRNA with the bacterial ribosome.169
The chemical structures of tetracycline antibiotics, natural tetracycline 114, and
semisynthetic derivatives doxycycline 112 and minocycline 113, screened in vitro
against C. pneumoniae, are presented in Figure 29, and their in vitro MIC values
using HEp-2 or HeLa 229 host cell lines are given in Table 9. All three compounds
display good efficacy (MIC 0.05–0.25 µg/mL) against C. pneumoniae. Currently,
doxycycline 112 and tetracycline 114 are recommended antibiotics for treatment of
chlamydial infection in humans.16
Figure 29. Chemical structures of tetracycline-class antibiotics with antichlamydial
activity.
Table 9. In vitro efficacy of tetracyclines against C. pneumoniae.
Tetracycline MIC range Cell line Ref.
Doxycycline 112 0.06–0.25 HEp-2 166
Minocycline 113 0.0625 HEp-2 170
Tetracycline 114 0.05–0.1 HeLa 229 171
Macrolides
Macrolide antibiotics are usually used to treat infections caused by Gram-positive
bacteria.172 The macrolide antibiotics have a large, usually 14-, 15-, or 16-
membered macrocyclic lactone ring with one or more deoxy sugars attached.
Macrolides belong to the polyketide class of natural products, and they act by
inhibiting the bacterial protein synthesis machinery, the ribosome.
The chemical structures of macrolide antibiotics and some experimental macro-
lides screened in vitro against C. pneumoniae are presented in Figure 30, and
their in vitro MIC values using a HEp-2 host cell line are given in Table 10.
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Azithromycin 115, clarithromycin 116 and erythromycin 118 display very good
antichlamydial in vitro inhibition activity (MIC 0.004–0.5 µg/mL), whereas dirithro-
mycin and roxithromycin show slightly diminished activities. MIC results from dif-
ferent studies are very consistent. The current recommendation for human treat-
ment is to use azithromycin 115 (MIC 0.06–0.5 µg/mL) or clarithromycin 116 (MIC
0.004–0.063 µg/mL) as the first-choice antibiotic of this class.16
Figure 30. Chemical structures of macrolide-class antibiotics with antichlamydial activity.
Table 10. In vitro efficacy of macrolides against C. pneumoniae.
Macrolide MIC range Cell line Ref.
Azithromycin 115 0.125–0.5 HEp-2 173
0.06–0.25 HEp-2 166
Clarithromycin 116 0.016–0.063 HEp-2 173
0.015–0.06 HEp-2 155
0.004–0.03 HEp-2 166
Dirithromycin 117 0.5–40 HEp-2 174
Erythromycin 118 0.063–0.25 HEp-2 173
0.016–0.5 HEp-2 174
Roxithromycin 119 0.0625–2 HEp-2 175
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Ketolides
Ketolide antibiotics are broad spectrum 14-membered semi-synthetic derivatives of
the macrolide erythromycin A.176 Main modifications are replacement of the neutral
L-cladinose sugar at position C-3 in erythromycin by a 3-ketone carbonyl, and at-
tachment of a cyclic carbamate group in the lactone ring. These structural modifica-
tions give ketolides improved pharmacodynamic and pharmacokinetic properties,
such as improved acid stability, reduced risk of resistance induction and higher lipo-
philicity when compared with 14-membered macrolides.177 Similarly to macrolides,
ketolides act by inhibiting the bacterial protein synthesis machinery, the ribosome.
Figure 31 presents the chemical structures of ketolide antibiotics and some ex-
perimental ketolides screened in vitro against C. pneumoniae, and Table 11
shows their in vitro MIC values using HEp-2 host cells. Cethromycin 120 (MIC
0.008–0.031 µg/mL) and telithromycin 121 (MIC 0.031–0.25 µg/mL) show very
good antichlamydial efficacy. However, none of the ketolide antibiotics are includ-
ed in current treatment recommendations for humans.16
Figure 31. Chemical structures of ketolide-class antibiotics with antichlamydial activity.
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Table 11. In vitro efficacy of ketolides against C. pneumoniae.
Ketolide MIC range Cell line Ref.
Cethromycin (ABT-773) 120 0.016–0.031 HEp-2 173
0.008–0.015 HEp-2 178
HMR 3647 121 0.031–2 HEp-2 175
Solithromycin (CEM-101, OP-1068) 122 0.25–1.0 HEp-2 179
Telithromycin 123 0.031–0.25 HEp-2 173
Rifamycins
The molecular structure of rifamycins consists of an aromatic moiety bridged at
nonadjacent positions by an aliphatic chain.180 The aromatic moiety can be a
naphthalene or naphthoquinone ring system, as in rifamycin, or a benzene or
benzoquinone ring. The rifamycins were first isolated by Sensi and co-workers in
1959.181
The rifamycins display a broad spectrum of antibiotic activity, especially against
Gram-positive bacteria.180 After evaluation of a large number of semisynthetic
analogues, rifampicin 126 with excellent oral bioavailability was developed. Rifam-
picin 126 shows more pronounced activity against Gram-positive bacteria, in par-
ticularly mycobacteria. In addition, activity against Gram-negative bacteria is im-
proved. The antibacterial action of rifampicin 126 results from its inhibition of DNA-
dependent RNA synthesis.182
The chemical structures of semisynthetic rifamycin antibiotic derivatives
screened in vitro against C. pneumoniae are presented in Figure 32, and their in
vitro MIC values using a HEp-2 host cell line are given in Table 12. All compounds
display excellent efficacy (MIC 0.00125–0.02 µg/mL) against C. pneumoniae,
however, rifamycins are currently not recommended for antichlamydial antibiotics
in humans.16
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Figure 32. Chemical structures of rifamycin-class antibiotics with antichlamydial activity.
Table 12. In vitro efficacy of rifamycins against C. pneumoniae.
Rifamycins MIC range Cell line Ref.
ABI-1131 124 0.00125–0.0025 HEp-2 183
Rifalazil (ABI-1648) 125 0.00125–0.0025 HEp-2 183
Rifampicin 126 0.005 HEp-2 184
Rifapentin 127 0.04–0.02 HEp-2 185
Natural non-antibiotic-derived compounds
Little research has been conducted on the antichlamydial properties of non-
antibiotic natural compounds.
In a study by Alvesalo et al., a library of 57 natural phenolic compounds or their
derivatives were tested against C. pneumoniae in vitro using HL cells.186 The
compounds included flavones, flavonols, flavonones, isoflavonones, coumarins,
catechins, phenolic acids, gallates, a stilbene or their semisynthetic derivatives.
Active compounds were found in several compound groups, especially in gallates
(dodecyl gallate 128, MIC = 18 µM), but also flavones (luteolin 70 MIC = 8.8 µM)
and flavonols (myricetin 131, MIC = 29 µM) with no cytotoxicity to host cells
(Figure 33).
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In a related study, two flavonoids luteolin 70, quercetin 71 and octyl gallate 129
were tested in an in vivo mouse model.187 Results were contradictory: octyl gallate
129 had no significant effect; quercetin 71 increased both the inflammatory re-
sponses and the chlamydial load in the lungs. On the other hand, luteolin 70 sup-
pressed the presence of Chlamydia and inflammation in lung tissue as well as
development of C. pneumoniae-specific antibodies.
A tea polyphenol product “Polyphenon 70S”, consisting of a mixture of flavan-3-ols,
gallocatechins and catechins, was found to inhibit C. pneumoniae growth in HL cells
completely at 0.8–1.6 mg/mL concentration, depending on the bacterium strain.188
Corn mint (Mentha arvensis L.) extract, and its main flavone components, aca-
cetin 132, linarin (diglycoside acacetin); and rosmarinic acid were evaluated
against C. pneumoniae infection.189 In vitro both flavones showed roughly 100%
inhibition at 100 µM concentration with no toxicity to the HL host cell line, whereas
the activity of corn mint extract and rosmarinic acid were lower. Corn mint extract
was tested in a mouse model in which the extract was able to reduce the inflam-
matory parameters related to C. pneumoniae infection and the number of
C. pneumoniae genome equivalents at biologically relevant amounts.
The antichlamydial properties of retinoic acid (Vitamin A) 130 have been stud-
ied in vitro and in vivo. The in vitro results showed two separate effects of retinoic
acid 130: firstly, retinoic acid prevents attachment of the organism to the host
endothelial cell surface and, secondly, inhibits growth in both epithelial and endo-
thelial cells.190 The in vivo results showed that retinoic acid 130 prevents
C. pneumoniae-induced foam cell development in a mouse model of atherosclerosis.191
Betulinic acid 2 has been found to be inactive against Staphylococcus aureus,
Escherichia coli,192 Bacillus subtilis, Micrococcus luteus,193 as well  as Enterococ-
cus faecalis and Pseudomonas aeruginosa.194 Generally, betulin derivatives seem
to have rather poor antibacterial activity.
Figure 33. Natural compounds with antichlamydial activity.
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3. Aims of the study
The aim of this study was to use the triterpene skeleton of an abundant birch bark
extractive betulin 1 to synthesize a library of derivatives with various functional
groups for bioactivity screening.
More specifically, the aims were:
x to prepare a library of betulin derivatives with diverse functional groups by
modifying reactive moieties of the betulin skeleton at 3-OH, 28-OH and
isopropenyl group at C22–C29
x to investigate the structure-activity relationships of betulin derivatives
against intracellular pathogenic bacteria, protozoan parasites and viruses
x to synthetize a library of novel heterocyclic betulin derivatives with more
hydrophilic drug-like properties and optimize their bioactivities against
Leishmania donovani.
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4. Experimental
4.1 Materials and methods
Commercially available reagents were used without further purification and all
solvents were HPLC grade. Anhydrous solvents were purchased from Sigma-
Aldrich. All reactions in anhydrous solvents were performed in oven-dried glass-
ware under an inert atmosphere of anhydrous argon or nitrogen. Thin layer chro-
matography (TLC) was performed on E. Merck Silica Gel 60 aluminium packed
plates, with visualization accomplished by UV illumination and staining with 5%
H2SO4 in  MeOH.  The 1H NMR spectra were measured on a Varian Mercury-VX
300 MHz or a Chemagnetics CMX 400 MHz spectrometer with chemical shifts
reported as parts per million (in CDCl3 at 23 °C, solvent peak at 7.26 ppm as an
internal standard or in DMSO-d6 at 23 °C, solvent peak at 2.50 ppm as an internal
standard). The 13C NMR spectra were obtained on a Varian Mercury-VX 75 MHz
or a Chemagnetics CMX 100 MHz spectrometer with chemical shifts reported as
parts per million (in CDCl3 at 23 °C, solvent peak at 77.0 ppm as an internal
standard or in DMSO-d6 at 23 °C, solvent peak at 39.50 ppm as an internal stand-
ard). HPLC-MS and elemental analyses were performed to determine the purity of
all tested compounds. The purity of all tested compounds was >95%. Mass spec-
tra were measured on a Bruker Daltonik Esquire-HPLC spectrometer, with an
XTerra MS RP18 column (4.6 × 30 mm, 2.5 µm) or on a JEOL JMS-AX505 spec-
trometer with direct input and electron ionization (EI). Elemental analyses were
performed by Robertson Microlit Laboratories, Madison, NJ, USA. Melting points
were obtained with a Sanyo Gallenkamp apparatus without correction. Fourier
transform infrared (FTIR) spectra were recorded on a Bruker Vertex 70 spec-
trometer with Pike MIRacle diamond crystal or with a Bruker Equinox 55 spec-
trometer including IRScope II and diamond anvil.
Biological assays, cell lines and methodology are described in details in the
original publications I–IV.
4.2 Results and discussion
The overall objective in the synthesis work was to produce desired test compounds
for bioactivity screening. Neither synthesis method development nor optimization
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of the reaction conditions was performed and in many cases yields are only mod-
erate, but still sufficient to obtain enough pure material for bioactivity assays.
The first objective was to prepare a library of betulin derivatives with diverse
functional groups by modifying the reactive moieties of the betulin skeleton at 3-
OH, 28-OH and isopropenyl group between C22–C29. Details of the chemical
synthesis procedures and characterization data are presented in Publications I, II
and IV. The chemical structures of all synthesized simple betulin derivatives are
presented in Table 13.
The second objective of the study was to synthesize a library of novel hetero-
cyclic betulin derivatives for bioactivity screening. Details of the chemical synthesis
procedures and characterization data are presented in Publication II. The chemical
structures of all synthesized heterocyclic betulin derivatives are presented in Table 14.
4.2.1 Synthesis of simple betulin derivatives (I, II, IV)
Synthesis of betulin esters and related derivatives (I, II, IV)
Many of the natural terpenes or aromatic acids possess numerous bioactivities in
nature, such as pheromones and semiochemicals in insects.195 At least 30 hy-
droxy- and polyhydroxybenzoic acids have been reported in the last 10 years to
have biological activities with potential use in pharmaceutical and agricultural
products to improve human health and nutrition.196 In addition, hydroxycinnamic
acids are a large group of phenolic compounds (e.g. caffeic, p-coumaric and feru-
lic acids), which have shown antioxidant and anticancer activities.197 Because both
betulin 1 and its naturally occurring carboxylic acid derivatives have been shown
to possess numerous bioactivities, it was hypothesized that it would be very inter-
esting to try combining these kinds of moieties in a single compound. Thus, sever-
al such carboxylic acids were chosen and esterified with betulin 1 to yield a set of
betulin esters and related derivatives for bioactivity screening [(Figure 34), see
Table 13 for the chemical structures of the compounds 133–139)]. Some of the
aromatic betulin derivatives were initially designed for cosmetic applications as
possible bioactive agents having UV-activity in a single molecule. These sub-
stances were also included in the bioactivity assays.
Ethyl chrysanthemate was hydrolyzed to produce chrysanthemic acid, which
was subsequently converted with oxalyl chloride to chrysanthemoyl chloride. Finally,
chrysanthemoyl chloride was reacted with 1 to afford a 1:3 mixture of cis and trans
28-O-chrysanthemoylbetulin 133. The treatment of carvacrol with chloroacetic acid
in an aqueous solution of sodium hydroxide gave carvacryloxyacetic acid,198 which
was esterified with 1 using titanium(IV) isopropoxide as a catalyst to produce betu-
linyl 28-carboxymethoxycarvacrolate 134. Treatment of 1 with nicotinic acid using
DCC as a coupling reagent gave 28-O-nicotinoylbetulin 135. Cinnamic acid was
converted to cinnamoyl chloride with thionyl chloride, which was subsequently
esterified with 1 to give 28-O-cinnamoylbetulin 136. N-Acetylanthranilic acid was
treated with oxalyl chloride to produce N-acetylanthraniloyl chloride, which was
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treated immediately with 1 to give 28-O-(N-acetylanthraniloyl)betulin 137. Betulin 1
was treated with t-BuOK followed by addition of methyl bromoacetate to give 28-
O-bromoacetylbetulin 138. 3,28-Di-O-levulinoylbetulin 139 was obtained by esteri-
fying of 1 with levulinic acid using PPTS as a catalyst.
Treatment of 1 with DHP produced a diastereomeric mixture of the corresponding
tetrahydropyranyl ether 140. The THP-protected betulin was subsequently acetylated
to give 141. Removal of the THP group with PPTS produced 3-O-acetylbetulin 142,22
which was treated with mesyl chloride to give 3-O-acetyl-28-O-mesylbetulin 143.
Betulin 1 was diacetylated to 144 with excess acetic anhydride, and the result-
ing diacetylbetulin was converted by acidic (HBr) treatment to 145 with double-
bond migration to position C18–C19. The alkene 145 was subsequently epox-
idized with 3-chloroperoxybenzoic acid (mCPBA) to yield the intermediate 146.
Finally, 28-O-acetylbetulin 147 was obtained by treating betulin 1 with 1.05
equiv of acetic anhydride. The subsequent oxidation of 147 with PCC afforded 28-
O-acetyl-3-oxobetulin 148.199
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Figure 34. Synthesis of betulin esters and related betulin derivatives. Conditions:
(a) (i) ethyl chrysanthemate, NaOH, MeOH-THF (2:1), 80 °C, 4 h, 91%, (ii) chry-
santhemic acid, (COCl)2, CH2Cl2, rt, 6 h, 81%, (iii) chrysanthemoyl chloride, DMAP,
py, 40 °C, 48 h, 63%; (b) (i) carvacrol, chloroacetic acid, NaOH, ǻ, 3 h, 45%, (ii)
carvacryloxyacetic acid, Ti(OPr-i)4,  PhMe,  ǻ,  6  h,  55%;  (c)  nicotinic  acid,  DCC,
DMAP, CH2Cl2, rt, 23 h, 31%; (d) (i) cinnamic acid, SOCl2, 40 °C, 2 h, 92%, (ii)
cinnamoyl chloride, DMAP, pyridine, 40 °C, 22 h, 21%; (e) (i) N-acetylanthranilic
acid, (COCl)2, rt, 3 d, 99%, (ii) N-acetylanthraniloyl chloride, DMAP, py, 40 °C, 40 h,
25%; (f) t-BuOK, methyl bromoacetate, THF, 75 °C, 10 min, 15%; (g) levulinic acid,
PPTS, PhMe, 175 °C, 23 h, 23%; (h) DHP, PPTS, CH2Cl2,  rt,  2 d, 30%; (i)  Ac2O,
DMAP, py, CH2Cl2, rt, 20 h, 95%; (j) PPTS, EtOH, rt, 14 d, 94%; (k) CH3SO2Cl, TEA,
CH2Cl2, 0 °C, 2 h, 99%; (l) Ac2O (6 equiv), DMAP, py, CH2Cl2, rt, 17 h, 97%; (m) HBr,
Ac2O, AcOH, PhMe, rt, 21 d, 42%; (n) mCPBA, Na2CO3, CHCl3, rt, 2 h, 65%; (o) Ac2O
(1.05 equiv), DMAP, py, CH2Cl2,  rt,  22  h,  45%;  (p)  PCC,  CH2Cl2, rt, 24 h, 57%.
THF = tetrahydrofuran; DCC = N,Nƍ-dicyclohexylcarbodiimide; DHP = 3,4-dihydro-2H-
pyran; PPTS = pyridinium p-toluenesulfonate; DMAP = 4-(dimethylamino)pyridine; py =
pyridine; PCC = pyridinium chlorochromate; mCPBA = 3-chloroperoxybenzoic acid.
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Synthesis of betulin oxidation products (I, IV)
Based on a thorough literature survey,6 it was hypothesized that oxidized betulin
derivatives may have improved bioactivity when compared to the starting material
betulin. Thus, a set of betulin oxidation products was synthesized for bioactivity
screening [(Figure 35), see Table 13 for chemical structures of compounds 2, 88
and 149–155)].
Oxidation of betulin 1 with Jones reagent (CrO3/H2SO4/H2O) gave betulonic ac-
id 149, which was subsequently methylated with TMSCHN2 to give methyl betu-
lonate 150. The subsequent treatment of 149 with oxalyl chloride gave betulonoyl
chloride,200 which was immediately reacted with vanillin or L-aspartic acid dimethyl
ester to produce vanillyl betulonate 151 and L-aspartyl amide of betulonic acid
152, respectively.
Reduction of betulonic acid 149 with NaBH4 gave betulinic acid 2,55 which was
subsequently methylated with TMSCHN2 to give methyl betulinate 153.201 28-
Oxyallobetulone 154 was synthesized by refluxing betulonic acid 149 with p-TSA.
When betulin 1 was oxidized with excess PCC, betulonic aldehyde 155202 was
formed. When a smaller molar amount of PCC was used, betulin aldehyde 88 was
isolated from a 3:1 mixture of betulonic aldehyde 155 and betulin aldehyde 88.
The synthesis of two additional oxidized betulin derivatives 28-O-acetyl-3-
oxobetulin 148 and dihydrobetulonic acid 158 is presented in Figure 34 and Figure 36.
Figure 35. Synthesis of oxidized betulin derivatives. Conditions: (a) H2CrO4, ace-
tone, 0 °C ĺ rt,  21  h,  44%;  (b)  TMSCHN2, PhMe-MeOH (3:2), rt, 40 min, 66%
152, 89% 153; (c) (i) (COCl)2, CH2Cl2, rt, 22 h, 85%, (ii) vanillin, DMAP, py, 40 °C,
21 h, 20%; (d) L-aspartic acid dimethyl ester hydrochloride, TEA, CH2Cl2, rt, 19 h,
42%; (e) NaBH4, i-PrOH, rt, 2.5 h, 82%; (f) p-TSA, H2O, CHCl3, ǻ, 3 h, 19%; (g)
PCC (1.8 equiv), CH2Cl2, rt, 40 min, 18%; (h) PCC (6 equiv), CH2Cl2, rt, 1 h, 82%.
TMS = trimethylsilyl; TEA = triethylamine. p-TSA = p-toluenesulfonic acid monohy-
drate.
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Synthesis of miscellaneous betulin derivatives (I, IV)
To gain a more comprehensive understanding of the structure-activity relation-
ships (SAR) of different betulin derivatives, a set of miscellaneous betulin deriva-
tives with diverse functional groups were synthesized (Figure 36, Table 13).
Allobetulin 156 was synthesized by refluxing a mixture of betulin 1 and p-TSA in
chloroform.203
Dihydrobetulin 157 was obtained by catalytic hydrogenation of 1 in the pres-
ence of palladium on carbon as a catalyst. The subsequent oxidation of dihy-
drobetulin 157 with Jones reagent produced dihydrobetulonic acid 158.
3-Deoxy-2,3-didehydrobetulin 159 was prepared by treating 1 with a mixture of
DEAD, PPh3 and 3,3-dimethylglutarimide.204 Subsequent acetylation of 159 gave
3-deoxy-2,3-didehydro-28-O-acetylbetulin 160.
Betulin 1 was oxidized with PCC to a 3:1 mixture of betulonic aldehyde 155 and
betulin aldehyde 88,202 which was subsequently treated with excess hydroxyla-
mine hydrochloride to produce oximes 161 and 162.205 Separate treatment of 161
and 162 with neat acetic anhydride gave the nitriles 163 and 164, respectively.
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Figure 36. Synthesis of miscellaneous betulin derivatives. Conditions: (a) p-TSA,
H2O, CHCl3,  ǻ,  3  h,  93%;  (b)  H2, 5% Pd/C, THF-MeOH (1:2), rt, 22 h, 99%; (c)
H2CrO4,  acetone,  rt,  20  h,  31%;  (d)  DEAD,  PPh3, 3,3-dimethylglutarimide, THF,
0 °C ĺ rt,  24  h,  31%;  (e)  Ac2O, DMAP,  py,  CH2Cl2, rt, 22 h, 81%; (f) PCC (1.8
equiv), CH2Cl2, rt, 40 min, 88:155 (1:3); (g) NH2OH·HCl, py-EtOH (1:3), 100 °C,
18 h, 10% 161, 33% 162;  (h)  Ac2O, 120 °C, 2 h, 34% 163, 46% 164.
DEAD = diethyl azodicarboxylate.
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Table 13. Summary and chemical structures of the simple betulin derivatives.
Compound R1 R2 R3
1 OH CH2OH CH3-C=CH2
133 OH CH3-C=CH2
134 OH CH3-C=CH2
135 OH N
O
O
CH3-C=CH2
136 OH CH3-C=CH2
137 OH
O
O HN
O
CH3-C=CH2
138 OH CH3-C=CH2
139 CH3-C=CH2
140 OH CH3-C=CH2
141 OAc CH3-C=CH2
142 OAc CH2OH CH3-C=CH2
143 OAc CH2OMs CH3-C=CH2
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144 OAc CH2OAc CH3-C=CH2
145 (vide supra) OAc CH2OAc CH3-CH-CH3
146 (vide supra) OAc CH2OAc CH3-CH-CH3
147 OH CH2OAc CH3-C=CH2
148 O= CH2OAc CH3-C=CH2
149 O= CO2H CH3-C=CH2
150 O= CO2Me CH3-C=CH2
151 O= CH3-C=CH2
152 O= CH3-C=CH2
2 OH CO2H CH3-C=CH2
153 OH CO2Me CH3-C=CH2
154 (vide supra) O= * *
155 O= CHO CH3-C=CH2
88 OH CHO CH3-C=CH2
156 (vide supra) OH * *
157 OH CH2OH CH3-CH-CH3
158 O= CO2H CH3-CH-CH3
159 - CH2OH CH3-C=CH2
160 - CH2OAc CH3-C=CH2
161 =NOH CH=NOH CH3-C=CH2
162 OH CH=NOH CH3-C=CH2
163 =NOAc CN CH3-C=CH2
164 OAc CN CH3-C=CH2
4.2.2 Synthesis of heterocyclic betulin derivatives (II)
It is clear from the chemical structure of betulin 1 that most of the betulin deriva-
tives presented in Table 13 are lipophilic and thus poorly soluble in water. This
may have important implications for the interpretation of the results of the bioactivity
assays. Observed differences in bioactivity between different modified betulin
derivatives may be explained at least partly by different partition coefficients (log P)
of these compounds. This prompted us to convert these hydrophobic triterpenoids
to more soluble and drug-like compounds by introducing a fused heterocyclic
system to the lupane skeleton.
A treatment of 146 (see Figure 34 for synthesis of 146) with pyridine p-
toluenesulfonate (PPTS) gave a mixture (4:1) of conjugated dienes, 3,28-di-O-
acetyllupa-12,18-diene 165a and 3,28-di-O-acetyllupa-18,21-diene 165b (Figure
37).206 Heterocycloadducts 166–188 were synthesized by reaction of a mixture of
betulin-derived dienes 165a/165b and urazines 195, which were generated in situ by
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oxidation of urazoles 194 with the hypervalent iodine reagent, (diacetoxyiodo)benzene
(Figure 38).207 In addition, reactions of commercially available 4-phenyl- or 4-methyl-
1,2,4-triazoline-3,5-dione with a mixture of dienes 165a/165b gave the corresponding
heterocycles 178 and 179. The subsequent hydrolysis of heterocycles 178 and 179
with NaOH provided the diols 180 and 181 as the hydrolysis products.
In order to synthesize heterocyclic derivatives with different acyl groups at C3
and C28, the dienes 165a/165b were hydrolyzed with NaOH treatment and the
obtained diols 189a/189b were subsequently acylated with various acyl chlorides.
The resulting acylated dienes 190a/190b (see Table 14 for acyl R2 groups, betulin
derivatives 182–188) were treated with 4-methyl- or 4-phenyl-1,2,4-triazoline-3,5-
dione to give the corresponding heterocycles 182–187. In addition, heterocycload-
duct 188,  with  bulky  R1 and R2 groups, was synthesized by treating 190a/190b
with tert-butyl-substituted in situ-generated urazine 195. In all cases, the only
isolable heterocyclic betulin derivatives 166–188 were those obtained from the
Diels-Alder reaction between the sterically least hindered diene 165a and urazines
195. The [4+2] cycloaddition reactions between the mixture of dienes 165a/165b
and other less reactive dienophiles, such as maleic anhydride, N-phenylmaleimide,
diethyl azodicarboxylate and dimethyl acetylenedicarboxylate were unsuccessful.
Figure 37. Synthesis of conjugated betulin dienes 165a/165b and heterocyclic
betulin derivatives 166–188. Conditions: (a) PPTS, Ac2O, PhMe, reflux, 3 h, 68%;
(b) 4-substituted urazole 194, PhI(OAc)2, CH2Cl2,  THF,  rt,  20  h;  (c)  4-methyl-  or
4-phenyl-1,2,4-triazoline-3,5-dione, CH2Cl2, THF, rt, 20 h; (d) NaOH, MeOH, THF,
rt, 18 h, 189a/189b 85%; (e) R2Cl, DMAP, py, CH2Cl2, 40 °C, 20 h.
The dienophilic urazines 195 and their corresponding urazole precursors 194 were
synthesized as follows (Figure 38).208 Reaction of a stoichiometric amount of ethyl
hydrazinecarboxylate 191 and isocyanates 192 yielded carbethoxysemicarbazides
193. When the substituent R1 of the carbethoxysemicarbazides 193 was aromatic
(see Table 14 for R1 groups, betulin derivatives 166–174), cyclization to the corre-
sponding urazoles 194 was carried out by heating in aqueous KOH solution. Acidi-
fication (HCl) of the basic solution afforded urazoles 194. When the substituent R1
was aliphatic (see Table 14 for R1 groups, betulin derivatives 175, 176 and 188),
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the cyclization reaction was carried out by sodium ethoxide in refluxing ethanol.
Acidification (HCl) of the basic solution afforded urazoles 194.
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N N
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Figure 38. Synthesis of urazines 195. Conditions: (a) PhMe, rt, 2 h to 80 °C, 2 h,
90–99%; (b) (i) 4 M KOH in H2O, 70 °C, 90 min, (ii) 37% HCl (see Table 14 for R1
groups, betulin derivatives 166–174)  37–88%;  (c)  (i)  Na,  EtOH,  85  °C,  24  h,  (ii)
1.25 M HCl in EtOH (see Table 14 for R1 groups, betulin derivatives 175, 176 and 188),
94–96%; (d) in situ PhI(OAc)2, CH2Cl2, THF.
Table 14. Summary and chemical structures of heterocyclic betulin derivatives.
Compound R1 R2
166 Bn Ac
167 3-MeO-Ph Ac
168 4-F-Ph Ac
169 3-NO2-Ph Ac
170 4-Cl-Ph Ac
171 4-Ac-Ph Ac
172 1-naphthyl Ac
173 indan-5-yl Ac
174 1,3-dioxol-5-yl Ac
175 n-Bu Ac
176 Et Ac
177 H Ac
178 Ph Ac
179 Me Ac
180 Ph H
181 Me H
182 Me COEt
183 Me COPr
184 Me COi-Pr
185 Me COcHex
186 Me COPh
187 Ph COPh
188 t-Bu COcHex
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4.2.3 SAR studies: Semliki Forest virus (I)
In the primary screen, the inhibition activity of 33 simple betulin derivatives and 18
heterocyclic betulin derivatives was assayed against SFV at 50 ȝM concentration.
In addition, the cytotoxicity of the compounds to a Huh-7 cell line was determined
(Figure 39, Figure 40). Based on the results from the primary screen, a total of 18
(marked by * in Figure 39 and Figure 40) promising compounds having good anti-
viral activity combined with low cytotoxicity to the Huh-7 cell line were selected for
determination of IC50 values (Figure 41).
In the set of simple betulin derivatives, only three derivatives having an unmodi-
fied hydroxy group at C3 showed good activity combined with low cytotoxicity. The
starting material betulin 1 inhibited SFV replication with an IC50 value of 46 ȝM,
and betulinic acid 2 and 28-O-tetrahydropyranylbetulin 140 displayed improved
activity with IC50 values 15 ȝM and 17 ȝM, respectively. Five compounds out of
seven having an acetyl group at C3 performed well, 3,28-di-O-acetylbetulin 144
having the best SFV inhibition with an IC50 value of 9 ȝM. Compounds having a
carbonyl group at C3 also performed well, with four out of seven compounds
showing good performance, of which betulonic acid 149 displayed best activity
with an IC50 value of 13 ȝM. For comparison, a standard SFV inhibitor, ribavirin,
has an IC50 value of 95 ȝM.
Figure 39. Antiviral effect of simple betulin derivatives against SFV in the primary
screen at 50 µM. For chemical structures, see Table 13. Compounds marked (*),
yielding <20% (dashed blue line) remaining viral replication (AV) and >80%
(dashed red line) cell viability (CV), were selected for determination of IC50 values.
In the subgroup of heterocyclic betulin derivatives, all compounds that displayed
good inhibition combined with low cytotoxicity had acetyl R2 groups at C3 and C28
and a bulky R1 substituent at N-4, except for compound 183 (IC50 = 30 µM), which
had propanoyl groups at C3 and C28 and methyl at N-4 (Figure 40). From the
group of betulin derivatives having bulky aromatic R1 moiety at N-4, benzyl 166
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(IC50 = 36 µM), phenyl 178 (IC50 = 20 µM) as well derivatives having an electron-
withdrawing group on the aromatic ring, performed well: 3-nitrophenyl 169
(IC50 = 23 µM) and 3-chlorophenyl 170 (IC50 = 22 µM) showed good activity.
Figure 40. Antiviral effect of heterocyclic betulin derivatives against SFV in the
primary screen at 50 µM. For chemical structures of compounds see Table 14.
Compounds marked (*), yielding <20% (dashed blue line) remaining viral replica-
tion (AV) and >80% (dashed red line) cell viability (CV), were selected for IC50 de-
termination.
Figure 41. IC50 values of betulin-derived compounds against Semliki Forest virus
(SFV). Positive control = ribavirin.
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It is reported that antiviral inhibition of betulin-derived compounds takes place
during the early or late stages of the virus life cycle.24,204 On the other hand, it can
be speculated that the inhibitory effect of the SFV inhibitor nucleoside analogue 3ƍ-
amino-3ƍ-deoxyadenosine (3ƍ-NH2-3ƍ-dAdo) occurs during the replication phase.209
Thus, synergism of the three representative and potent betulin derivatives 28-O-
tetrahydropyranylbetulin 140, betulinic acid 2 and heterocycloadduct 178 was
assayed in combination with (3ƍ-NH2-3ƍ-dAdo). The best synergism was achieved
by combination of 5 ȝM 3ƍ-NH2-3ƍ-dAdo and 2 ȝM of the heterocycle 178, showing
an interaction index (I) value of 0.16.
Finally, the three compounds 28-O-tetrahydropyranylbetulin 140, betulinic acid 2
and heterocycloadduct 178 were assayed against another alphavirus Sindbis (SIN). All
three compounds were also effective against SIN, with lower IC50 values when com-
pared to SFV, betulinic acid 2 having the best activity at a IC50 value of 0.5 ȝM.
4.2.4 SAR studies: Leishmania donovani (II)
Initial antileishmanial activity of heterocyclic compounds 166–181 was screened
against Leishmania donovani axenic amastigotes at 50 µM on a microplate assay
with alamarBlue as previously described.210 The screening results of the first batch
with derivatives having acetyl R2 groups at C3 and C28 showed that small R1
substituents at the nitrogen atom gave the best antileishmanial activity (Figure 42).
Derivatives 176 (R1 = Et; inhibition = 88%), 177 (R1 = H; inhibition = 88%) and 179
(R1 = Me; inhibition = 98%) displayed the best activity at 50 µM.
Therefore, a second batch of heterocyclic betulin derivatives 182–186 was syn-
thesized such that the acyl groups at R2 were altered and the R1 group was kept
as methyl. In addition, two cycloadducts 187 and 188 with bulky R1 and R2 groups
were synthesized. Also in this case, the screening results showed that small acyl
R2 groups at C3 and C28 (182 R2 = Et; inhibition = 93%) were more active than
derivatives with bulky acyl groups.
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Figure 42. Antileishmanial activity of heterocyclic betulin derivatives against
L. donovani axenic amastigotes. Determined at 50 µM concentration of betulin
derivative with the exception of compounds 183 and 184, which were used at
15 µM due to their poor solubility. The most potent compounds are marked (*).
Pos. control = amphotericin B (1 µM). Neg. control = culture medium and DMSO.
See Table 14 for chemical structures.
The most potent derivatives (176, 177, 179 and 182, Figure 42) with a small acyl
group at R2 and small substituent R1 (Me or Et) at the nitrogen on the initial micro-
plate assay were selected for further investigation: determination of GI50 on axenic
amastigotes, cytotoxicity for THP-1 macrophages, and antileishmanial activity
against L. donovani amastigotes growing inside macrophages (Figure 43). The
methyl derivative 179 had the best GI50 value at 8.9 µM. However, it showed cyto-
toxicity against macrophage cell line THP-1. Other compounds showed slightly
higher but very similar GI50 values and displayed cytotoxicity only at highest 50 µM
concentration.
Finally, the compounds were tested for antileishmanial activity against L. donovani
amastigotes growing inside macrophages at concentrations that showed less than
40% cytotoxicity to the macrophages. When compared to initial screening with
axenic amastigotes at 50 µM, compound 182 showed similar strong activity against
L. donovani amastigotes growing inside macrophages. At 25 µM, 176, 177 and
182 still showed good activity and the relatively cytotoxic derivative 179 showed
good inhibition even at 12.5 µM concentration.
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Figure 43. GI50,  cytotoxicity  to  THP-1  cells  as  well  as  antileishmanial  activity  of
176, 177, 179 and 182 against L. donovani amastigotes growing in THP-1 cells at
concentrations showing <40% (dashed line) cytotoxicity to THP-1 cells.
4.2.5 SAR studies: Leishmania donovani (III)
Similarly to Publication II, the antileishmanial activities of simple betulin derivatives
at 50 µM were screened using a fluorescent viability microplate assay with
L. donovani axenic amastigotes (Figure 44).
Betulin 1 showed moderate antileishmanial activity against L. donovani axenic
amastigotes, showing 35% inhibition at 50 µM in a microplate assay. Acetylation,
esterification or etherification of the hydroxy groups at C3 or C28 in most cases
retained antileishmanial activity. Only 28-O-(N-acetylanthraniloyl)betulin 137 and
28-O-bromoacetylbetulin 138 showed improved leishmanicidal activity, compared
with 1.
Oxidized betulin derivatives seem to have similar or increased antileishmanial
activity when compared to 1. Furthermore, 28-O-Acetyl-3-oxobetulin 148, methyl
betulonate 150, betulonic aldehyde 155 and betulinic acid 2 all showed moderate
40% inhibition at 50 µM. L-Aspartyl amide of betulonic acid 152, betulin aldehyde
88 and dihydrobetulonic acid 158 displayed improved antileishmanial growth inhi-
bition between 64–72%, and betulonic acid 149 had remarkable antileishmanial
activity with 98% inhibition at 50 µM.
In addition, oxime derivatives 161 and 162 and the betulin derivative 164 SAL-
II-141 with a nitrile group at C28 showed increased inhibition (63–73%) at 50 µM.
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Figure 44. Antileishmanial activity of simple betulin derivatives at 50 µM against
L. donovani axenic amastigotes. The most potent compounds are marked (*). Pos.
control = amphotericin B (1 µM). Neg. control = culture medium and DMSO. See
Table 13 for chemical structures.
The most potent betulin derivatives (138, 149, 152, 158 and 161) from initial
screening were selected for further investigation: GI50 values, cytotoxicity to mac-
rophage THP-1 cell line, as well as activity against L. donovani growing inside
macrophages were determined (Figure 45).
Betulonic acid 149 showed the best GI50 value of 14.6 µM. However, it also
showed cytotoxicity against the THP-1 cell line at all test concentrations. The L-
aspartyl amide derivative 152 displayed good GI50 values of 21.2 µM with no cyto-
toxicity to the THP-1 cell line. The oxime derivative 161 also displayed good GI50
values of 22.8 µM, but also increased general cytotoxicity. 28-O-bromoacetylbetulin
138 had a moderate GI50 value of 34.9 µM with no toxicity to the THP-1 cells.
Dihydrobetulonic acid 158 had a moderate GI50 value (56.0 µM), but also in-
creased general toxicity. Compounds 138 and 152 were moderately active (inhibi-
tion >50%) against L. donovani amastigotes growing in THP-1 cells at 50 µM. At
12.5 µM concentration, only oxime derivative 161 showed moderate inhibition,
whereas the rest of the compounds were relatively inactive.
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Figure 45. GI50, cytotoxicity to THP-1 cells, and antileishmanial activity of 138,
149, 152, 158 and 161 against L. donovani amastigotes growing in THP-1 cells at
concentrations showing <40% (dashed line) cytotoxicity to THP-1 cells.
4.2.6 SAR studies: Chlamydia pneumoniae (IV)
A total of 32 betulin derivatives, including 5 heterocyclic adducts (compounds 176,
178, 182, 185 and 187), were screened for activity against Chlamydia pneumoniae at
1 µM concentration (Figure 46). In addition, the cytotoxicity of the compounds was
screened at 1 and 8 µM concentration against HL cells (only the results of the 8 µM
assay are presented in Figure 46). Five derivatives, methyl betulonate 150, dihy-
drobetulonic acid 158, betulin-3,28-dioxime 161, betulin-28-oxime 162 and 3-acetoxy-
mebetulinyl-28-nitrile 164 showed high (>70% growth inhibition) antichlamydial activity.
These five compounds were selected for dose–response experiments to de-
termine MIC concentrations. Only compound 161 was able to completely eradicate
C. pneumoniae from the HL cells, having a MIC value of 1 µM. Furthermore, a
50% inhibition activity of betulin-3,28-dioxime 161 was achieved with a nanomolar
concentration of 290 nM or 125 nM depending on the assay method. For compari-
son, one of the most potent antichlamydial compounds known, rifampicin 126,
displayed a MIC value of 12 nM.
Chlamydia stimulates the production of host cytosolic phospholipase A2
(cPLA2). Preventing this enzyme from functioning is known to cause inhibition of
chlamydial growth.211 Thus, the effect of ten betulin derivatives was assayed
against the PLA2 enzyme of HL cells. Betulin 1 showed PLA2 inhibition of 62.5% at
0.5% (w/v) concentration. The potent antichlamydial derivatives betulin-3,28-dioxime
161 and betulin-28-oxime 162 displayed the highest PLA2 inhibition of 75% at
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0.5% (w/v) concentration. Despite good PLA2 inhibition activity of compounds 161
and 162, no clear correlation was observed between antichlamydial activity and
PLA2 inhibition of the betulin derivatives.
Figure 46. Antichlamydial activity of betulin derivatives at 1 µM against Chlamydia
pneumoniae and host cell viability at 8 µM. The most potent compounds are
marked (*). See Table 13 and Table 14 for chemical structures.
4.2.7 Cytotoxicity of betulin compounds (I, II, III, IV)
The cytotoxic effects of the test compounds to cell viability were evaluated with two
methods using three cell lines (Figure 47, Figure 48). The methods included an ATP
assay using HL and Huh-7 cell lines, and an alamarBlue assay using an THP-1 cell
line. In general, betulin compounds were well tolerated by the test cell lines at a
concentration of 8 µM or 50 µM. However, in some cases there were clear differ-
ences between the cell line tolerances to certain betulin derivatives. For example,
138 was found to be toxic to the Huh-7 cell line, but nontoxic to the other two cell
lines tested. Conversely, betulonic acid 149 and dihydrobetulonic acid 158 were
nontoxic to the Huh-7 cell line, but relatively toxic to HL and THP-1 cells. These
kinds of toxicity differences should be taken into an account when testing cytotoxicity,
and several cell lines should be used to exclude possible false non-toxic compounds.
The cytotoxicity of the heterocyclic betulin derivatives was also relatively low
(Figure 48). However, in this case, not all derivatives were tested extensively with
all three cell lines. Unfortunately, the most active heterocyclic betulin derivatives
against Leishmania donovani, i.e. 48 and 50, were also significantly toxic to the
THP-1 cell line.
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Figure 47. Cytotoxicity of simple betulin derivatives to HL cells (8 µM), Huh-7 cells
(50 µM) and THP-1 cells (50 µM). Bars represents cell viability after treatment with
the test compound. Compounds marked (^) were not assayed with HL cells and
compounds marked (‘) were not assayed with Huh-7 cells. Toxicity to THP-1 cells
was assayed only with compounds marked (*).
Figure 48. Cytotoxicity of heterocyclic betulin derivatives to HL cells (8 µM), Huh-7
cells (50 µM) and THP-1 cells (50 µM). Bars represent cell viability after treatment
with the test compound. Toxicity to HL cells was assayed only with compounds
marked (^) and toxicity to THP-1 cells tested only with compounds marked (*).
Compounds marked (‘) were not tested with Huh-7 cells.
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4.3 Conclusion
New inexpensive therapeutic agents are urgently needed due to increasing drug
resistance of disease agents and to ensure the availability of needed drugs in the
developing countries. In this study, two sets of betulin derivatives were synthe-
sized and screened for their antiviral, antileishmanial and antibacterial activities.
The first set of 34 compounds included relatively easily synthesizable betulin
derivatives, such as esters, various oxidation products (e.g. carboxylic acids, ke-
tones and aldehydes); and miscellaneous betulin derivatives such as oximes and
nitriles or compounds where hydroxyl group of ring A was cleaved or double bond
in betulin isopropenyl group was hydrogenated.
The second set of 23 compounds consisted of novel heterocyclic betulin deriva-
tives in which the triazole ring is fused by the Diels-Alder reaction to the lupane
skeleton of betulin. First, mixture of conjugated dienes 3,28-di-O-acetyllupa-12,18-
diene 165a and 3,28-di-O-acetyllupa-18,21-diene 165b was prepared in four
steps. Formed mixture was reacted with urazines, which were generated in situ by
oxidation of urazoles with the hypervalent iodine reagent, (diacetoxyiodo)benzene.
Diversity of heterocyclic betulin derivatives was increased by using different ura-
zole intermediates (which were synthesized in two steps starting from ethyl hydra-
zinecarboxylate and various isocyanates) and different ester groups at 3-OH and
28-OH in the betulin skeleton.
In the antiviral assays against SFV, betulin acetyl esters performed well; for ex-
ample 28-O-tetrahydropyranylbetulin 140 and 3,28-di-O-acetylbetulin 144 displayed
IC50 values of 17 ȝM and 9 ȝM, respectively. Additionally, oxidation products betu-
linic acid 2 and betulonic acid 149 displayed good activity, with IC50 values of
13 ȝM and 15 ȝM, respectively. In the subgroup of heterocyclic betulin derivatives,
compounds having acetyl R2 groups at C3 and C28 and an aromatic group R1 at
N-4 displayed generally good activity. Derivative 178 (IC50 = 20 µM) with a phenyl
at R1, as well as derivatives having an electron-withdrawing group on the aromatic
ring performed well.
In the antileishmanial studies, L-aspartyl amide derivative 152 displayed a good
GI50 value of 21.2 µM with no cytotoxicity to the THP-1 cell line. Furthermore, the
dioxime derivative 161 and 28-O-bromoacetylbetulin 138 displayed relatively good
GI50 values. Unfortunately, betulonic acid 149, while having good antileishmanial
activity, also showed cytotoxicity against the THP-1 cell line. The heterocyclic
betulin derivatives with small R1 (Me or Et) substituents at the nitrogen atom of the
triazole moiety combined with the sterically least hindered acyl groups at the R2
positions in the betulin skeleton promoted antileishmanial activity. The most potent
derivatives against Leishmania donovani amastigotes were compounds 176, 177,
179 and 182, compound 179 having the best GI50 value of 8.9 µM.
Five betulin derivatives, methyl betulonate 150, dihydrobetulonic acid 158, betu-
lin-3,28-dioxime 161, betulin-28-oxime 162 and 3-acetoxymebetulinyl-28-nitrile 163,
showed high (>70% growth inhibition) antichlamydial activity against Chlamydia
pneumoniae. The most potent derivative, betulin-3,28-dioxime 161, displayed 50%
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inhibition activity at a nanomolar concentration of 290 nM or 125 nM depending on
the assay method.
We have shown that, by simple chemical modifications, the antibacterial, anti-
protozoal and antiviral activities of the ubiquitous naturally occurring triterpene,
betulin, can be improved considerably. It is possible to derive potent antimicrobial
compounds with low micromolar or even nanomolar inhibition values. In most
cases, a single derivative showed very different activities at different bioassays.
For example, several O-betulinyl acetates were active against SFV, but totally
inactive against L. donovani and C. pneumoniae. Thus, it is also quite impossible
to predict the general activity of a certain derivative against other microbial or viral
strains. For example, several potent antichlamydial compounds were totally inac-
tive against other bacterial and fungal species such as Staphylococcus aureus,
Escherichia coli, Pseudomonas aeruginosa, Enterobacter aerogenes, Enterococ-
cus faecalis and Candida albicans (unpublished data, manuscript in preparation).
Further studies are needed to develop more potent betulin derivatives with an-
timicrobial properties, improved water solubility, and zero cytotoxicity to host cell
lines. Moreover, thorough early ADME (absorption, distribution, metabolism and
excretion), biological mechanism and animal studies are needed to evaluate the
potency of betulin-derived compounds in vivo.
80
References
1 Immonen, K., Nurmi, A. Biopolymeerin lisäaine. 2011. FI20115239A.
2 Ukkonen, K., Erä, V. Birch bark extractives. Kemia-Kemi 1979, 5, 217.
3 Ekman, R. The suberin monomers and triterpenoids from the outer bark of
Betula verrucosa Ehrh. 1985, Holzforschung 1983, 37, 205.
4 Eckerman, C., Ekman, R. Comparison of solvents for extraction and crystalli-
zation of betulinol from birch bark waste. Paperi ja puu 1985, 3, 100.
5 Koskimies, S., Hulkko, J., Pitkänen, P., Heiskanen, N., Yli-Kauhaluoma, J.,
Wähälä, K. Method for the manufacture of oligo- and polyesters from a mix-
ture of carboxylic acids obtained from suberin and/or cutin and the use
thereof. 2007, WO2007045728.
6 Alakurtti, S., Mäkelä, T., Koskimies, S., Yli-Kauhaluoma, J. Pharmacological
properties of the ubiquitous natural product betulin. Eur. J. Pharm. Sci. 2006,
29, 1.
7 Leung, J., Ng, M., Chu, J. Replication of alphaviruses: A review on the entry
process of alphaviruses into cells. Adv. Virol. 2011, Article ID 249640.
8 Strauss, J., Strauss, E. The alphaviruses: Gene expression, replication, and
evolution. Microbiol. Rev. 1994, 58, 491.
9 Weaver, S., Ferro, C., Barrera, R., Boshell, J., Navarro, J. Venezuelan eq-
uine encephalitis. Annu. Rev. Entomol. 2004, 49, 141.
10 Pialoux, G., Gauzere, B., Jaureguiberry, S., Strobel, M. Chikungunya, an
epidemic arbovirosis. Lancet Infect. Dis. 2007, 7, 319.
11 World Health Organization, WHO (who.int/health-topics/leishmaniasis.htm)
(2000).
12 Saha, P., Mukhopadhyay, D., Chatterjee, M. Immunomodulation by chemo-
therapeutic agents against leishmaniasis Int. Immunopharmacol. 2011, 11,
1668.
13 Croft, S., Seifert, K., Yardley, V. Current scenario of drug development for
leishmaniasis. Indian J. Med. Res. 2006, 123, 399.
81
14 Sundar, S. Drug resistance in Indian visceral leishmaniasis. Trop. Med. Int.
Health 2001, 6, 849.
15 Jha, T., Sundar, S., Thakur, C., Bachmann, P., Karbwang, J., Fischer, C.,
Voss, A., Berman, J. Miltefosine, an oral agent, for the treatment of Indian
visceral leishmaniasis. N. Engl. J. Med. 1999, 341, 1795.
16 Hammerschlag, M. Treatment of chlamydial infections. Expert Opin. Phar-
macother. 2012, 13, 545.
17 Boman, J., Hammerschlag, M. Chlamydia pneumoniae and atherosclerosis:
critical assessment of diagnostic methods and relevance to treatment stud-
ies. Clin. Microbiol. Rev. 2002, 15, 1.
18 Stratton, C., Sriram, S. Association of Chlamydia pneumoniae with central
nervous system disease. Microbes Infect. 2003, 5, 1249.
19 Bodetti, T., Jacobson, E., Wan, C., Hafner, L., Pospischil, A., Rose, K.,
Timms, P. Molecular evidence to support the expansion of the host range of
Chlamydophila pneumoniae to include reptiles as well as humans, horses,
koalas and amphibians. Syst. Appl. Microbiol. 2002, 25, 146.
20 Godzik, K., O’Brien, E., Wang, S., Kuo, C. In vitro susceptibility of human
vascular wall cells to infection with Chlamydia pneumoniae. J. Clin. Microbiol.
1995, 33, 2411.
21 Newman, D., Cragg, G. Natural products as sources of new drugs over the
last 25 years. J. Nat. Prod. 2007, 70, 461.
22 Kim, D., Chen, Z., Van Tuyen, N., Pezzuto, J., Qiu, S., Lu, Z. A concise
semi-synthetic approach to betulinic acid from betulin. Synth. Commun.
1997, 27, 1607.
23 Huang, L., Ho, P., Lee, K., Chen, C. Synthesis and anti-HIV activity of bi-
functional betulinic acid derivatives. Bioorg. Med. Chem. 2006, 14, 2279.
24 Soler, F., Poujade, C., Evers, M., Carry, J., Henin, Y., Bousseau, A., Huet,
T., Pauwels, R., De Clercq, E., Mayaux, J., Le Pecq, J., Dereu, N. Betulinic
acid derivatives: A new class of specific inhibitors of human immunodeficien-
cy virus type 1 entry. J. Med. Chem. 1996, 39, 1069.
25 Kanamoto, T., Kashiwada, Y., Kanbara, K., Gotoh, K., Yoshimori, M., Goto,
T., Sano, K., Nakashima, H. Anti-human immunodeficiency virus activity of
82
YK-FH312 (a betulinic acid derivative), a novel compound blocking viral mat-
uration. Antimicrob. Agents Chemother. 2001, 45, 1225.
26 Smith, P., Ogundele, A., Forrest, A., Wilton, J., Salzwedel, K., Doto, J.,
Allaway, G., Martin, D. Phase I and II study of the safety, virologic effect, and
pharmacokinetics/pharmacodynamics of single-dose 3-O-(30,30-
dimethylsuccinyl) betulinic acid (bevirimat) against human immunodeficiency
virus infection. Antimicrob Agents Chemother. 2007, 51, 3574.
27 Wainberg, A., Albert, J. Can the further clinical development of bevirimat be
justified? AIDS 2010, 24, 773.
28 Pisha, E., Chai, H., Lee, I., Chagwedera, T., Farnsworth, N., Cordell, G.,
Beecher, C., Fong, H., Kinghorn, A., Brown, D., Wani, M., Wall, M., Hieken,
T., Das Gupta, T., Pezzuto, J. Discovery of betulinic acid as a selective inhib-
itor of human melanoma that functions by induction of apoptosis. Nat. Med.
1995, 1, 1046.
29 Fulda, S., Friesen, C., Los, M., Scaffidi, C., Mier, W., Benedict, M., Nunez,
G., Krammer, P., Peter, M., Debatin, K. Betulinic acid triggers CD95 (APO-
1/Fas)- and p53-independent apoptosis via activation of caspases in neu-
roectodermal tumors. Cancer Res. 1997, 57, 4956.
30 Tan, Y., Yu, R., Pezzuto, J. Betulinic acid-induced programmed cell death in
human melanoma cells involves mitogen-activated protein kinase activation.
Clin. Cancer Res. 2003, 9, 2866.
31 http://www.ictvonline.org/virusTaxonomy.asp?version=2012
32 Baltimore, D. Expression of animal virus genomes. Microbiol. Mol. Biol. R.
1971, 35, 235.
33 Prescott, L., Harley, J., Klein, D. Microbiology.   2.  ed. 1993. Dubuque (IA):
Wm. C. Brown Publishers 1993.
34 Ray, A. Intracellular interactions between nucleos(t)ide inhibitors of HIV re-
verse transcriptase. AIDS Rev. 2005, 7, 113.
35 Huffman, J., Sidwell, R., Khare, G., Witkowski, J., Allen, L., Robins, R. In
vitro effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole,
ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses. Antimicrob.
Agents Chemother. 1973, 3, 235.
83
36 Smee, D., Alaghamandan, H., Kini, G., Robins, R. Antiviral activity and mode
of action of ribavirin 5'-sulfamate against Semliki Forest Virus. Antiviral Res.
1988, 10, 253.
37 Huggins, J., Robins, R., Canonico, P. Synergistic antiviral effects of ribavirin
and the C-nucleoside analogs tiazofurin and selenazofurin against Togavi-
ruses, Bunyaviruses, and Arenaviruses. Antimicrob. Agents Chemother.
1984, 26, 476.
38 De Clercq, E. Antiviral and antimetabolic activities of neplanocins. Antimi-
crob. Agents Chemother. 1985, 28, 84.
39 Van Aerschot, A., Herdewijn, P., Janssen, G., Cools, M., De Clercq, E. Syn-
thesis and antiviral activity evaluation of 3'-fluoro-3'-deoxyribonucleosides:
Broad-spectrum antiviral activity of 3'-fluoro-3'-deoxyadenosine. Antiviral
Res. 1989, 12, 133.
40 De Clercq, E., Bernaerts, R., Shealy, Y., Montgomery, J. Broad-spectrum
antiviral activity of carbodine, the carbocyclic analogue of cytidine. Biochem.
Pharmacol. 1990, 39, 319.
41 De Clercq, E., Murase, J., Marquez, V. Broad-spectrum antiviral and cyto-
cidal activity of cyclopentenylcytosine, a carbocyclic nucleoside targeted at
CTP synthetase. Biochem. Pharmacol. 1991, 41, 1821.
42 Briolant, S., Garin, D., Scaramozzino, N., Jouan, A., Crance, J. In vitro inhibi-
tion of Chikungunya and Semliki Forest Viruses replication by antiviral com-
pounds: Synergistic effect of interferon-alpha and ribavirin combination. Anti-
viral Res. 2004, 61, 111.
43 Pohjala, L., Utt, A., Varjak, M., Lulla, A., Merits, A., Ahola, T., Tammela, P.
Inhibitors of alphavirus entry and replication identified with a stable
Chikungunya replicon cell line and virus-based assays. PLoS One, 2011, 6,
e28923.
44 Peng, W., Peltier, D., Larsen, M., Kirchhoff, P., Larsen, S., Neubig, R., Miller,
D. Identification of thieno[3,2-b]pyrrole derivatives as novel small molecule
inhibitors of neurotropic alphaviruses. J. Infect. Dis. 2009, 199, 950.
45 Sindac, J., Yestrepsky, B., Barraza, S., Bolduc, K., Blakely, P., Keep, R.,
Irani, D., Miller, D., Larsen, S. Novel inhibitors of neurotropic alphavirus repli-
cation that improve host survival in a mouse model of acute viral Encephali-
tis. J. Med. Chem. 2012, 55, 3535.
84
46 Delogu, I., Pastorino, B., Baronti, C., Nougairede, A., Bonnet, E., de Lam-
ballerie, X. In vitro antiviral activity of arbidol against Chikungunya virus and
characteristics of a selected resistant mutant. Antiviral Res. 2011, 90, 99.
47 Hoffmann, H-H., Kunz, A., Simona, V., Palese, P., Shaw, M. Broad-spectrum
antiviral that interferes with de novo pyrimidine biosynthesis. Proc. Natl.
Acad. Sci. U. S. A. 2011, 108, 5777.
48 Markland, W., McQuaid, T., Jain, J., Kwong, A. Broad-spectrum antiviral
activity of the IMP dehydrogenase inhibitor VX-497: A comparison with rib-
avirin and demonstration of antiviral additivity with alpha interferon. Antimi-
crob. Agents Chemother. 2000, 44, 859.
49 Helenius, A., Marsh, M., White, J. Inhibition of Semliki Forest Virus penetra-
tion by lysosomotropic weak bases. J. Gen. Virol. 1982, 58, 47.
50 De Lamballerie, X., Boisson, V., Reynier, J., Enault, S., Charrel, R., Flahault,
A., Roques, P., Le Grand, R. On Chikungunya acute infection and chloro-
quine treatment. Vector Borne Zoonotic Dis. 2008, 8, 837.
51 Kim, H., Patkar, C., Warrier, R., Kuhn, R., Cushman, M. Design, synthesis,
and evaluation of dioxane-based antiviral agents targeted against the sindbis
virus capsid protein. Bioorg. Med. Chem. Lett. 2005, 15, 3207.
52 Li, Y., Wang, L., Li, S., Chen, X., Shen, Y., Zhang, Z., He, H., Xu, W., Shu,
Y., Liang, G., Fang, R., Hao, X. Seco-pregnane steroids target the subge-
nomic RNA of alphavirus-like RNA viruses. Proc. Natl. Acad. Sci. U. S. A.
2007, 104, 8083.
53 Kashiwada, Y., Hashimoto, F., Cosentino, L., Chen, C-H., Garrett, P., Lee, K-
H. Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV
agent. J. Med. Chem. 1996, 39, 1016.
54 Li, F., Goila-Gaur, R., Salzwedel, K., Kilgore, N., Reddick, M, Matallana, C.,
Castillo, A., Zoumplis, D., Martin, D., Orenstein, J., Allaway, G., Freed, E.,
Wild, C. PA-457: A potent HIV inhibitor that disrupts core condensation by
targeting a late step in Gag processing. Proc. Natl. Acad. Sci. U. S. A. 2003,
100, 13555.
55 Flekhter, O., Nigmatullina, L., Baltina, L., Karachurina, L., Galin, F., Zarudii,
F., Tolstikov, G., Boreko, E., Pavlova, N., Nikolaeva, S., Savinova, O. Syn-
thesis of betulinic acid from betulin extract and study of the antiviral and an-
tiulcer activity of some related terpenoids. Pharm. Chem. J. 2002, 36, 484.
85
56 Baltina, L., Flekhter, O., Nigmatullina, L., Boreko, E., Pavlova, N., Nikolaeve,
S., Savinova, O., Tolstikov, G. Lupane triterpenes and derivatives with antivi-
ral activity. Bioorg. Med. Chem. Lett. 2003, 13, 3549.
57 Pavlova, N., Savinova, O., Nikolaeva, S., Boreko, E., Flekhter, O. Antiviral
activity of betulin, betulinic and betulonic acids against some enveloped and
non-enveloped viruses. Fitoterapia 2003, 74, 489.
58 Handman, E. Cell biology of Leishmania. Adv. Parasitol. 1999, 44, 1.
59 http://en.wikipedia.org/wiki/File:Leishmaniasis_life_cycle_diagram_en.svg
60 Alexander, J., Satoskar, A., Russell, D. Leishmania species: Models of intra-
cellular parasitism. J. Cell Sci. 1999, 112, 2993.
61 WHO. Control of Leishmaniases. 1990. Geneva: World Health Organization.
62 Banuls, A-L., Hide, M., Prugnolle, F. Leishmania and the Leishmaniases: A
parasite genetic update and advances in taxonomy, epidemiology and path-
ogenicity in humans. Adv. Parasitol. 2007, 64, 1.
63 Alvar, J., Aparicio, P., Aseffa, A., Den Boer, M., Canavate, C., Dedet, J-P.,
Gradoni, L., Ter Horst, R., Lopez-Velez, R., Moreno, J. The Relationship be-
tween leishmaniasis and AIDS: The Second 10 Years. Clin. Microbiol. Rev.
2008, 21, 334.
64 Kedzierski, L., Zhu, Y., Handman, E. Leishmania vaccines: Progress and
problems. Parasitology 2006, 133, S87.
65 Tabbara, K. Progress towards a Leishmania vaccine. Saudi Med. J. 2006,
27, 942.
66 Croft, S., Coombs, G. Leishmaniasis - current chemotherapy and recent
advances in the search for novel drugs. Trends Parasitol. 2003, 19, 502.
67 Demicheli, C., Ochoa, R., da Silva, J., Falcao, C., Rossi-Bergmann, B., de
Melo, A., Sinisterra, R., Frezard, F. Oral delivery of meglumine antimoniate-
beta-cyclodextrin complex for treatment of leishmaniasis. Antimicrob. Agents
Chemother. 2004, 48, 100.
68 Sundar, S., More, D., Singh, M., Singh, V., Sharma, S., Makharia, A., Kumar,
P., Murray, H. Failure of pentavalent antimony in visceral leishmaniasis in In-
dia: Report from the center of the Indian epidemic. Clin. Infect. Dis. 2000, 31,
1104.
86
69 Burguera, J., Burguera, M., Petit de Pena, Y., Lugo, A., Anez, N. Selective
determination of antimony (III) and antimony (IV) in serum and urine and of
total antimony in skin biopsies of patients with entaneous leishmaniasis
treated with meglumine antimoniate. J. Trace Elem. Med. Biol. 1993, 10, 66.
70 Cunningham, M., Zvelebil, M., Fairlamb, A. Mechanism of inhibition of trypa-
nothione reductase and glutathione reductase by trivalent organic arsenicals.
Eur. J. Biochem. 1994, 221, 285.
71 Sudhandiran, G., Shaha, C. Antimonial-induced increase in intracellular Ca2+
through non-selective cation channels in the host and the parasite is respon-
sible for apoptosis of intracellular Leishmania donovani amastigotes. J. Biol.
Chem. 2003, 278, 25120.
72 Fox, K., Sansom, C., Stevens, M. Footprinting studies on the sequence-
selective binding of pentamidine to DNA. FEBS Lett. 1990, 266, 150.
73 Assan, R., Perronne, C., Assan, D., Chotard, L., Mayaud, C., Matheron, S.,
Zucman, D. Pentamidine-induced derangements of glucose homeostasis.
Determinant roles of renal failure and drug accumulation. A study of 128 pa-
tients. Diabetes Care, 1995, 18, 47.
74 Antoniou, T., Gough, K. Early-onset pentamidine-associated second-degree
heart block and sinus bradycardia: Case report and review of the literature.
Pharmacotherapy, 2005, 25, 899.
75 Bray, P., Barrett, M., Ward, S., de Koning, H. Pentamidine uptake and re-
sistance in pathogenic protozoa: Past, present and future. Trends Parasitol.
2003, 19, 232.
76 Saha, A., Mukherjee, T., Bhaduri, A. Mechanism of action of amphotericin B
on Leishmania donovani promastigotes. Mol. Biochem. Parasitol. 1986, 19,
195.
77 Hann, I., Prentice, H. Lipid-based amphotericin B: A review of the last 10
years of use. Int. J. Antimicrob. Agents, 2001, 17, 161.
78 Ostrosky-Zeichner, L., Marr, K., Rex, J., Cohen, S. Amphotericin B: Time for
a new ''gold standard''. Clin. Infect. Dis. 2003, 37, 415.
79 Sundar, S., Agrawal, N., Arora, R., Agarwal, D., Rai, M., Chakravarty, J.
Short-course paromomycin treatment of visceral leishmaniasis in India: 14-
Day vs 21-day treatment. Clin. Infect. Dis. 2009, 49, 914.
87
80 Sundar, S., Jha, T., Thakur, C., Sinha, P., Bhattacharya, S. Injectable paro-
momycin for visceral leishmaniasis in India. N. Engl. J. Med. 2007, 356,
2571.
81 Maarouf, M., de Kouchkovsky, Y., Brown, S., Petit, P., Robert-Gero, M. In
vivo interference of paromomycin with mitochondrial activity of Leishmania.
Exp. Cell. Res. 1997, 232, 339.
82 Maarouf, M., Lawrence, F., Croft, S., Robert-Gero, M. Ribosomes of Leish-
mania are a target for the aminoglycosides. Parasitol. Res. 1995, 81, 421.
83 Yeates, C. Sitamaquine (GlaxoSmithKline/Walter Reed Army Institute). Curr.
Opin. Investig. Drugs 2002, 3, 1446.
84 Jha, T., Sundar, S., Thakur, C., Felton, J., Sabin, A., Horton, J. A phase II
dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis
in India. Am. J. Trop. Med. Hyg. 2005, 73, 1005.
85 Vercesi, A., Docampo, R. Ca2+ transport by digitoninpermeabilized Leish-
mania donovani. Effects of Ca2+, pentamidine and WR-6026 on mitochondrial
membrane potential in situ. Biochem. J. 1992, 284, 463.
86 Vercesi, A., Rodrigues, C., Catisti, R., Docampo, R. Presence of a
Na(+)/H(+) exchanger in acidocalcisomes of Leishmania donovani and their
alkalization by anti-leishmanial drugs. FEBS Lett. 2000, 473, 203.
87 Croft, S., Engel, J. Miltefosine - discovery of the antileishmanial activity of
phospholipid derivatives. Trans. R. Soc. Trop. Med. Hyg. 2006, 100, S4.
88 Bhattacharya, S., Sinha, P., Sundar, S., Thakur, C., Jha, T., Pandey, K.,
Das, V., Kumar, N., Lal, C., Verma, N., Singh, V., Ranjan, A., Verma, R., An-
ders, G., Sindermann, H., Ganguly, N. Phase 4 trial of miltefosine for the
treatment of Indian visceral leishmaniasis. J. Infect. Dis. 2007, 196, 591.
89 Sindermann, H., Engel, J. Development of miltefosine as an oral treatment
for leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 2006, 100, S17.
90 Lux, H., Heise, N., Klenner, T., Hart, D., Opperdoes, F. Ether - lipid (alkyl-
phospholipid) metabolism and the mechanism of action of ether-lipid ana-
logues in Leishmania. Mol. Biochem. Parasitol. 2000, 111, 1.
91 Luque-Ortega, J., Rivas, L. Miltefosine (hexadecylphosphocholine) inhibits
cytochrome c oxidase in Leishmania donovani promastigotes. Antimicrob.
Agents Chemother. 2007, 51, 1327.
88
92 Rakotomanga, M., Blanc, S., Gaudin, K., Chaminade, P., Loiseau, P.
Miltefosine affects lipid metabolism in Leishmania donovani promastigotes.
Antimicrob. Agents Chemother. 2007, 51, 1425.
93 Calvopina, M., Guevara, A., Armijos, R., Hashiguchi, Y., Davidson, R.,
Cooper, P. Itraconazole in the treatment of new world mucocutaneous leish-
maniasis. Int. J. Dermatol. 2004, 43, 659.
94 Saenz, R., Paz, H., Berman, J. Efficacy of ketoconazole against Leishmania
braziliensis panamensis cutaneous leishmaniasis. Am. J. Med. 1990, 89,
147.
95 Alrajhi, A., Ibrahim, E., Devol, E., Khairat, M., Faris, R., Maguire, J. Flucona-
zole for the treatment of cutaneous leishmaniasis caused by Leishmania ma-
jor. N. Engl. J. Med. 2002, 346, 891.
96 Martinez, S., Marr, J. Allopurinol in the treatment of American cutaneous
leishmaniasis. N. Engl. J. Med. 1992, 326, 741.
97 Velez, I., Agudelo, S., Hendrickx, E., Puerta, J., Grogl, M., Modabber, F.,
Berman, J. Inefficacy of allopurinol as monotherapy for Colombian cutaneous
leishmaniasis: A randomized, controlled trial. Ann. Intern. Med. 1997, 126,
232.
98 Arevalo, I., Ward, B., Miller, R., Meng, T., Najar, E., Alvarez, E. Matlash-
ewski, G., Llanos-Cuentas, A. Successful treatment of drug-resistant cutane-
ous leishmaniasis in humans by use of imiquimod, an immunomodulator.
Clin. Infect. Dis. 2001, 33, 1847.
99 Dogra, J. A double-blind study on the efficacy of oral dapsone in cutaneous
leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 1991, 85, 212.
100 Prata, A., Silva-Vergara, M., Costa, L., Rocha, A., Krolewiecki, A., Silva, J.,
de Paula, E., Pimenta, F., Giraldo, L. Efficacy of azithromycin in the treat-
ment of cutaneous leishmaniasis. Rev. Soc. Bras. Med. Trop. 2003, 36, 65.
101 Layegh, P., Yazdanpanah, M., Vosugh, E., Pezeshkpoor, F., Shakeri, M.,
Moghiman, T. Efficacy of azithromycin versus systemic meglumine antimoni-
ate (glucantime) in the treatment of cutaneous leishmaniasis. Am.  J.  Trop.
Med. Hyg. 2007, 77, 99.
102 Al-Abdely, H., Graybill, J., Loebenberg, D., Melby, P. Efficacy of the triazole
SCH 56592 against Leishmania amazonensis and Leishmania donovani in
89
experimental murine cutaneous and visceral leishmaniases. Antimicrob.
Agents Chemother. 1999, 43, 2910.
103 Pagniez, F., Abdala-Valencia, H., Marchand, P., Leborgne M., Le Baut, G.,
Robert-Piessard, S., Le Pape, P. Antileishmanial activities and mechanisms
of action of indole-based azoles. J. Enzyme Inhib. Med. Chem. 2006, 21,
277.
104 Verma, A., Srivastava, S., Sane, S., Marrapu, V., Srinivas, N., Yadav, M.,
Bhandari, K., Gupta S. Antileishmanial activity of benzocycloalkyl azole
oximino ethers: The conformationally constraint analogues of oxiconazole.
Acta Trop, 2011, 117, 157.
105 Bhandari, K., Srinivas, N., Marrapu, V., Verma, A., Srivastava, S., Gupta, S.
Synthesis of substituted aryloxy alkyl and aryloxy aryl alkyl imidazoles as an-
tileishmanial agents. Bioorg. Med. Chem. Lett. 2010, 20, 291.
106 Mendez, S., Traslavina, R., Hinchman, M., Huang, L., Green, P., Cynamon,
M., Welch, J. The antituberculosis drug pyrazinamide affects the course of
cutaneous leishmaniasis in vivo and increases activation of macrophages
and dendritic cells. Antimicrob. Agents Chemother. 2009, 53, 5114.
107 Wang, M., Zhu, X., Srivastava, A., Liu, Q., Sweat, M., Pandharkar, T., Ste-
phens, C., Riccio, E., Parman, T., Munde, M., Mandal, S., Madhubala, R.,
Tidwell, R., Wilson, D., Boykin, D., Hall, J., Kyle, D., Werbovetz, K. Novel ar-
ylimidamides for treatment of visceral leishmaniasis. Antimicrob. Agents
Chemother. 2010, 54, 2507.
108 Palit, P., Ali, N. Oral therapy with amlodipine and lacidipine, 1,4-
dihydropyridine derivatives showing activity against experimental visceral
leishmaniasis. Antimicrob. Agents Chemother. 2008, 52, 374.
109 Agarwal, K., Sharma, V., Shakya, N., Gupta, S. Design and synthesis of
novel substituted quinazoline derivatives as antileishmanial agents. Bioorg.
Med. Chem. Lett. 2009, 19, 5474.
110 Nanayakkara, N., Ager, A., Bartlett, M., Yardley, V., Croft, S., Khan, I.,
McChesney, J., Walker, L. Antiparasitic activities and toxicities of individual
enantiomers of the 8-aminoquinoline 8-[(4-amino-1-methylbutyl)amino]-6-
methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline succinate. Antimicrob.
Agents Chemother. 2008, 52, 2130.
90
111 Fournet,  A.,  Ferreira,  M.,  Rojas  De Arias,  A.,  Torres  De Ortiz,  S.,  Fuentes,
S., Nakayama, H., Schinini,  A., Hocquemiller, R. In vivo efficacy of oral and
intralesional administration of 2-substituted quinolines in experimental treat-
ment of new world cutaneous leishmaniasis caused by Leishmania ama-
zonensis. Antimicrob. Agents Chemother. 1996, 40, 2447.
112 Nakayama, H., Loiseau, P., Bories, C., Torres de Ortiz, S., Schinini, A.,
Serna, E., Rojas de Arias, A., Fakhfakh, M., Franck, X., Figadere, B.,
Hocquemiller, R., Fournet, A. Efficacy of orally administered 2-substituted
quinolines in experimental murine cutaneous and visceral leishmaniases. An-
timicrob. Agents Chemother. 2005, 49, 4950.
113 Palit, P., Paira, P., Hazra, A., Banerjee, S., Gupta, A., Dastidar, S., Mondal,
N. Phase transfer catalyzed synthesis of bisquinolines: Antileishmanial activi-
ty in experimental visceral leishmaniasis and in vitro antibacterial evaluation.
Eur. J. Med. Chem. 2009, 44, 845.
114 Khaliq, T., Misra, P., Gupta, S., Reddy, K., Kant, R., Maulik, P., Dube, A.,
Narender, T. Peganine hydrochloride dihydrate an orally active antileishma-
nial agent. Bioorg. Med. Chem. Lett. 2009, 19, 2585.
115 Vennerstrom, J., Lovelace, J., Waits, V., Hanson, W., Klayman, D. Berberine
derivatives as antileishmanial drugs. Antimicrob. Agents Chemother. 1990,
34, 918.
116 Yang, M., Arai, C., Bakar, A., Lu, J., Ge, J., Pudhom, K., Takasu, K., Kasai,
K., Kaiser, M., Brun, R. Yardley, V., Itoh, I., Ihara, M. Fluorinated rhodacya-
nine (SJL-01) possessing high efficacy for visceral leishmaniasis (VL). J.
Med. Chem. 2010, 53, 368.
117 Serrano-Martin, X., Payares, G., De Lucca, M., Martinez, J., Mendoza-Leon,
A., Benaim, G. Amiodarone and miltefosine act synergistically against
Leishmania mexicana and can induce parasitological cure in a murine model
of cutaneous leishmaniasis. Antimicrob. Agents Chemother. 2009, 53, 5108.
118 Mittra, B., Saha, A., Chowdhury, A., Pal, C., Mandal, S., Mukhopadhyay, S.,
Bandyopadhyay, S., Majumder, H. Luteolin, an abundant dietary component
is a potent anti-leishmanial agent that acts by inducing topoisomerase II-
mediated kinetoplast DNA cleavage leading to apoptosis. Mol. Med. 2000, 6,
527.
91
119 Sen, G., Mandal, S., Roy, S., Mukhopadhyay, S., Biswas, T. Therapeutic use
of quercetin in the control of infection and anemia associated with visceral
leishmaniasis. Free Radical Biol. Med. 2005, 38, 1257.
120 Croft, S., Hogg, J., Gutteridge, W., Hudson, A., Randall, A. The activity of
hydroxynaphthoquinones against Leishmania donovani. J. Antimicrob.
Chemother. 1992, 30, 827.
121 Reimao, J., Colombo, F., Pereira-Chioccola, V., Tempone, A. Effectiveness
of liposomal buparvaquone in an experimental hamster model of Leishmania
(L.) infantum chagasi. Exp. Parasitol. 2012, 130, 195.
122 Torres-Santos, E., Rodrigues, J., Moreira, D., Kaplan, M., Rossi-Bergmann,
B. Improvement of In vitro and in vivo antileishmanial activities of 29,69-
dihydroxy-49-methoxychalcone by entrapment in poly(D,L-lactide) nanoparti-
cles. Antimicrob. Agents Chemother. 1999, 43, 1776.
123 Torres-Santos, E., Sampaio-Santos, M., Buckner, F., Yokoyama, K., Gelb,
M., Urbina J., Rossi-Bergmann, B. Altered sterol profile induced in Leishma-
nia amazonensis by a natural dihydroxymethoxylated chalcone. J. Antimi-
crob. Chemother. 2009, 63, 469.
124 Chen, M., Christiensen, S., Theander, T., Kharasmi, A. Antileishmanial activi-
ty of licochalcone A in mice infected with Leishmania major and in hamsters
infected with Leishmania donovani. Antimicrob. Agents Chemother. 1994,
38, 1339.
125 Zhai, L., Chen, M., Blom, J., Theander, T., Christensen, S., Kharazmi, A. The
antileishmanial activity of novel oxygenated chalcones and their mechanism
of action. J. Antimicrob. Chemother. 1999, 43, 793.
126 Medda, S., Mukhopadhyay, S., Basu, M. Evaluation of the in vivo activity and
toxicity of amarogentin, an antileishmanial agent, in both liposomal and nio-
somal forms. J. Antimicrob. Chemother. 1999, 44, 791.
127 Waechter, A., Ferreira, M., Fournet, A., Rojas de Arias, A., Nakayama, H.,
Torres, S., Hocquemiller, R., Cave, A. Experimental treatment of cutaneous
leishmaniasis with argentilactone isolated from Annona haematantha. Planta
Med. 1997, 63, 433.
128 Croft, S., Snowdon, D., Yardley, V. The activities of four anticancer alkyllyso-
phospholipids against Leishmania donovani, Trypanosoma cruzi and Trypa-
nosoma brucei. J. Antimicrob. Chemother. 1996, 38, 1041.
92
129 Cabrera-Serra, M., Valladares, B., Pinero J. In vivo activity of perifosine
against Leishmania amazonensis. Acta Trop. 2008, 108, 20.
130 Rodriguez, N., Bailey, B., Martin, M., Oldfield, E., Urbina, J., Docampo, R.
Radical cure of experimental cutaneous leishmaniasis by the bisphospho-
nate pamidronate. J. Infect. Dis. 2002, 186, 138.
131 Yardley, V., Khan, A., Martin, M., Slifer, T., Araujo, F., Moreno, S., Docampo,
R., Croft, S., Oldfield, E. In vivo activities of farnesyl pyrophosphate synthase
inhibitors against Leishmania donovani and Toxoplasma gondii. Antimicrob.
Agents Chemother. 2002, 46, 929.
132 Roldos, V., Nakayama, H., Rolo, M., Trucco, F., Torres, S., Vegan, C., Mar-
rero-Ponce, Y., Heguaburu, V., Yaluff, G., Gomez-Barrio, A., Sanabria, L.,
Ferreira, M., Rojas de Arias, A., Pandolfi, E. Activity of a hydroxybibenzyl
bryophyte constituent against Leishmania spp. and Trypanosoma cruzi: In
silico, in vitro and in vivo activity studies. Eur. J. Med. Chem. 2008, 43, 1797.
133 Miguel, D., Yokoyama-Yasunaka, J., Uliana, S. Tamoxifen is effective in the
treatment of Leishmania amazonensis infections in mice. PLoS Negl. Trop.
Dis. 2008, 2, e249.
134 Maes, L., Germonprez, N., Quirijnen, L., Van Puyvelde, L., Cos, P., Vanden
Berghe, D. Comparative activities of the triterpene saponin maesabalide III
and liposomal amphotericin B (AmBisome) against Leishmania donovani in
hamsters. Antimicrob. Agents Chemother. 2004, 48, 2056.
135 Inocencio da Luz, R., Vermeersch, M., Deschacht, M., Hendrickx, S., Van
Assche, T., Cos P., Maes L. In vitro and in vivo prophylactic and curative ac-
tivity of the triterpene saponin PX-6518 against cutaneous Leishmania spe-
cies. J. Antimicrob. Chemother. 2011, 66, 350.
136 Germonprez, N., Maes, L., Van Puyvelde, L., Van Tri, M., Tuan, D., De
Kimpe, N. In vitro and in vivo anti-leishmanial activity of triterpenoid saponins
isolated from Maesa balansae and some chemical derivatives. J. Med.
Chem. 2005, 48, 32.
137 Sen, R., Ganguly, S., Saha, P., Chatterjee, M. Efficacy of artemisinin in ex-
perimental visceral leishmaniasis. Int. J. Antimicrob. Agents 2010, 36, 43.
138 Sauvain, M., Kunesch, N., Poisson, J., Gantier, J-C., Gayral, P., Dedet, J-P.
Isolation of leishmanicidal triterpenes and lignans from the Amazonian liana
Doliocarpus dentatus (Dilleniaceae). J. Phytother. Res. 1996, 10, 1.
93
139 Takahashi, M., Fuchino, H., Sekita, S., Satake, M. In vitro leishmanicidal
activity of some scarce natural products. Phytother. Res. 2004, 18, 573.
140 Chowdhury, A., Mandal, S., Goswami A., Ghosh, M., Mandal, L.,
Chakraborty, D., Ganguly, A., Tripathi, G., Mukhopadhyay, S., Bandyopadh-
yay, S., Majumder, H. Dihydrobetulinic acid induces apoptosis in Leishmania
donovani by targeting DNA topoisomerase I and II: Implications in antileish-
manial therapy. Mol. Med. 2003, 9, 26.
141 Chowdhury, S., Mukherjee, T., Sengupta, S., Chowdhury, S., Mukhopadh-
yay, S., Majumder, H. Novel betulin derivatives as antileishmanial agents
with mode of action targeting type IB DNA topoisomerase. Mol. Pharmacol.
2011, 80, 694.
142 Beagley, K., Huston, W., Hansbro, P., Timms, P. Chlamydial infection of
immune cells: Altered function and implications for disease. Crit. Rev. 2009,
29, 275.
143 Beatty, W., Morrison, R., Byrne, G. Persistent Chlamydiae: From cell culture
to a paradigm for chlamydial pathogenesis. Microb. Rev. 1994, 58, 686.
144 Ward, M., Murray, A. Control mechanisms governing the infectivity of Chla-
mydia trachomatis for HeLa cells: Mechanisms of endocytosis. J. Gen. Mi-
crobiol. 1984, 130, 1765.
145 Hodinka, R., Davis, C., Choong, J., Wyrick, P. Ultrastructural study of endo-
cytosis of Chlamydia trachomatis by McCoy cells. Infect. Immun. 1988, 56,
1456.
146 http://en.wikipedia.org/wiki/Chlamydophila_pneumoniae
147 Hogan, R., Mathews, S., Mukhopadhyay, S., Summersgill, J., Timms, P.
Chlamydial persistence: Beyond the biphasic paradigm. Infect. Immun. 2004,
72, 1843.
148 Patton, D., Askienazy-Elbhar, M., Henry-Suchet, J., Campbell, L., Cappuc-
cio, A., Tannous, W., Wang, S., Kuo, C. Detection of Chlamydia trachomatis
in fallopian tube tissue in women with postinfectious tubal infertility. Am. J.
Obstet. Gynecol. 1994, 171, 95.
149 Hammerschlag, M., Chirgwin, K., Roblin, P., Gelling, M., Dumornay, W.,
Mandel, L., Smith, P., Schachter, J. Persistent infection with Chlamydia
94
pneumoniae following acute respiratory illness. Clin. Infect. Dis. 1992, 14,
178.
150 Kuo, C., Grayston, J. In vitro drug susceptibility of Chlamydia sp. strain
TWAR. Antimicrob. Agents Chemother. 1988, 32, 257.
151 Kuo, C., Jackson, L., Campbell, L., Grayston, J. Chlamydia pneumoniae
(TWAR). Clin. Microbiol. Rev. 1995, 8, 451.
152 Grayston, J. Infections caused by Chlamydia pneumoniae strain TWAR. Clin.
Infect. Dis. 1992, 15, 757.
153 De Sarro, A., De Sarro, G. Adverse reactions to fluoroquinolones. An over-
view on mechanistic aspects. Curr. Med. Chem. 2001, 8, 371.
154 Roblin, P., Hammerschlag, M. In vitro activity of a new 8-methoxyquinolone,
BAY 12-8039, against Chlamydia pneumoniae. Antimicrob. Agents
Chemother. 1998, 42, 951.
155 Malay, S., Roblin, P., Reznik, T., Kutlin, A., Hammerschlag, M. In vitro activi-
ties of BMS-284756 against Chlamydia trachomatis and recent clinical iso-
lates of Chlamydia pneumoniae. Antimicrob. Agents Chemother. 2002, 46,
517.
156 Fung-Tomc, J., Minassian, B., Huczko, B., Aleksunes, L., Stickle, T., Washo,
T., Gradelski, E., Valera L., Bonner, D. Antibacterial spectrum of a novel des-
fluoro(6) quinolone, BMS-284756. Antimicrob. Agents Chemother. 2000, 44,
3351.
157 Miyashita, N., Niki, Y., Matsushima, T. In vitro and in vivo activities of
sitafloxacin against Chlamydia spp. Antimicrob. Agents Chemother. 2001,
45, 3270.
158 Hammerschlag, M., Hyman, C., Roblin, P. In Vitro Activities of five quin-
olones against Chlamydia pneumoniae. Antimicrob. Agents Chemother.
1992, 36, 682.
159 Ameyama, S., Shinmura, Y., Takahata, M. Inhibitory Activities of quinolones
against DNA gyrase of Chlamydia pneumoniae. Antimicrob. Agents
Chemother. 2003, 47, 2327.
160 Roblin, P., Reznik, T., Hammerschlag, M. In vitro activity of garenoxacin
against recent clinical isolates of Chlamydia pneumoniae. Int. J. Antimicrob.
Agents. 2003, 21, 578.
95
161 Roblin, P., Hammerschlag, M. In vitro activity of gatifloxacin against Chla-
mydia trachomatis and Chlamydia pneumoniae. J. Antimicr. Chemother.
1999, 44, 549.
162 Soejima, R., Niki, Y., Kishimoto, T., Miyashita, N., Kubota, Y., Nakata, K. In
vitro and in vivo activities of sparfloxacin and reference drugs against Chla-
mydia pneumonia. J. Infect. Chemother. 1995, 1, 107.
163 Roblin, P., Reznik, T., Kutlin, A., Hammerschlag, M. In vitro activities of
gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chla-
mydia pneumoniae. Antimicrob. Agents Chemother. 1999, 43, 2806.
164 Yamaguchi, K. Evaluation of in vitro and in vivo antibacterial activity of to-
sufloxacin tosilate. J. Infect. Chemother. 2001, 7, 205.
165 Roblin, P., Montalban, G., Hammerschlag, M. In vitro activities of OPC-
17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia
pneumoniae. Antimicrob. Agents Chemother. 1994, 38, 1402.
166 Hammerschlag, M., Qumei, L., Roblin, P. In Vitro activities of azithromycin,
clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneu-
moniae. Antimicrob. Agents Chemother. 1992, 36, 1573.
167 Roblin, P., Kutlin, A., Hammerschlag, M. In vitro activity of trovafloxacin
against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 1997, 41,
2033.
168 Chopra, I., Roberts, M. Tetracycline antibiotics: Mode of action, applications,
molecular biology, and epidemiology of bacterial resistance. Microbiol. Mol.
Biol. Rev. 2001, 65, 232.
169 Schnappinger, D., Hillen, W. Tetracyclines: Antibiotic action, uptake, and
resistance mechanisms. Arch. Microbiol. 1996, 165, 359.
170 Yamaguchi, H., Friedman, H., Yamamoto, M., Yasuda, K., Yamamoto, Y.
Chlamydia pneumoniae resists antibiotics in lymphocytes. Antimicrob.
Agents Chemother. 2003, 47, 1972.
171 Kuo, C., Grayston, J. In vitro drug susceptibility of Chlamydia sp. strain
TWAR. Antimicrob. Agents Chemother. 1988, 32, 257.
172 Gamerdinger, M., Deuerling, E. Macrolides: The plug is out. Cell 2012, 151,
469.
96
173 Miyashita, N., Fukano, H., Yoshida, K., Niki, Y., Matsushima, T. In vitro ac-
tivity of cethromycin, a novel antibacterial ketolide, against Chlamydia pneu-
moniae. J. Antimicrob. Chemother. 2003, 52, 497.
174 Roblin, P., Kutlin, A., Sokolovskaya, N., Hammerschlag, M. In vitro activity of
dirithromycin against Chlamydia pneumoniae. J. Antimicrob. Chemother.
1997, 39, 647.
175 Roblin, P., Hammerschlag, M. In vitro activity of a new ketolide antibiotic,
HMR 3647, against Chlamydia pneumoniae. Antimicrob. Agents Chemother.
1998, 42, 1515.
176 Agouridas, C., Denis, A., Auger, J-M., Benedetti, Y., Bonnefoy, A., Bretin, F.,
Chantot, J-F., Dussarat, A., Fromentin, C., Gouin D’Ambrie`res, S., Lachaud,
S., Laurin, P., Le Martret, O., Loyau, V., Tessot N. Synthesis and antibacteri-
al activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): A new
class of antibacterials highly potent against macrolide-resistant and -
susceptible respiratory pathogens. J. Med. Chem. 1998, 41, 4080.
177 Zeitlinger, M., Wagner, C., Heinisch, B. Ketolides - the modern relatives of
macrolides. The pharmacokinetic perspective. Clin. Pharmacokinet. 2009,
48, 23.
178 Strigl, S., Roblin, P., Reznik, T., Hammerschlag, M. In vitro activity  of  ABT
773, a new ketolide antibiotic, against Chlamydia pneumoniae. Antimicrob.
Agents Chemother. 2000, 44, 1112.
179 Roblin, P., Kohlhoff, S., Parker, C., Hammerschlag, M. In vitro activity of
CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and
Chlamydia (Chlamydophila) pneumoniae. Antimicrob. Agents Chemother.
2010, 54, 1358.
180 Floss, H., Yu, T-W. Rifamycins - mode of action, resistance, and biosynthe-
sis. Chem. Rev. 2005, 105, 621.
181 Sensi, P., Margilith, P., Timbal, M. Rifamycin, a new antibiotic. Farmaco, Ed.
Sci. 1959, 14,146.
182 Calvori, C., Frontali, L., Leoni, L., Tecce, G. Effect of rifamycin on protein
synthesis. Nature 1965, 207, 417.
183 Roblin, P., Reznik, T., Kutlin, A., Hammerschlag, M. In vitro activities  of  ri-
famycin derivatives ABI-1648 (rifalazil, KRM-1648), ABI-1657, and ABI-1131
97
against Chlamydia trachomatis and recent clinical isolates of Chlamydia
pneumoniae. Antimicrob. Agents Chemother. 2003, 47, 1135.
184 Gieffers, J., Solbach W., Maass, M. In vitro susceptibilities of Chlamydia
pneumoniae strains recovered from atherosclerotic coronary arteries. Antimi-
crob. Agents Chemother. 1998, 42, 2762.
185 Gieffers, J., Solbach, W., Maass, M. In vitro susceptibility and eradication of
Chlamydia Pneumoniae cardiovascular strains from coronary artery endothe-
lium and smooth muscle cells. Cardiovasc. Drugs Ther. 2001, 15, 259.
186 Alvesalo, J., Vuorela, H., Tammela, P., Leinonen, M., Saikku, P., Vuorela, P.
Inhibitory effect of dietary phenolic compounds on Chlamydia pneumoniae in
cell cultures. Biochem. Pharmacol. 2006, 71, 735.
187 Törmäkangas, L., Vuorela, P., Saario, E., Leinonen, M., Saikku, P., Vuorela,
H. In vivo treatment of acute Chlamydia pneumoniae infection with the flavo-
noids quercetin and luteolin and an alkyl gallate, octyl gallate, in a mouse
model. Biochem. Pharmacol. 2005, 70, 1222.
188 Yamazaki, T., Inoue, M., Sasaki, N., Hagiwara, T., Kishimoto, T., Shiga, S.,
Ogawa, M., Matsumoto, T. In vitro inhibitory effects of tea polyphenols on the
proliferation of Chlamydia trachomatis and Chlamydia pneumoniae. Jpn. J.
Infect. Dis. 2003, 56, 143.
189 Salin, O., Törmäkangas, L., Leinonen, M., Saario, E., Hagström, M., Ketola,
R., Saikku, P., Vuorela, H., Vuorela, P. Corn mint (Mentha arvensis) Extract
diminishes acute Chlamydia pneumoniae infection in vitro and in vivo. J.
Agric. Food Chem. 2011, 59, 12836.
190 Puolakkainen, M., Lee, A., Nosaka, T., Fukushi, H., Kuo, C-C., Campbell, L.
Retinoic acid inhibits the infectivity and growth of Chlamydia pneumoniae in
epithelial and endothelial cells through different receptors. Microb. Pathog.
2008, 44, 410.
191 Jiang, S-J., Campbell, L., Berry, M., Rosenfeld, M., Kuo, C. Retinoic acid
prevents Chlamydia pneumoniae-induced foam cell development in a mouse
model of atherosclerosis. Microb. Infect. 2008, 10, 1393.
192 Hess, S., Brum, R., Honda, N., Cruz, A., Moretto, E., Cruz, R., Messana, I.,
Ferrari, F., Cechinel Filho, V., Yunes, R. Antibacterial activity and phyto-
chemical analysis of Vochysia divergens (Vochysiaceae). J. Ethnopharma-
col. 1995, 47, 97.
98
193 Nick, A., Wright, A., Rali, T., Sticher, O. Antibacterial triterpenoids from Dille-
nia papuana and their structure–activity relationships. Phytochemistry 1995,
40, 1691.
194 Fontanay, S., Grare, M., Mayer, J., Finance, C., Duval, R. Ursolic, oleanolic
and betulinic acids: Antibacterial spectra and selectivity indexes. J. Eth-
nopharmacol. 2008, 120, 272.
195 http://www.pherobase.com/
196 Khadem, S., Marles, R. Monocyclic phenolic acids; hydroxy- and polyhy-
droxybenzoic acids: Occurrence and recent bioactivity studies. Molecules,
2010, 15, 7985.
197 Rocha, L., Monteiro, M., Teodoro, A. Anticancer properties of hy-
droxycinnamic acids - a review. Cancer Clin. Oncol. 2012, 1, 109.
198 Leffler, M., Calkins, A. l-Menthoxyacetic acid. Org. Synth. 1943, 23, 52.
199 Corey, E., Suggs, J. Pyridinium chlorochromate. An efficient reagent for
oxidation of primary and secondary alcohols to carbonyl compounds. Tetra-
hedron Lett. 1975, 16, 2647.
200 Petrenko N., Elantseva N., Petukhova V., Shakirov M., Shults E., Tolstikov
G. Synthesis of betulonic acid derivatives containing aminoacid fragments.
Chem. Nat. Comp. 2002, 38, 331.
201 Presser, A., Hufner, A. Trimethylsilyldiazomethane – a mild and efficient
reagent for the methylation of carboxylic acids and alcohols in natural prod-
ucts. Monatsh. Chem. 2004, 135, 1015.
202 Komissarova, N., Belenkova, N., Spirikhin, L., Shitikova, O., Yunusov, M.
Selective oxidation of betulin by Cr(VI) reagents. Chem. Nat. Comp. 2002,
38, 58.
203 Green, B., Bentley, M., Chung, B., Lynch, N., Jensen, B. Isolation of betulin
and rearrangement to allobetulin. A biomimetic natural product synthesis. J.
Chem. Educ. 2007, 84, 1985.
204 Sun, I-C., Wang, H-K., Kashiwada, Y., Shen, J-K., Cosentino, L., Chen, C-H.,
Yang, L-M., Lee, K-H. Anti-aids agents. 34. Synthesis and structureíactivity
relationships of betulin derivatives as anti-hiv agents J. Med. Chem. 1998,
41, 4648.
99
205 Flekhter, O., Ashavina, O., Boreko, E., Karachurina, L., Pavlova, N., Kabal-
nova, N., Savinova, O., Galin, F., Nikolaeva, S., Zarudii, F., Baltina, L.,
Tolstikov, G. Synthesis of 3-O-acetylbetulinic and betulonic aldehydes ac-
cording to Svern and the pharmacological activity of related oximes. Pharm.
Chem. J. 2002, 36, 303.
206 a) Suokas, E., Hase, T. Triterpenes. A novel acid catalysed double bond
migration in 3ȕ,28-diacetoxy-lup-20(30)-ene (betulin diacetate). Acta Chem.
Scand. B, 1975, 29, 139. b) Suokas, E., Hase, T. Triterpenes. p-
Toluenesulfonic acid catalysed rearrangement of 18Į,19Į and 18ȕ,19ȕ iso-
mers of 3ȕ,28-diacetoxy-epoxylupane. Acta Chem. Scand. B, 1977, 31, 182.
207 Moriarty, R., Prakash, I., Penmasta, R. An improved synthesis of ethyl azodi-
carboxylate and 1,2,4-triazoline-3,5-diones using hypervalent iodine oxida-
tion. Synth. Commun. 1987, 17, 409.
208 a) Cookson, R., Gupte, S., Stevens, I., Watts, C. 4-Phenyl-1,2,4-triazoline-
3,5-dione. Org. Synth. 1971, 51, 121. b) Kiriazis, A., Rüffer, T., Jäntti, S.,
Lang, H., Yli-Kauhaluoma, J. Stereoselective aza DielsíAlder reaction on
solid phase:Ԝ A facile synthesis of hexahydrocinnoline derivatives. J. Comb.
Chem. 2007, 9, 263.
209 Pohjala, L., Barai, V., Azhayev, A., Lapinjoki, S., Ahola, T. A luciferase-based
screening method for inhibitors of alphavirus replication applied to nucleoside
analogues. Antivir. Res. 2008, 78, 215.
210 a) Debrabant, A., Joshi, M., Pimenta, P., Dwyer, D. Generation of Leishma-
nia donovani axenic amastigotes: Their growth and biological characteristics.
Int. J. Parasitol. 2004, 34, 205. b) Shimony, O., Jaffe, C. Rapid fluorescent
assay for screening drugs on Leishmania amastigotes. J. Microbiol. Methods
2008, 75, 196.
211 Su, H., McClarty, G., Dong, F., Hatch, G., Pan, Z., Zhong, G. Activation of
Raf/MEK/ERK/cPLA2 signaling pathway is essential for chlamydial acquisi-
tion of host glycerophospholipids. J. Biol. Chem. 2004, 279, 9409.
Publications II and IV of this publication are not included in the PDF version.

PUBLICATION I
Betulin-derived compounds 
as inhibitors of alphavirus 
replication
In: J. Nat. Prod. (72), pp. 1917–1926.
Copyright 2009 American Chemical Society and 
American Society of Pharmacognosy.
Reprinted with permission from the publisher. 
I/1
I/1
Betulin-Derived Compounds as Inhibitors of Alphavirus Replication
Leena Pohjala,†,‡,⊥ Sami Alakurtti,§,| Tero Ahola,‡ Jari Yli-Kauhaluoma,§ and Pa¨ivi Tammela*,†
Centre for Drug Research, Faculty of Pharmacy, P.O. Box 56, FI-00014 UniVersity of Helsinki, Finland, Institute of Biotechnology, P.O. Box
56, FI-00014 UniVersity of Helsinki, Finland, DiVision of Pharmaceutical Chemistry, Faculty of Pharmacy, P.O. Box 56, FI-00014 UniVersity
of Helsinki, Finland, DiVision of Pharmaceutical Biology, Faculty of Pharmacy, P.O. Box 56, FI-00014 UniVersity of Helsinki, Finland, and
Technical Research Centre of Finland, VTT, P.O. Box 1000, FI-02044 VTT (Espoo), Finland
ReceiVed May 29, 2009
This paper describes inhibition of Semliki Forest virus (SFV) replication by synthetic derivatives of naturally occurring
triterpenoid betulin (1). Chemical modifications were made to OH groups at C-3 and C-28 and to the C-20-C-29
double bond. A set of heterocyclic betulin derivatives was also assayed. A free or acetylated OH group at C-3 was
identified as an important structural contributor for anti-SFV activity, 3,28-di-O-acetylbetulin (4) being the most potent
derivative (IC50 value 9.1 µM). Betulinic acid (13), 28-O-tetrahydropyranylbetulin (17), and a triazolidine derivative
(41) were also shown to inhibit Sindbis virus, with IC50 values of 0.5, 1.9, and 6.1 µM, respectively. The latter three
compounds also had significant synergistic effects against SFV when combined with 3′-amino-3′-deoxyadenosine. In
contrast to previous work on other viruses, the antiviral activity of 13 was mapped to take place in virus replication
phase. The efficacy was also shown to be independent of external guanosine supplementation.
The genus AlphaVirus consists of enveloped viruses with a single-
stranded positive-sense RNA genome of approximately 11.5
kilobases. These widely distributed viruses infect avian and
mammalian hosts, spreading in nature by using Aedes sp. mosqui-
toes as vectors. In vertebrate cells, the infection is acute and
cytopathic; most of the amplification occurs in small rodents,
whereas humans and other larger mammals are usually dead-end
hosts.1 One of the most prominent human epidemics caused by
alphaviruses was the recent Chikungunya outbreak, which occurred
at different sites surrounding the Indian Ocean in 2006 and involved
more than 1.5 million cases.2 In 2007, an outbreak of 205 confirmed
cases in northern Italy was also reported, raising awareness of the
potential for rapid transmission of tropical arthropod-borne diseases
to temperate areas.3,4 Chikungunya and other alphaviruses found
on the Eurasian and African continents primarily cause polyarthritis,
accompanied by rash-like symptoms and myalgia.5 In contrast,
viruses of the same genus found on the American continents, such
as Western, Eastern, and Venezuelan equine encephalitis viruses,
are primarily associated with small epidemics of encephalitis in
both humans and domestic animals.6 Even though alphaviruses are
considered a potential cause of both economic loss and human
suffering and mortality, currently available pharmacotherapy for
alphavirus-borne diseases is limited to relatively inefficient ribavirin
and interferon combinations and to symptomatic relief.
Betulin 1 (lup-20(29)-ene-3�,28-diol), a pentacyclic, lupane-type
triterpene, is a major constituent of the bark of white birches (Betula
sp.) that are found in abundance in northern temperate zones. A
more water-soluble compound, betulinic acid, is also present in birch
bark in minor quantities (0.3% of dry weight in B. pendula7).
However, the distribution of these compounds in nature is not
limited to this genus but covers a variety of plant species, including
well-known medicinal plants on most continents.8-10 The spectrum
of naturally occurring betulin-related compounds also includes
betulonic acid, 3-O-sulfates,11 28-O-glycosides, and esters such as
nicotinates and caffeates.12,13
Due to the ease of isolation in large quantities and accessibility
for chemical modification of the hydroxy groups at positions C-3
and C-28, betulin derivatives have been investigated for a variety
of applications. Betulin by itself is quite inactive in pharmaceutical
applications; however, it can be oxidized with the Jones’ reagent
(CrO3/aq. H2SO4) to betulonic acid. Betulonic acid, in turn, can be
reduced with NaBH4 selectively to betulinic acid,14 which is an
important and pharmaceutically more active precursor for further
modifications. The chemistry and therapeutic potential of betulin-
derived compounds have been most widely studied for use against
certain cancers and human immunodeficiency virus type 1 (HIV-
1), and different betulin derivatives are currently undergoing clinical
trials for both indications.15 In anti-HIV therapy, two separate
mechanisms of action have been proposed, involving both early
and late stages in the virus infection cycle. A C-3-substituted
betulinic acid derivative, bevirimat [3-O-(3′,3′-dimethylsuccinyl)-
betulinic acid], has been shown to inhibit HIV-1 maturation by a
previously undescribed mechanism, i.e., by blocking the processing
of Gag polyprotein between the capsid and p2 spacer sequences
and leading to aberrant maturation and decreased infectivity of the
virions.16 Phase II clinical trials with bevirimat were positively
reported in 2007, indicating favorable pharmacokinetics and
preliminary data on efficacy in patients with HIV.17,18 On the other
hand, the C-28-substituted aminoalkyl betulin derivatives ICH9564
and A43-D inhibit HIV-1 entry by targeting the V3 loop of HIV
gp120.19
Beyond antiretroviral therapy, reports on the antiviral properties
of betulin derivatives mainly involve the effects of naturally
occurring derivatives on DNA viruses. As such, betulin alone and
in combination with aciclovir has been reported to inhibit Herpes
simplex virus types I and II (HSV I and II), showing approximately
10-fold increased sensitivity to HSV-I when compared to HSV-
II.20 Betulinic acid and betulonic acid are also active against HSV,
as well as against influenza A and ECHO-6 picornavirus. Betulinic
acid was reported to be more potent in the two former cases and
betulonic acid in the latter case.21 Furthermore, the naturally
occurring 3-epi-betulinic acid 3-O-sulfate was recently demonstrated
to inhibit HSV, influenza A, and respiratory syncytial virus (RSV).22
A small set of synthetic C-3- and C-28-substituted betulin deriva-
tives has also been assayed against HSV and influenza A,
emphasizing the potential role of C-28-substitution in antiviral
activity.23
In the present study, anti-alphaviral properties of 51 betulin
derivatives were assayed against Semliki Forest virus (SFV), which
is an extensively studied member of the AlphaVirus genus. Another
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treatment of 11 with oxalyl chloride in CH2Cl2 gave betulonoyl
chloride,31 which was immediately allowed to react with vanillin
in the presence of DMAP in pyridine to produce vanillyl betulonate
(12) in 20% yield. Reduction of 11 with NaBH4 in 2-propanol gave
betulinic acid (13) in 82% yield,32 which was subsequently
methylated with TMSCHN2 in PhMe-MeOH to give 14 in 89%
yield.33 Similarly, treatment of 11 with TMSCHN2 in PhMe-MeOH
produced methyl betulonate (15) in 66% yield. Treatment of 11, in
turn, with oxalyl chloride in CH2Cl2 followed by L-aspartic acid
dimethyl ester in the presence of TEA in CH2Cl2 gave the
corresponding L-aspartyl amide of betulonic acid (16) in 42%
yield.31
Treatment of 1 with PPTS and DHP in CH2Cl2 produced a
diastereomeric mixture of the corresponding tetrahydropyranyl ether
(17) in 30% yield (Scheme 4). The THP-protected betulin was
subsequently acetylated to give 18 in excellent 95% yield. Removal
of the THP group with PPTS in EtOH produced 3-O-acetylbetulin
(19) in 94% yield.29 Subsequent treatment of 19 with CH3SO2Cl
in the presence of TEA in CH2Cl2 gave 3-O-acetyl-28-O-mesyl-
betulin (20) in 99% yield.
Betulin (1) was oxidized with PCC (6 equiv) in CH2Cl2 to give
betulonic aldehyde (21) in 82% yield (Scheme 5).34 When a smaller
molar amount of PCC (1.8 equiv) was used, a 3:1 mixture of 21
and betulin aldehyde (22) was produced. Part of the mixture was
Scheme 3. Synthesis of Compounds 12-16a
a Conditions: (a) H2CrO4, acetone, 0 °C f rt, 21 h, 44%; (b) (i) (COCl)2, CH2Cl2, rt, 22 h, 85%, (ii) vanillin, DMAP, py, 40 °C, 21 h, 20%; (c) NaBH4, i-PrOH,
rt, 2.5 h, 82%; (d) TMSCHN2, PhMe-MeOH (3:2), rt, 40 min, 89% 14, 66% 15; (e) L-aspartic acid dimethyl ester hydrochloride, TEA, CH2Cl2, rt, 19 h, 42%. TMS
) trimethylsilyl; TEA ) triethylamine.
Scheme 4. Synthesis of Compounds 17-20a
a Conditions: (a) DHP, PPTS, CH2Cl2, rt, 2 days, 30%; (b) Ac2O, DMAP, py, CH2Cl2, rt, 20 h, 95%; (c) PPTS, EtOH, rt, 14 days, 94%; (d) CH3SO2Cl, TEA,
CH2Cl2, 0 °C, 2 h, 99%. DHP ) 3,4-dihydro-2H-pyran; PPTS ) pyridinium p-toluenesulfonate.
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member, Sindbis virus (SIN), was also shown to be sensitive to
selected betulin-derived compounds. The anti-SFV activity of
betulinic acid was mapped into the replication phase of the virus,
and the derivatives of different structural subgroups were shown
to exhibit strong synergism in SFV inhibition when combined with
3′-amino-3′-deoxyadenosine.
Results and Discussion
To date, only a limited number of organic small molecules have
been found to inhibit alphavirus replication, and most of the existing
reports concern nucleoside analogues with often nonoptimal
selectivity indices (see ref 24 for review). However, the need for
wider structural diversity among the inhibitors of these viruses has
been emphasized by the recent epidemic outbreaks. Natural products
have often been proven invaluable in the search for novel
antimicrobial agents. In the context of alphavirus inhibitors, a seco-
pregnane steroid and steroidal glycosides were recently investigated
as inhibitors of SFV subgenomic RNA production.25 The current
study elucidates the effects of lupane-type triterpenoids on SFV.
Even though betulin-derived compounds are known for their various
antimicrobial and antineoplastic properties, their effectiveness on
RNA viruses remained uncharacterized.
Synthesis of Betulin Derivatives. Compound 2, 28-O-acetyl-
betulin, was obtained in moderate yield (45%) by treating 1 with
acetic anhydride in the presence of DMAP and pyridine in CH2Cl2
(Scheme 1). Subsequent oxidation of 2 with PCC in CH2Cl2
afforded 28-O-acetyl-3-oxobetulin (3) in 57% yield.26 3,28-Di-O-
acetylbetulin (4), in turn, was obtained in excellent (97%) yield by
treating 1 with excess acetic anhydride. Treatment of 4 with HBr
in toluene caused the migration of the C-20-C-29 double bond of
4 to the C-18-C-19 position, giving 3,28-di-O-acetyllup-18-ene
(5) in 42% yield.27-29 The C-18-C-19 double bond of 5 was
epoxidized with mCPBA in CHCl3 to provide the intermediate 6
in 65% yield.
3-Deoxy-2,3-didehydrobetulin (7) was prepared in 31% yield by
treating 1 with a mixture of DEAD, PPh3, and 3,3-dimethylgluta-
rimide in THF30 (Scheme 2). Subsequent acetylation of 7 gave
3-deoxy-2,3-didehydro-28-O-acetylbetulin (8) in 81% yield. Di-
hydrobetulin (9) was obtained in 99% yield after the catalytic
hydrogenation of 1 using Pd/C as a catalyst. Subsequent oxidation
with the Jones reagent in acetone produced the target compound,
dihydrobetulonic acid (10), in 31% yield.
Oxidation of 1 with the Jones reagent in acetone afforded
betulonic acid (11)14 in 44% yield (Scheme 3). Subsequent
Scheme 1. Synthesis of Compounds 2-6a
a Conditions: (a) Ac2O (1.05 equiv), DMAP, py, CH2Cl2, rt, 22 h, 45%; (b) PCC, CH2Cl2, rt, 24 h, 57%; (c) Ac2O (6 equiv), DMAP, py, CH2Cl2, rt, 17 h, 97%;
(d) HBr, Ac2O, AcOH, PhMe, rt, 21 days, 42%; (e) mCPBA, Na2CO3, CHCl3, rt, 2 h, 65%. DMAP ) 4-(dimethylamino)pyridine; py ) pyridine; PCC ) pyridinium
chlorochromate; mCPBA ) 3-chloroperoxybenzoic acid.
Scheme 2. Synthesis of Compounds 7-10a
a Conditions: (a) DEAD, PPh3, 3,3-dimethylglutarimide, THF, 0 °C f rt, 24 h, 31%; (b) Ac2O, DMAP, py, CH2Cl2, rt, 22 h, 81%; (c) H2, 5% Pd/C, THF-MeOH
(1:2), rt, 22 h, 99%; (d) H2CrO4, acetone, rt, 20 h, 31%. DEAD ) diethyl azodicarboxylate; THF ) tetrahydrofuran.
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treatment of 11 with oxalyl chloride in CH2Cl2 gave betulonoyl
chloride,31 which was immediately allowed to react with vanillin
in the presence of DMAP in pyridine to produce vanillyl betulonate
(12) in 20% yield. Reduction of 11 with NaBH4 in 2-propanol gave
betulinic acid (13) in 82% yield,32 which was subsequently
methylated with TMSCHN2 in PhMe-MeOH to give 14 in 89%
yield.33 Similarly, treatment of 11 with TMSCHN2 in PhMe-MeOH
produced methyl betulonate (15) in 66% yield. Treatment of 11, in
turn, with oxalyl chloride in CH2Cl2 followed by L-aspartic acid
dimethyl ester in the presence of TEA in CH2Cl2 gave the
corresponding L-aspartyl amide of betulonic acid (16) in 42%
yield.31
Treatment of 1 with PPTS and DHP in CH2Cl2 produced a
diastereomeric mixture of the corresponding tetrahydropyranyl ether
(17) in 30% yield (Scheme 4). The THP-protected betulin was
subsequently acetylated to give 18 in excellent 95% yield. Removal
of the THP group with PPTS in EtOH produced 3-O-acetylbetulin
(19) in 94% yield.29 Subsequent treatment of 19 with CH3SO2Cl
in the presence of TEA in CH2Cl2 gave 3-O-acetyl-28-O-mesyl-
betulin (20) in 99% yield.
Betulin (1) was oxidized with PCC (6 equiv) in CH2Cl2 to give
betulonic aldehyde (21) in 82% yield (Scheme 5).34 When a smaller
molar amount of PCC (1.8 equiv) was used, a 3:1 mixture of 21
and betulin aldehyde (22) was produced. Part of the mixture was
Scheme 3. Synthesis of Compounds 12-16a
a Conditions: (a) H2CrO4, acetone, 0 °C f rt, 21 h, 44%; (b) (i) (COCl)2, CH2Cl2, rt, 22 h, 85%, (ii) vanillin, DMAP, py, 40 °C, 21 h, 20%; (c) NaBH4, i-PrOH,
rt, 2.5 h, 82%; (d) TMSCHN2, PhMe-MeOH (3:2), rt, 40 min, 89% 14, 66% 15; (e) L-aspartic acid dimethyl ester hydrochloride, TEA, CH2Cl2, rt, 19 h, 42%. TMS
) trimethylsilyl; TEA ) triethylamine.
Scheme 4. Synthesis of Compounds 17-20a
a Conditions: (a) DHP, PPTS, CH2Cl2, rt, 2 days, 30%; (b) Ac2O, DMAP, py, CH2Cl2, rt, 20 h, 95%; (c) PPTS, EtOH, rt, 14 days, 94%; (d) CH3SO2Cl, TEA,
CH2Cl2, 0 °C, 2 h, 99%. DHP ) 3,4-dihydro-2H-pyran; PPTS ) pyridinium p-toluenesulfonate.
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are shown in Table 3. As discussed in more detail in the
structure-activity relationship section, the values range from 9.1
µM (compound 4) to 48.5 µM (compound 3). For comparison, a
standard SFV inhibitor, ribavirin, has an IC50 value of 95 µM in
the assay. In an extended cytotoxicity analysis at 500 µM
concentration performed on all cluster 1 compounds, only betulonic
aldehyde (21) affected the surviving fraction of Huh-7 cells (cell
viability 52% after 24 h exposure). For other cluster 1 compounds,
this high concentration, which is close to the solubility limits, was
well tolerated (cell viability values >80%).
Structure-Activity Relationships. The primary screening
data and the results of the potency analysis were used to examine
the structural determinants for the anti-alphaviral activity of betulin
derivatives and to study the chemical space of antivirally active
betulin-derived compounds. Betulin (1) inhibited SFV replication
with an IC50 value of 45.5 µM. Removal of the C-20-C-29 double
bond yielded compound 9, which failed to show antiviral activity.
Both betulinic acid (13) and betulonic acid (11) yielded improved
antiviral potency compared to 1 (IC50 values 14.6 and 13.3 µM
and p values in Student’s t test <0.05 in both cases). Oxidation of
the OH moieties also compensated for the loss of double-bond
exclusion activity, even though the potency of the 20-29-saturated
dihydrobetulonic acid (10) remained inferior to its unsaturated
counterpart 11. Removal or oxidation of the secondary OH group
at C-3 disturbed the anti-SFV activity, as demonstrated by the
Scheme 6. Synthesis of Compounds 27-33a
a Conditions: (a) (i) ethyl chrysanthemate, NaOH, MeOH-THF (2:1), 80 °C, 4 h, 91%, (ii) chrysanthemic acid, (COCl)2, CH2Cl2, rt, 6 h, 81%, (iii) chrysanthemoyl
chloride, DMAP, py, 40 °C, 48 h, 63%; (b) (i) carvacrol, chloroacetic acid, NaOH, ∆, 3 h, 45%, (ii) carvacryloxyacetic acid, Ti(OPr-i)4, PhMe, ∆, 6 h, 55%; (c)
levulinic acid, PPTS, PhMe, 175 °C, 23 h, 23%; (d) nicotinic acid, DCC, DMAP, CH2Cl2, rt, 23 h, 31%; (e) (i) cinnamic acid, SOCl2, 40 °C, 2 h, 92%, (ii) cinnamoyl
chloride, DMAP, pyridine, 40 °C, 22 h, 21%; (f) (i) N-acetylanthranilic acid, (COCl)2, rt, 3 days, 99%, (ii) N-acetylanthraniloyl chloride, DMAP, py, 40 °C, 40 h, 25%;
(g) t-BuOK, methyl bromoacetate, THF, 75 °C, 10 min, 15%. DCC ) N,N′-dicyclohexylcarbodiimide.
Scheme 7. Synthesis of Compounds 34-51a
a Synthesis of heterocyclic betulin derivatives 34-51 will be described in
detail elsewhere.
Table 1. Heterocyclic Betulin Derivatives 34-51
.
compound R1 R2
34 3-MeO-Ph Ac
35 1,3-dioxol-5-yl Ac
36 indan-5-yl Ac
37 4-F-Ph Ac
38 3-NO2-Ph Ac
39 3-Cl-Ph Ac
40 PhCH2 Ac
41 Ph Ac
42 n-Bu Ac
43 Et Ac
44 Ph H
45 Me COEt
46 Me COPr
47 Me COi-Pr
48 Me COcHex
49 Me COPh
50 Ph COPh
51 t-Bu COcHex
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separated by SiO2 column chromatography, and 22 was isolated in
18% yield. The rest of the mixture was treated with an excess of
hydroxylamine hydrochloride in pyridine-EtOH to produce oximes
23 and 24 in 10% and 33% yields, respectively.35 Separate treatment
of 23 and 24 with neat acetic anhydride at 120 °C gave nitriles 25
and 26 in 34% and 46% yields, respectively.
The last series of the synthetic triterpenoids commenced by
treating ethyl chrysanthemate with NaOH in THF-MeOH to
produce chrysanthemic acid (91% yield), which was subsequently
allowed to react with oxalyl chloride in CH2Cl2 to give chrysan-
themoyl chloride in 81% yield (Scheme 6). Chrysanthemoyl
chloride was reacted with 1 to produce a 1:3 mixture of cis- and
trans-28-O-chrysanthemoylbetulin (27) in 63% yield. Treatment of
carvacrol in the presence of chloroacetic acid and NaOH in water
gave carvacryloxyacetic acid (45% yield),36 which was reacted with
1 in PhMe using titanium(IV) isopropoxide as an esterification
catalyst to produce betulinyl 28-carboxymethoxycarvacrolate (28)
in 55% yield. A mixture of 1, levulinic acid, and PPTS was reacted
in PhMe to produce 3,28-di-O-levulinoylbetulin (29) in 23% yield.
Treatment of 1 with nicotinic acid in the presence of DCC and
DMAP in CH2Cl2 gave 28-O-nicotinoylbetulin (30) in 31% yield.
Cinnamic acid was treated with thionyl chloride to produce
cinnamoyl chloride, which was treated immediately with 1 to give
28-O-cinnamoylbetulin (31) in 21% yield. N-Acetylanthranilic acid
was treated with oxalyl chloride to produce N-acetylanthraniloyl
chloride, which was treated immediately with 1 to give 28-O-(N-
acetylanthraniloyl)betulin (32) in 25% yield. Finally, betulin 1 was
treated with t-BuOK in THF followed by addition of methyl
bromoacetate to give 28-O-bromoacetylbetulin (33) in 15% yield.
For the synthesis of heterocyclic betulin derivatives 34-51
(Scheme 7, Table 1), 3,28-di-O-acetyl-18,19-epoxylupane (6) was
treated with PPTS in PhMe to give a mixture (4:1) of conjugated
dienes, 3,28-di-O-acetyllupa-12,18-diene and 3,28-di-O-acetyllupa-
18,21-diene, in 68% yield.37 Reactions of 4-phenyl- or 4-methyl-
1,2,4-triazoline-3,5-dione or reactions of various 4-substituted
urazoles38 with a mixture of dienes gave the corresponding
heterocycles (34-43) with acetyl R2 groups in moderate (16% to
62%) yields after the urazoles were oxidized to the corresponding
urazines with iodobenzene diacetate in situ.39 For the synthesis of
heterocycles (44-51) with different R2 ester groups, a mixture of
3,28-di-O-acetyllupa-12,18-diene and 3,28-di-O-acetyllupa-18,21-
diene was treated with NaOH in THF-MeOH to remove the acetyl
groups. Subsequent acylation with various acyl chlorides yielded
a mixture of dienes (44-51) with new R2 ester groups. Synthesis
of betulin heterocycloadducts will be described in detail elsewhere.
Inhibition of SFV by Betulin Derivatives. The primary screen
of 51 betulin-derived compounds against SFV, combined with a
counterscreen for Huh-7 cell viability, was run in order to determine
the tentative inhibitory potential of each derivative. A relatively
high test concentration (50 µM) was selected for the primary screen
with the added intention of tracking weakly active derivatives for
structure-activity comparisons. The results of the primary screen
were expressed as surviving fractions (remaining percentages of
viral replication or cell viability) after exposure to each compound.
These data were used to divide the derivatives according to their
properties into the following four clusters: cluster 1, selective and
efficient antiviral activity (compounds yielding <20% remaining
viral replication and >80% cell viability); cluster 2a, moderate but
selective antiviral activity (remaining viral replication <50% and
cell viability >80%); cluster 2b, efficient but moderately selective
antiviral activity (remaining viral replication <20% and cell viability
between 50% and 80%); cluster 3, antivirally inactive derivatives
and compounds with unacceptable cytotoxicity (virus replication
>50%/cell viability <50%).
Table 2 presents the results of the primary screen, listing the
antiviral and cell viability surviving fractions and the corresponding
cluster number for each compound. Compounds in cluster 1
represent the best lead candidates and were thus selected for further
evaluation by dose-response experiments. The anti-SFV IC50 (50%
inhibitory concentration) values for this set of compounds, derived
from the fitting of data into a sigmoidal dose-response curve model,
Scheme 5. Synthesis of Compounds 21-26a
a Conditions: (a) PCC (6 equiv), CH2Cl2, rt, 1 h, 82%; (b) PCC (1.8 equiv), CH2Cl2, rt, 40 min, 22:21 (1:3); (c) NH2OH ·HCl, py-EtOH (1:3), 100 °C, 18 h, 10%
23, 33% 24; (d) Ac2O, 120 °C, 2 h, 34% 25, 46% 26.
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are shown in Table 3. As discussed in more detail in the
structure-activity relationship section, the values range from 9.1
µM (compound 4) to 48.5 µM (compound 3). For comparison, a
standard SFV inhibitor, ribavirin, has an IC50 value of 95 µM in
the assay. In an extended cytotoxicity analysis at 500 µM
concentration performed on all cluster 1 compounds, only betulonic
aldehyde (21) affected the surviving fraction of Huh-7 cells (cell
viability 52% after 24 h exposure). For other cluster 1 compounds,
this high concentration, which is close to the solubility limits, was
well tolerated (cell viability values >80%).
Structure-Activity Relationships. The primary screening
data and the results of the potency analysis were used to examine
the structural determinants for the anti-alphaviral activity of betulin
derivatives and to study the chemical space of antivirally active
betulin-derived compounds. Betulin (1) inhibited SFV replication
with an IC50 value of 45.5 µM. Removal of the C-20-C-29 double
bond yielded compound 9, which failed to show antiviral activity.
Both betulinic acid (13) and betulonic acid (11) yielded improved
antiviral potency compared to 1 (IC50 values 14.6 and 13.3 µM
and p values in Student’s t test <0.05 in both cases). Oxidation of
the OH moieties also compensated for the loss of double-bond
exclusion activity, even though the potency of the 20-29-saturated
dihydrobetulonic acid (10) remained inferior to its unsaturated
counterpart 11. Removal or oxidation of the secondary OH group
at C-3 disturbed the anti-SFV activity, as demonstrated by the
Scheme 6. Synthesis of Compounds 27-33a
a Conditions: (a) (i) ethyl chrysanthemate, NaOH, MeOH-THF (2:1), 80 °C, 4 h, 91%, (ii) chrysanthemic acid, (COCl)2, CH2Cl2, rt, 6 h, 81%, (iii) chrysanthemoyl
chloride, DMAP, py, 40 °C, 48 h, 63%; (b) (i) carvacrol, chloroacetic acid, NaOH, ∆, 3 h, 45%, (ii) carvacryloxyacetic acid, Ti(OPr-i)4, PhMe, ∆, 6 h, 55%; (c)
levulinic acid, PPTS, PhMe, 175 °C, 23 h, 23%; (d) nicotinic acid, DCC, DMAP, CH2Cl2, rt, 23 h, 31%; (e) (i) cinnamic acid, SOCl2, 40 °C, 2 h, 92%, (ii) cinnamoyl
chloride, DMAP, pyridine, 40 °C, 22 h, 21%; (f) (i) N-acetylanthranilic acid, (COCl)2, rt, 3 days, 99%, (ii) N-acetylanthraniloyl chloride, DMAP, py, 40 °C, 40 h, 25%;
(g) t-BuOK, methyl bromoacetate, THF, 75 °C, 10 min, 15%. DCC ) N,N′-dicyclohexylcarbodiimide.
Scheme 7. Synthesis of Compounds 34-51a
a Synthesis of heterocyclic betulin derivatives 34-51 will be described in
detail elsewhere.
Table 1. Heterocyclic Betulin Derivatives 34-51
.
compound R1 R2
34 3-MeO-Ph Ac
35 1,3-dioxol-5-yl Ac
36 indan-5-yl Ac
37 4-F-Ph Ac
38 3-NO2-Ph Ac
39 3-Cl-Ph Ac
40 PhCH2 Ac
41 Ph Ac
42 n-Bu Ac
43 Et Ac
44 Ph H
45 Me COEt
46 Me COPr
47 Me COi-Pr
48 Me COcHex
49 Me COPh
50 Ph COPh
51 t-Bu COcHex
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IC50 value 36 µM). Derivatives having an electron-withdrawing
group on the aromatic ring, 3-chlorophenyl (39) and 3-nitrophenyl
(38), were selective and potent SFV inhibitors, having IC50 values
of 22 and 23 µM, respectively (Table 3). However, 4-fluorophenyl-
substituted 37 had poor activity. Derivatives having an electron-
donating group in the aromatic ring, 3-methoxyphenyl (34), 1,3-
dioxol-5-yl (35), and indan-5-yl (36), had no activity against SFV.
However, further removal of the acetyl groups from the antivi-
rally active heterocycle 41 resulted in loss of activity (compound
44), but substitution of the acetyl groups by benzoyl at both
positions (50) yielded a moderately active compound (cluster 2a;
Table 2). In addition, the 4-methyl-1,2,4-triazoline-3,5-dione adducts
47, 48, and 49, combined with either isopropanoyl, cyclohexanoyl,
or phenyl 3,28-diesters of betulin, scored into cluster 2a. Indication
of cytotoxicity was observed in the case of the corresponding
propanoyl 3,28-diester (45). Derivate 51, with bulky substituents
(tert-butyl group in N-4, cyclohexanoyl groups in C-3, and hydroxy
groups in C-28), scored into cluster 2a. However, the most efficient
inhibition of SFV among this subset of heterocycles was achieved
with a cycloadduct between 4-methylurazine and 3,28-di-O-
butyrylbetulin-12,18-diene (46). This compound scored into cluster
1 in the primary screen and yielded an IC50 value of 30 µM.
Inhibition of SIN by Betulin-Derived Compounds. Sindbis
virus (SIN), the causative agent of Pogosta disease (also known as
Carelian fever), is another alphavirus that is widely distributed over
the European, Asian, and African continents. SIN and SFV represent
separate clusters in the alphavirus phylogenetic tree, generated by
comparing E1 glycoprotein sequences. SIN and SFV also fall into
different serocomplexes according to antibody cross-reactivity.
However, the replicase proteins are relatively highly conserved
within the genus.1
Three betulin derivatives from different structural subclasses
showing antiviral potency and selectivity, i.e., 13, 17, and 41, were
assayed for inhibitory potency against SIN using a radiometric RNA
labeling assay. The dose-response curves presented in Figure 1
demonstrate the sensitivity of SIN toward these compounds; the
IC50 values extracted from the data were 0.5 µM (pIC50 -6.34 (
0.09), 1.9 µM (pIC50 -5.72 ( 0.10), and 6.1 µM (pIC50 -5.21 (
0.16) for 13, 17, and 41, respectively. In all three cases, the studied
SIN strain exhibited greater sensitivity toward the derivatives
compared to SFV.
Synergism Studies. Antiviral therapy is often conducted as a
combination of multiple drugs targeting different sites in virus
replication.40 Parallel administration of inhibitors with different
molecular targets is considered beneficial in terms of improved
efficacy and/or prevention of resistance. Previously we reported
the anti-alphaviral efficacy of several modified nucleosides, includ-
ing 3′-amino-3′-deoxyadenosine (3′-NH-3′-dAdo) with an IC50 value
of 18 µM in the reporter gene assay.23 The inhibition of the virus
life cycle by nucleoside analogues is likely to take place during
the replication phase, targeting viral polymerases or components
of cellular nucleoside metabolism, whereas betulin-derived com-
pounds have been related to a variety of antiviral mechanisms
mainly in the early and late stages of the virus life cycle (see below).
Thus, we investigated the possibility of synergistic inhibition of
SFV by 3′-NH-3′-dAdo together with derivatives 13, 17, and 41.
The IC50 values for each interaction partner were determined by
using varying concentrations of 3′-NH-3′-dAdo and test compound
in combination (see Experimental Section and Supporting Informa-
tion for experimental details). The strong Loewe synergism that
was demonstrated in these experiments is visualized by the bending
of the isobolograms below the additivity-indicating diagonal line
in Figure 2. Calculation of Berembel interaction indices for
individual combinations indicated that the most intense Loewe
synergism was achieved when 5 µM 3′-NH-3′-dAdo was combined
with low or moderate concentrations of each betulin derivative. At
this nucleoside concentration, 0.08 µM and 0.4 µM 13 yielded
interaction index values of I ) 0.28 and 0.25, respectively. For 0.4
µM 28-O-tetrahydropyranylbetulin (17), an I value of 0.24 was
obtained, whereas combining 5 µM nucleoside with the heterocycle
41 resulted in the most intense synergism at 2 µM (I ) 0.16).
Increasing compound 17 and 41 concentrations closer to their IC50
values gave moderate or strong synergism (I values at 10 µM
concentration of betulin derivatives with different 3′-NH-3′-dAdo
concentration ranged from 0.25 to 0.47), whereas similar conditions
with 13 yielded additive rather than synergistic inhibition (I values
from 0.52 to 1.26). Complete tables of interaction indices for all
three compounds with 3′-NH-3′-dAdo, as well as the equations used
to calculate the indices, are provided as part of the Supporting
Information.
Mapping of the Target Site for Anti-SFV Activity. Since
the antiviral effects of betulin derivatives are associated with a range
Figure 1. Dose-dependent activity of (a) betulinic acid (13), (b)
28-O-tetrahydropyranylbetulin (17), and (c) 4-phenyl-substituted
betulin heterocycle 41 against Sindbis virus (SIN). The dose-response
experiments were performed using the radiometric RNA labeling
assay (see Supporting Information) using serial dilutions ranging
from 16 pM to 50 µM. Nonlinear regression was used to fit the
data into sigmoidal dose-response curves; values are means ( SD
(n ) 4).
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inactive 3-deoxy-2,3-didehydro derivatives 7 and 8, as well as the
inactivity of oxime derivative 23. Interestingly, betulonic aldehyde
(21) demonstrated selective antiviral activity in the primary screen,
whereas betulin aldehyde (22) had an inverse activity profile.
However, in the extended cytotoxicity assay at higher concentration,
22 also had indications of host cell toxicity.
Conversely to the inactive methyl esters of both betulinic acid
and betulonic acid (compounds 14 and 15, respectively), 28-O-
acetylbetulin (2) was a potent SFV inhibitor (IC50 value 12.1 µM).
The inhibitory capacity was retained, yet with loss in potency, in
the presence of the individually inactivating 28-O-acetyl-3-oxo-
betulin (3). Acetylation of both the C-3 and C-28 hydroxy groups
in 1 to yield 4 improved the antiviral activity, yielding an IC50 value
of 9.1 µM. Migration of the terminal double bond from C-20-C-
29 to C-18-C-19 [3,28-di-O-acetyllup-18-ene (5)] reduced the
antiviral activity to 43 µM. Further introduction of 18-19-epoxide
resulted in equally effective and potent activity (compound 6; IC50
value 13 µM), when compared to 4. However, acetylation of 1 at
C-3 as such (derivative 19) or when combined with 28-O-
tetrahydropyranyl derivatization in 18, as well as addition of the
28-O-tetrahydropyranyl (THP) moiety alone (17), yielded cluster
1 compounds 17, 18, and 19 with IC50 values of 17.2, 24.7, and
24.2 µM, respectively. On the other hand, mesylation of the 3-O-
acylation product at C-28 resulted in only moderately active
compound 20, scoring into cluster 2a with surviving viral fraction
of 46% (Table 2). Introducing a nitrile moiety at C-28 led to even
more diminished antiviral activity (26 in cluster 3 and 25 in cluster
2a).
As indicated by the lack of antiviral activity of 3-deoxy and
3-oxime derivatives, maintaining the secondary OH group at C-3
contributed to the anti-SFV activity of the betulin-derived com-
pounds. However, the IC50 values for derivatives with free versus
acetylated C-3 OH groups did differ from each other, 3,28-di-O-
acetylbetulin (9) being the most potent derivative. Thus, the
influence of C-28 substitution on anti-SFV activity was further
examined with C-3-unmodified derivatives. Unfortunately, the
activity of betulin C-28 esters of naturally occurring and biologically
active terpenoid or aromatic carboxylic acids was poor. Esters of
betulin and chrysanthemic acid 27, carvacryloxyacetic acid 28,
N-acetylanthranilic acid 32, or cinnamic acid 31 as well as the 3,28-
dilevulinate of betulin (29) had no detectable antiviral activity,
whereas the 28-nicotinate of betulin (30) was moderately active,
scoring into cluster 2a (Table 2). The antiviral activity of cytotoxic
28-O-bromoacetylbetulin (33) was poor. 28-Vanillinyl betulonate
(12) scored into cluster 2a, whereas the L-aspartyl amide of betulonic
acid (16) was cytotoxic.
In addition to the C-3- and C-28-modified derivatives, a set of
heterocyclic compounds was synthesized by the [4+2] cycloaddition
reaction between N-substituted 1,2,4-triazolidine-3,5-diones (ura-
zines) and 3�,28-diacyloxylupa-12,18-dienes (34-51; see Table 1).
The heterocycloadducts with 4-n-butyl and 4-ethyl substituents, 42
and 43, were active against SFV, even though the 4-ethyl derivative
43 also affected Huh-7 cell viability (Table 2). The heterocycload-
duct with phenyl at N-4 (compound 41) inhibited SFV, with an
IC50 value of approximately 20 µM, and a switch to the N-4 benzyl
group was accompanied by a slight loss in potency (derivative 40
Table 2. Antiviral (AV) and Cytotoxic Effects (CV) of
Betulin-Derived Compounds
compound
virus
replication (%)
cell
viability (%) cluster
1 7 83 1
2 3 87 1
3 11 83 1
4 21 97 2a
5 15 87 1
6 16 92 1
7 121 85 3
8 98 95 3
9 95 81 3
10 14 102 1
11 13 89 1
12 43 89 2a
13 18 123 1
14 68 1 3
15 71 83 3
16 40 30 3
17 11 92 1
18 10 91 1
19 3 86 1
20 46 99 2a
21 8 90 1
22 1 0 3
23 121 80 3
24 55 82 3
25 73 85 3
26 60 69 3
27 95 90 3
28 80 103 3
29 74 109 3
30 43 94 2a
31 111 96 3
32 82 94 3
33 125 11 3
34 121 93 3
35 97 92 3
36 81 93 3
37 64 95 3
38 3 108 1
39 1 95 1
40 1 101 1
41 13 87 1
42 19 81 1
43 24 40 3
44 73 85 3
45 21 75 2b
46 18 93 1
47 24 106 2a
48 44 97 2a
49 22 108 2a
50 50 88 2a
51 40 83 2a
The data present results from the primary screen of betulin-derived
compounds in anti-SFV and ATP cell viability assays (see the
Supporting Information for experimental details). The numbers represent
surviving fractions (the remaining percentages of viral replication or cell
viability) in each assay. All experiments were made in triplicate using a
concentration of 50 µM of each compound.
Table 3. IC50 Values of Betulin-Derived Compounds against
Semliki Forest Virus (SFV)a
compound IC50 µM (pIC50)
1 45.5 (-4.34 ( 0.18)
2 12.1 (-4.92 ( 0.16)
3 48.5 (-4.32 ( 0.15)
4 9.1 (-5.04 ( 0.26)
5 43.2 (-4.37 ( 0.20)
6 13.3 (-4.94 ( 0.45)
10 30.6 (-4.52 ( 0.23)
11 13.3 (-4.88 ( 0.15)
13 14.6 (-4.84 ( 0.28)
17 17.2 (-4.76 ( 0.24)
18 24.7 (-4.61 ( 0.15)
19 24.2 (-4.62 ( 0.25)
21 38.3 (-4.42 ( 0.28)
38 22.9 (-4.64 ( 0.16)
39 22.1 (-4.65 ( 0.15)
40 35.9 (-4.44 ( 0.12)
41 19.7 (-4.71 ( 0.13)
42 37.9 (-4.42 ( 0.20)
46 30.1 (-4.52 ( 0.18)
ribavirin 95.1 (-4.02 ( 0.27)
a Dose-response experiments were performed using a luminometric
anti-SFV assay (see Supporting Information) using serial dilutions of
each derivative and fitting the data into sigmoidal dose-response
curves; values are means ( SD (n ) 6).
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IC50 value 36 µM). Derivatives having an electron-withdrawing
group on the aromatic ring, 3-chlorophenyl (39) and 3-nitrophenyl
(38), were selective and potent SFV inhibitors, having IC50 values
of 22 and 23 µM, respectively (Table 3). However, 4-fluorophenyl-
substituted 37 had poor activity. Derivatives having an electron-
donating group in the aromatic ring, 3-methoxyphenyl (34), 1,3-
dioxol-5-yl (35), and indan-5-yl (36), had no activity against SFV.
However, further removal of the acetyl groups from the antivi-
rally active heterocycle 41 resulted in loss of activity (compound
44), but substitution of the acetyl groups by benzoyl at both
positions (50) yielded a moderately active compound (cluster 2a;
Table 2). In addition, the 4-methyl-1,2,4-triazoline-3,5-dione adducts
47, 48, and 49, combined with either isopropanoyl, cyclohexanoyl,
or phenyl 3,28-diesters of betulin, scored into cluster 2a. Indication
of cytotoxicity was observed in the case of the corresponding
propanoyl 3,28-diester (45). Derivate 51, with bulky substituents
(tert-butyl group in N-4, cyclohexanoyl groups in C-3, and hydroxy
groups in C-28), scored into cluster 2a. However, the most efficient
inhibition of SFV among this subset of heterocycles was achieved
with a cycloadduct between 4-methylurazine and 3,28-di-O-
butyrylbetulin-12,18-diene (46). This compound scored into cluster
1 in the primary screen and yielded an IC50 value of 30 µM.
Inhibition of SIN by Betulin-Derived Compounds. Sindbis
virus (SIN), the causative agent of Pogosta disease (also known as
Carelian fever), is another alphavirus that is widely distributed over
the European, Asian, and African continents. SIN and SFV represent
separate clusters in the alphavirus phylogenetic tree, generated by
comparing E1 glycoprotein sequences. SIN and SFV also fall into
different serocomplexes according to antibody cross-reactivity.
However, the replicase proteins are relatively highly conserved
within the genus.1
Three betulin derivatives from different structural subclasses
showing antiviral potency and selectivity, i.e., 13, 17, and 41, were
assayed for inhibitory potency against SIN using a radiometric RNA
labeling assay. The dose-response curves presented in Figure 1
demonstrate the sensitivity of SIN toward these compounds; the
IC50 values extracted from the data were 0.5 µM (pIC50 -6.34 (
0.09), 1.9 µM (pIC50 -5.72 ( 0.10), and 6.1 µM (pIC50 -5.21 (
0.16) for 13, 17, and 41, respectively. In all three cases, the studied
SIN strain exhibited greater sensitivity toward the derivatives
compared to SFV.
Synergism Studies. Antiviral therapy is often conducted as a
combination of multiple drugs targeting different sites in virus
replication.40 Parallel administration of inhibitors with different
molecular targets is considered beneficial in terms of improved
efficacy and/or prevention of resistance. Previously we reported
the anti-alphaviral efficacy of several modified nucleosides, includ-
ing 3′-amino-3′-deoxyadenosine (3′-NH-3′-dAdo) with an IC50 value
of 18 µM in the reporter gene assay.23 The inhibition of the virus
life cycle by nucleoside analogues is likely to take place during
the replication phase, targeting viral polymerases or components
of cellular nucleoside metabolism, whereas betulin-derived com-
pounds have been related to a variety of antiviral mechanisms
mainly in the early and late stages of the virus life cycle (see below).
Thus, we investigated the possibility of synergistic inhibition of
SFV by 3′-NH-3′-dAdo together with derivatives 13, 17, and 41.
The IC50 values for each interaction partner were determined by
using varying concentrations of 3′-NH-3′-dAdo and test compound
in combination (see Experimental Section and Supporting Informa-
tion for experimental details). The strong Loewe synergism that
was demonstrated in these experiments is visualized by the bending
of the isobolograms below the additivity-indicating diagonal line
in Figure 2. Calculation of Berembel interaction indices for
individual combinations indicated that the most intense Loewe
synergism was achieved when 5 µM 3′-NH-3′-dAdo was combined
with low or moderate concentrations of each betulin derivative. At
this nucleoside concentration, 0.08 µM and 0.4 µM 13 yielded
interaction index values of I ) 0.28 and 0.25, respectively. For 0.4
µM 28-O-tetrahydropyranylbetulin (17), an I value of 0.24 was
obtained, whereas combining 5 µM nucleoside with the heterocycle
41 resulted in the most intense synergism at 2 µM (I ) 0.16).
Increasing compound 17 and 41 concentrations closer to their IC50
values gave moderate or strong synergism (I values at 10 µM
concentration of betulin derivatives with different 3′-NH-3′-dAdo
concentration ranged from 0.25 to 0.47), whereas similar conditions
with 13 yielded additive rather than synergistic inhibition (I values
from 0.52 to 1.26). Complete tables of interaction indices for all
three compounds with 3′-NH-3′-dAdo, as well as the equations used
to calculate the indices, are provided as part of the Supporting
Information.
Mapping of the Target Site for Anti-SFV Activity. Since
the antiviral effects of betulin derivatives are associated with a range
Figure 1. Dose-dependent activity of (a) betulinic acid (13), (b)
28-O-tetrahydropyranylbetulin (17), and (c) 4-phenyl-substituted
betulin heterocycle 41 against Sindbis virus (SIN). The dose-response
experiments were performed using the radiometric RNA labeling
assay (see Supporting Information) using serial dilutions ranging
from 16 pM to 50 µM. Nonlinear regression was used to fit the
data into sigmoidal dose-response curves; values are means ( SD
(n ) 4).
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in vivo antiviral efficacy: Wen and co-workers45 conclude that both
betulinic acid and betulonic acid inhibit SARS-CoV replication,
but only betulinic acid inhibits 3CL-purified 3C protease. Previous
work on the effects of triterpenoid drugs on HSV also supported
the hypothesis that the antiviral efficacy of such agents may be a
combination of different activities in cell culture, rather than directly
associated with any specific phase in the virus life cycle.46 Such
findings may put into question the usefulness of the compounds
from a rational drug design viewpoint, but may reflect nature’s
strategy for sustained bioactivity. On the other hand, chemically
modified betulin derivatives, such as those in anti-HIV drug
discovery, are thought to exert their activity via more limited sets
of targets, which is also supported by the generation of resistant
HIV strains via point mutations.47,48 The results from the current
screen elucidate a pattern in which most of the relatively simple
derivatives inhibit SFV replication, whereas, among the more
complex structures, the antiviral activity is not ubiquitous but shared
only by certain structural subclasses. On the other hand, betulinic
acid (13) is distinguished from the two derivatives (17 and 41) on
the basis of its behavior in the administration time experiments.
Betulin-derived compounds form a family of natural compounds
that, along with their synthetic derivatives, have a broad spectrum
of antineoplastic and antimicrobial activities. The present results,
together with prior reports on SARS-CoV and ECHO-6 picornavi-
rus, provide evidence for the sensitivity of positive-stranded RNA
viruses toward betulin-derived compounds. The inhibitory activity
against Semliki Forest virus and Sindbis virus, together with the
lack of early signs of toxicity, raise hopes about the therapeutic
potential of betulin-derived compounds used against these pathogens
either alone or in combination with other antiviral therapy.
Experimental Section
General Experimental Procedures. Details of the chemical syn-
thesis procedures and characterization as well as the biological
experiments are presented in the Supporting Information.
Bioassays. Full-length infectious cDNA clones of SFV and SIN49,50
were used to generate virus stocks for the BHK-21 cell culture
infections. A validated and automated luciferase-based reporter gene
assay with marker virus SFV-Rluc23 was used to screen for anti-SFV
activity in conditions where a low-multiplicity infection [0.001 plaque-
forming units (PFU)/cell] was allowed to proceed for more than 2
infectious cycles during a 14 h incubation. 3′-Amino-3′-deoxyadenosine
was used as a positive control in the screen; 20 µM of this nucleoside
yielded surviving fractions of 12% to 25% in the assay. The counter-
screen for mammalian cell viability was performed by determining the
intracellular ATP contents of Huh-7 cells (a continuous cell line derived
from human hepatocellular carcinoma) after 24 h exposure to each
derivative, as previously described.51 Labeling by [3H]-uridine was used
to determine the viral RNA synthesis rate in SIN virus studies. In the
synergism studies, the Loewe additivity model52 served to predict the
expected effects of combinations of selected betulin derivatives and a
nucleoside analogue, 3′-amino-3′-deoxyadenosine. The observed and
expected effects were then compared by analysis of isobolograms and
interaction indices (I).52 In order to gain preliminary information on
the target site of anti-SFV activity of the betulin-derived compounds,
high-multiplicity infections [5 PFU/cell] were accompanied with
administration of betulin derivatives at 0, 1, or 2 h or withdrawal of
the compounds at 1 h. Here, the luciferase activity resulting from
translation of Renilla luciferase together with SFV nonstructural proteins
was analyzed at 5 h. The presence of unspecific replication inhibition
by depletion of cellular guanosine pools was also studied by guanosine
supplementation.
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of target sites, an administration time experiment using a high-
multiplicity infection of SFV-Rluc was applied in order to gain
preliminary information on the target site of the reported anti-SFV
activity. Compounds 13, 17, and 41 were administered into cell
cultures at different time points in conditions where the majority
of cells were infected at once. The time scale of this experiment
represents a single virus replication cycle, as the luciferase reporter
gene was expressed by the translation of viral nonstructural proteins,
and the readout was thus taken at 4.5 h (see the Supporting
Information for experimental details). As illustrated in Figure 3,
none of the three betulin derivatives showed antiviral efficacy when
present in the cultures only at the time of viral adsorption (0-1 h).
The same was also observed for the 3′-amino-3′-deoxyadenosine
that was used for comparison. On the other hand, delivery of the
compounds just after the removal of the viral inocula (at 1 h) yielded
inhibition comparable to the effect obtained when the agent was
present throughout the experiment. Furthermore, postponing the
administration to 2 h led to attenuated efficacy, yet the response
was still detectable in the case of 13.
Even though physicochemical and kinetic features, such as
hydrophobicity of the triterpenoids and nucleoside phosphorylation,
may affect the interpretation, the entry phase does not appear to be
the target of the reported anti-alphaviral activity. In the case of
betulinic acid, the activity is associated with the early replication
phase, whereas the two other betulin-derived compounds give less
obvious results. The end point in the experimental setup is in the
translation and processing of viral polyprotein (into which the Rluc
gene is inserted; see ref 24). Thus, inhibitors of viral maturation
would give seemingly negative results in this particular setup. On
the other hand, our previous work indicated that the sensitivity of
an in vitro antiviral assay is highly dependent on the infection
multiplicity used (L. Pohjala, unpublished results). However,
repeating the experiment with a higher concentration (200 µM)
yielded similar results, as shown in Figure 3, at 50 µM. Yet the
effect of inferior potency cannot be completely ruled out by this
means since the target site for the anti-alphaviral activity of 17
and 41 may lie in steps of the virus life cycle occurring after the
production of nonstructural polyproteins. Each of the replication
phases consists of several substages, which are typically inhibited
by different sets of chemical agents.40
As betulin-derived compounds are known to have a wide
spectrum of antimicrobial, anti-inflammatory, and antineoplastic
effects,15 these findings could be reconciled by a general underlying
mechanism, such as interference with cellular nucleoside metabo-
lism. Indeed, certain classical inhibitors of RNA virus replication
that also share anti-inflammatory properties (e.g., ribavirin and
mycophenolic acid) exert their action via depletion of cellular GTP
pools.41,42 This mode of action is characterized by the loss of
inhibitory effect when the cultures are supplemented with external
guanosine to compensate for depletion in cellular guanosine
biosynthesis. However, the betulin-derived compounds 13, 17, and
41 maintained their antiviral activity in the presence of 50 µg/mL
(177 µM) guanosine supplementation also (data not shown),
implying that any contribution of this mechanism to the observed
anti-SFV activity is minor at most. The existence of more specific
virus-related targets is also supported by the distinct structure-activity
relationships reported for different pharmacological uses.15
The study of antiviral mechanisms of betulin-derived compounds
has involved several molecular targets. For relatively simple,
naturally occurring compounds such as betulin and betulinic acid,
the proposed targets include HIV-1 reverse transcriptase,43 HIV
gp41,44 and severe acute respiratory syndrome coronavirus (SARS-
CoV) 3CL protease.45 Recent work on the SARS protease implies
that modulation of a single molecular target may not correlate with
Figure 2. Synergistic activities of (a) betulinic acid (13), (b) 28-
O-tetrahydropyranylbetulin (17), and (c) 4-phenyl-substituted betulin
heterocycle 41 in combination with 3′-amino-3′-deoxyadenosine
against SFV presented as isobolograms. The synergism studies were
performed by titrating different concentrations (from 0.5 to 50 µM)
of 3′-amino-3′-deoxyadenosine against the serial dilutions of each
betulin derivative (from 80 pM to 50 µM). D1/Dm1 and D2/Dm2
values were derived from the data according to ref 48. Ratios were
calculated for IC50 values of each compound alone and in the
presence of different concentrations of 3′-amino-3′-deoxyadenosine
in the combination. The diagonal line in each figure presents a
visualization of Loewe additive effects.
Figure 3. Effect of administration time on antiviral effect of betulin-
derived compounds 13, 17, and 41 against SFV. Each of the
compounds was present in high-multiplicity infected cultures (5
PFU/cell) either throughout the experiment (0-5 h), during virus
adsorption (0-1 h), at 1-5 h, or at 2-5 h. The results represent
the surviving virus fraction, determined as remaining luciferase
reporter gene activity in each sample at 5 h; values are means (
SD (n ) 4).
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in vivo antiviral efficacy: Wen and co-workers45 conclude that both
betulinic acid and betulonic acid inhibit SARS-CoV replication,
but only betulinic acid inhibits 3CL-purified 3C protease. Previous
work on the effects of triterpenoid drugs on HSV also supported
the hypothesis that the antiviral efficacy of such agents may be a
combination of different activities in cell culture, rather than directly
associated with any specific phase in the virus life cycle.46 Such
findings may put into question the usefulness of the compounds
from a rational drug design viewpoint, but may reflect nature’s
strategy for sustained bioactivity. On the other hand, chemically
modified betulin derivatives, such as those in anti-HIV drug
discovery, are thought to exert their activity via more limited sets
of targets, which is also supported by the generation of resistant
HIV strains via point mutations.47,48 The results from the current
screen elucidate a pattern in which most of the relatively simple
derivatives inhibit SFV replication, whereas, among the more
complex structures, the antiviral activity is not ubiquitous but shared
only by certain structural subclasses. On the other hand, betulinic
acid (13) is distinguished from the two derivatives (17 and 41) on
the basis of its behavior in the administration time experiments.
Betulin-derived compounds form a family of natural compounds
that, along with their synthetic derivatives, have a broad spectrum
of antineoplastic and antimicrobial activities. The present results,
together with prior reports on SARS-CoV and ECHO-6 picornavi-
rus, provide evidence for the sensitivity of positive-stranded RNA
viruses toward betulin-derived compounds. The inhibitory activity
against Semliki Forest virus and Sindbis virus, together with the
lack of early signs of toxicity, raise hopes about the therapeutic
potential of betulin-derived compounds used against these pathogens
either alone or in combination with other antiviral therapy.
Experimental Section
General Experimental Procedures. Details of the chemical syn-
thesis procedures and characterization as well as the biological
experiments are presented in the Supporting Information.
Bioassays. Full-length infectious cDNA clones of SFV and SIN49,50
were used to generate virus stocks for the BHK-21 cell culture
infections. A validated and automated luciferase-based reporter gene
assay with marker virus SFV-Rluc23 was used to screen for anti-SFV
activity in conditions where a low-multiplicity infection [0.001 plaque-
forming units (PFU)/cell] was allowed to proceed for more than 2
infectious cycles during a 14 h incubation. 3′-Amino-3′-deoxyadenosine
was used as a positive control in the screen; 20 µM of this nucleoside
yielded surviving fractions of 12% to 25% in the assay. The counter-
screen for mammalian cell viability was performed by determining the
intracellular ATP contents of Huh-7 cells (a continuous cell line derived
from human hepatocellular carcinoma) after 24 h exposure to each
derivative, as previously described.51 Labeling by [3H]-uridine was used
to determine the viral RNA synthesis rate in SIN virus studies. In the
synergism studies, the Loewe additivity model52 served to predict the
expected effects of combinations of selected betulin derivatives and a
nucleoside analogue, 3′-amino-3′-deoxyadenosine. The observed and
expected effects were then compared by analysis of isobolograms and
interaction indices (I).52 In order to gain preliminary information on
the target site of anti-SFV activity of the betulin-derived compounds,
high-multiplicity infections [5 PFU/cell] were accompanied with
administration of betulin derivatives at 0, 1, or 2 h or withdrawal of
the compounds at 1 h. Here, the luciferase activity resulting from
translation of Renilla luciferase together with SFV nonstructural proteins
was analyzed at 5 h. The presence of unspecific replication inhibition
by depletion of cellular guanosine pools was also studied by guanosine
supplementation.
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Leishmanicidal activity of 24 derivatives of naturally occurring and abundant triterpenes belonging to the lupane series, betulin,
betulinic acid and betulonic acid, is described in this study. The easily modified positions of the lupane skeleton, the hydroxy
groups of C-3 and C-28, as well as the carbon–carbon double bond C-20–C-29 were used as a starting point to prepare
a library of triterpenoid derivatives for bioactivity studies. The compounds were evaluated against Leishmania donovani axenic
amastigotes on a microplate assay at 50 lM. GI50 values of the most effective compounds were evaluated, as well as their
cytotoxicity on the human macrophage cell line THP-1, and anti-leishmanial activity against L. donovani-infected THP-1
macrophages was determined. Betulonic acid was the most potent derivative, yielding a GI50 value of 14.6 lM. Promising
and distinct structure–activity relationships were observed, and these compounds can be regarded as significant lead molecules
for further improvement and optimization.
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INTRODUCTION
Leishmaniases are diseases caused by protozoan parasites that affect
millions of people in more than 88 countries worldwide. These
parasites are transmitted by female sand flies belonging to the genus
Phlebotomus and Lutzomyia in the Old and New World, respectively.
Leishmaniasis causes three main forms of clinical disease: (1) visceral
leishmaniasis, the most severe form, is usually fatal if not treated and
affects internal organs such as the liver, spleen and bone marrow; (2)
mucocutaneous leishmaniasis, a chronic form, causes extensive
destruction and disfiguration of the nasopharynx region; and (3)
cutaneous leishmaniasis, the mildest form, is usually self-healing
within a few months to years, causing scarring at the site of the
lesion(s). First-line drugs include pentavalent antimony (Sbv) com-
pounds, pentamidine or amphotericin B. All these drugs are admini-
strated by injection and require clinical supervision or hospitalization
because of the possibility of severe side effects. However, parasite
resistance to Sbv drugs has resulted in the discontinued use of these
compounds in some endemic regions for visceral leishmaniasis.1
Liposomal amphotericin B shows reduced toxicity, but is prohibitively
expensive for use in less-developed countries. Recently, miltefosine, an
alkylphospholipid derivative and the first orally administered drug,
has been approved for use in India. However, the teratogenic effects of
this drug prevent its use in pregnant women,2,3 and parasite resistance
is easily generated in the laboratory.4 As such, there is an urgent need
for the development and testing of new compounds for the treatment
of all clinical forms of leishmaniasis.
Betulin 1 (lup-20(29)-ene-3b,28-diol) is an abundant naturally
occurring triterpene found in the plant kingdom (Figure 1). It is the
principal extractive (up to 30% of dry weight) of the bark of white-
barked birch trees (Betula sp.).5 This pentacyclic triterpene can be
converted into betulinic acid 2,6 which has shown anti-inflammatory,7
antimalarial8 and especially cytotoxic activity against several tumor
cell lines by inducing apoptosis in cells.9,10 Some betulin derivatives
have also shown remarkable anti-human immunodeficiency virus
activity with new mechanisms of action.11,12 Structure–activity rela-
tionship studies and pharmacological properties of betulin and its
derivatives have been reviewed recently.13
Previously, dihydrobetulinic acid 3 was examined as a new lead
compound for anti-leishmanial therapy.14 It was shown that it
targeted DNA topoisomerases I and II by preventing DNA cleavage
and formation of an enzyme–DNA complex, which ultimately
induced apoptosis in Leishmania donovani promastigotes and amas-
tigotes in infected macrophages with an IC50 value of 2.6 and 4.1mM,
respectively. Parasitic burden in golden hamsters was reduced by 92%
after a 6-week treatment with dihydrobetulinic acid 3 (10mg kg1
body weight). In another study, in which leishmanicidal inhibition
activity of a plethora of natural products was screened, betulinic acid 2
isolated in small quantities from Betula platyphylla var. japonica was
found to be weakly active against Leishmania major promastigotes, the
extracellular form of the parasite, with an IC50 value of 88mM.15 It was
also noted that in triterpenes with ursane, oleanane or lupane
skeletons, a carboxyl substituent was required for anti-leishmanial
activity. In a related study, it was shown that a rare natural product,
betulin aldehyde 4, obtained from Doliocarpus dentatus (Aubl.)
showed in vitro activity against Leishmania amazonensis amastigotes
in infected macrophages, reducing infection by 88% at 136mM and by
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58% at 68mM.16 At these doses, 4 also showed some toxicity against
peritoneal macrophages, with survival indices of 70 and 80%, respec-
tively. Previously, we studied anti-leishmanial activity of heterocyclic
betulin derivatives, in which the heterocycloadduct between 3,28-di-
O-acetyllupa-12,18-diene and 4-methylurazine 5 was the most effec-
tive derivative with a GI50 value of 8.9mM against L. donovani
amastigotes.17 These results prompted us to investigate more closely
the anti-leishmanial activity of 24 betulin derivatives that have been
chemically modified in positions C-3, C-28 and C-20–C-29 of the
lupane skeleton.
RESULTS AND DISCUSSION
We found that betulin 1 (isolated from Betula sp.) has moderate anti-
leishmanial activity against L. donovani axenic amastigotes, showing
35% inhibition at 50mM in a microplate assay (Table 1). Acetylation,
esterification or etherification of the hydroxy groups at C-3 or C-28 in
most cases retained anti-leishmanial activity. We observed that 28-O-
Cinnamoylbetulin 6 was totally inactive and 28-O-nicotinoylbetulin 7,
28-O-tetrahydropyranylbetulin 8, 28-O-chrysanthemoylbetulin 9 and
betulinyl-28-O-carboxymethoxycarvacrolate 10 were only slightly
active. Only 28-O-(N-acetylanthraniloyl)betulin 11 and 28-O-bro-
moacetylbetulin 12 showed improved anti-leishmanicidal activity
(59 and 86% inhibition at 50mM, respectively), compared with 1. In
addition, 3-O-acetylbetulin 13 had similar anti-leishmanial inhibition
activity compared with the starting material betulin 1, whereas 3,28-
di-O-acetylbetulin 14 and 3,28-di-O-levulinoylbetulin 15 were totally
inactive.
Oxidation of 1 seems to have a beneficial effect on anti-leishmanial
activity. Betulin aldehyde 4 displayed improved anti-leishmanial
activity with a 64% inhibition at 50mM. Betulinic acid 2 possessed
moderate anti-leishmanial activity with a 40% inhibition at 50mM. 28-
O-Acetyl-3-oxobetulin 16 and betulonic aldehyde 17 showed moder-
ate anti-leishmanial activity similar to the starting material 1, but
betulonic acid 18 had remarkable anti-leishmanial activity with a 98%
inhibition at 50mM. Reduction of the carbon–carbon double bond of
betulonic acid 18 to the corresponding dihydrobetulonic acid 19
decreased anti-leishmanial activity to 72% at 50mM. Furthermore,
methylation of betulonic acid 18 to methyl betulonate 20 decreased
the inhibition activity at 50mM to 40%. L-aspartyl amide of betulonic
acid 21 showed reduced leishmanicidal activity compared with betu-
lonic acid 18, with a 69% inhibition at 50mM. Vanillyl betulonate 22
was totally inactive.
Removal of the C-3 hydroxy group of 1 resulted in 3-deoxy-2,3-
didehydrobetulin 23, the anti-leishmanial activity of which diminished
to 13% at 50mM. Oxime derivatives 24 and 25 showed good leishma-
nicidal activities at 50mM, with 69 and 73% inhibition, respectively.
Moreover, betulin derivative 26 with a nitrile group at C-28 showed
good anti-leishmanial activity with a 63% inhibition at 50mM.
Derivatives (12, 18, 19, 21 and 25) that showed the best anti-
leishmanial activity on microplate assay at 50mM against L. donovani
axenic amastigotes were selected for further investigations: GI50 values,
cytotoxicity to the macrophage cell line THP-1 and anti-leishmanial
activity against the L. donovani-infected macrophage cell line THP-1
were evaluated. Betulonic acid 18 showed the best GI50 value of
14.6mM on microplate assay against L. donovani axenic amastigotes,
followed by L-aspartyl amide derivative 21 and oxime derivative 25,
with GI50 values of 21.2 and 22.8mM, respectively (Table 1). 28-O-
Bromoacetylbetulin 12 and dihydrobetulonic acid 19 had moderate
GI50 values of 34.9 and 56.0mM, respectively. Cytotoxicity of deriva-
tives 12, 18, 19, 21 and 25 was tested against the macrophage cell line
THP-1 at concentrations of 50, 25 and 12.5mM (Table 2). Betulonic
acid 18 showed cytotoxicity against the THP-1 cell line at all test
concentrations. Dihydrobetulonic acid 19 and oxime derivative 25
showed cytotoxicity against the THP-1 cell line at 50 and 25mM, but at
12.5mM concentration, cytotoxicity of 19 and 25 was reduced to 22.0
and 13.6%, respectively. L-aspartyl amide derivative 21 and 28-O-
bromoacetylbetulin 12 were nontoxic to macrophage cell line THP-1
at all test concentrations.
Finally, anti-leishmanial activity of compounds 12, 19, 21 and 25
was tested against L. donovani-infected macrophage cell line THP-1,
with concentrations that showedo30% cytotoxicity to the THP-1 cell
line (Table 3). In all cases, anti-leishmanial activity was reduced when
compared with that in the corresponding microplate assay with
L. donovani axenic amastigotes. L-aspartyl amide derivative 21 and
28-O-bromoacetylbetulin 12 showed good anti-leishmanial activity at
50mM, inhibiting 53 and 56% of the intracellular parasites, respectively
(compared with 69 and 86% inhibition using axenic amastigotes in
the microplate assay, respectively). At 25mM, 28-O-bromoacetylbetulin
12 still had the best activity of the compounds examined showing 34%
inhibition, dihydrobetulonic acid 19 and L-aspartyl amide derivative
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Figure 1 Chemical structures of betulin 1, betulinic acid 2, dihydrobetulinic acid 3, betulin aldehyde 4 and betulin heterocycloadduct between 3,28-di-O-
acetyllupa-12,18-diene and 4-methylurazine 5.
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21 were only weakly active at this concentration. Finally, at 12.5mM
concentration, oxime derivative 25 showed the best anti-leishmanial
activity with a 52% inhibition, whereas L-aspartyl amide derivative 21
was totally inactive and the rest showed only weak activity.
We have shown that by simple chemical modification, anti-leish-
manial activity of ubiquitous naturally occurring triterpene, betulin,
can be improved considerably. It is possible to derive relatively potent
anti-leishmanial compounds with low micromolar GI50 values. In
Table 1 Anti-leishmanial activities at 50lM on microplate assay and GI50 values for the most potent synthetic betulin derivatives against
Leishmania donovani axenic amastigotes
R3
R2
R1
1
Compound R1 R2 R3
Inhibition (%)
at 50 µM
GI50
(µM)
2OH CH OH CH3-C=CH2 35.0
6 OH CH3-C=CH2 0.0
7 OH CH3-C=CH2 8.8
8 OH CH3-C=CH2 10.5  
9 OH CH3-C=CH2 13.4  
10 OH CH3-C=CH2 16.6  
11 OH CH3-C=CH2
12 OH CH3-C=CH2
13 OAc 3-C=CH2
14 OAc 2OAc  CH3-C=CH2 0.0
15 CH3-C=CH2 0.0
4 3-C=CH2
2 2 3-C=CH2
16 2OAc 3-C=CH2
17 3-C=CH2
18 2 3-C=CH2
19 2 3CHCH3
20 2 3-C=CH2
21 O= CH3-C=CH2
22 O= CH3-C=CH2 0.0
23 2
H CH
CH
H CH
H CH
Me CH
OH CH3-C=CH2
24 3-C=CH2
25 3-C=CH2
26 3-C=CH2
59.2
86.0 34.9 
37.4
64.3
39.8
40.6
46.2
97.6 14.6 
72.1 56.0 
40.1
69.3 21.2 
13.2
69.1
72.9 22.8 
62.7
Positive 
controla
OH CH
CH
OH CHO CH
OH CO
O= CH
O= CHO CH
O= CO
O= CO
O= CO
- CH
OH CH=NOH CH
=NOH CH=NOH CH
OAc CN CH
95
Negative 
controlb 0.0
Abbreviation: DMSO, dimethyl sulfoxide.
aAmphotericin B (1mM).
bCulture medium+DMSO.
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general, carbonyl or carboxyl groups at C-3 or C-28 have a beneficial
effect in anti-leishmanial inhibition activity, and these compounds can
be regarded as significant lead molecules for further improvement and
optimization. Further studies are required to develop more potent
betulin derivatives with leishmanicidal properties, and with no toxicity
in macrophage cell lines or in human host cells. Moreover, thorough
early ADME, biological mechanism and animal studies are required to
evaluate anti-leishmanial activity in vivo.
EXPERIMENTAL SECTION
Chemical syntheses of betulin derivatives screened in this study for anti-
leishmanial activity are described in detail elsewhere.18 Anti-leishmanial activ-
ities of betulin derivatives were screened using a fluorescent viability microplate
assay with L. donovani (MHOM/SD/1962/1S-Cl2d) axenic amastigotes and
alamarBlue (resazurin, AbD Serotec, Oxford, UK) as described previously.19–21
Initial screening was carried out by assessing the inhibition of amastigote
growth at 50mM of betulin derivative. All compounds were tested at least twice
in triplicate. Complete medium, both with and without dimethyl sulfoxide, was
used as negative controls (0% inhibition of amastigote growth). The most
potent betulin derivatives from initial screening were selected for further
investigation. For these compounds, the GI50 value (concentration for 50%
growth inhibition) was also determined, as well as screening for activity on
infected macrophages. The latter assay was carried out as previously described
using the retinoic acid-treated human macrophage cell line THP-1 infected
with L. donovani expressing the luciferase gene (Ld:pSSU-int/LUC) at a 3:1
parasite:macrophage ratio.17,22 Compounds (at 50, 25 and 12.5mM) to be tested
were added for 48h, and luminescence was determined after adding a luciferase
substrate and measuring in a microplate reader. Amphotericin B was included
as a positive control on each plate and resulted in 490% inhibition at 1mM.
The effect of compounds on THP-1 cells alone was assessed using the
alamarBlue viability assay.
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Table 2 Cytotoxicity of the most potent synthetic betulin derivatives
on macrophage cell line THP-1
Inhibition of growth (%)
Compound 50mM 25mM 12.5mM
12 0.0 0.0 0.0
18 85.3 77.7 38.2
19 80.2 30.0 22.0
21 0.0 14.0 3.6
25 61.4 55.2 13.6
Table 3 Anti-leishmanial activities of the most potent synthetic
betulin derivatives against macrophage cell line THP-1 infected
with Leishmania donovani
Inhibition of growth (%)
Compound 50mM 25mM 12.5mM
12 56.3 34.4 17.8
19 nt 20.6 14.3
21 53.3 16.0 0.0
25 nt nt 51.5
Abbreviation: nt, not tested because the toxicity to the THP-1 cell line was 430% at that
concentration.
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multiple sclerosis. C. pneumoniae is susceptible to antibiotics that interfere with DNA and
protein synthesis. However, its complex life cycle and its chlamydial persistence, which can
last for years, as well as, importantly, the lack of specific diagnostic tests for detection of the
organism in clinical samples, make the current treatment regimens unsatisfactory. Out of 32
betulin derivatives, five betulin derivatives showed high (>70% growth inhibition) antichlamydial
activity against C. pneumoniae at 1 µM concentration. The most potent derivative displayed a
remarkable 50% inhibition at nanomolar concentration.
ISBN, ISSN ISBN 978-951-38-8013-2 (Soft back ed.)
ISBN 978-951-38-8014-9  (URL: http://www.vtt.fi/publications/index.jsp)
ISSN-L 2242-119X
ISSN 2242-119X (Print)
ISSN 2242-1203 (Online)
Date September 2013
Language English, Finnish abstract
Pages 99 p. + app 43 p.
Keywords Betulin, betulinic acid, terpene, organic synthesis, derivative, bioactivity, Semliki
Forest virus, Leishmania sp., Chlamydia pneumoniae
Publisher VTT Technical Research Centre of Finland
P.O. Box 1000, FI-02044 VTT, Finland, Tel. 020 722 111

Julkaisun sarja ja numero
VTT Science 39
Nimeke Betuliinijohdannaisten syntetisointi solunsisäisiä
patogeenejä vastaan
Tekijä(t) Sami Alakurtti
Tiivistelmä Metsäteollisuus käyttää koivua raaka-aineenaan suunnattomia määriä. Sivuotteena syntyvä
koivunkuori poltetaan energian tuotantoon. Koivun ulkokuori sisältää runsaasti betuliini-nimistä
triterpeeniä jopa 30 % kuivapainostaan. Betuliini voidaan helposti eristää kuoresta liuotinuutolla.
Betuliinia voidaan käyttää sellaisenaan tai lähtöaineena muille tuotteille ja hienokemikaaleille.
Useiden pieneliöiden ja virusten kasvava lääkeresistenssi on maailmanlaajuinen ongelma,
minkä takia on ilmennyt suuri tarve kehittää uusia lääkeaineita niitä vastaan. Tässä väitöskirja-
työssä syntetisoitiin kaksi betuliinijohdannaisryhmää ja yhdisteiden tehokkuutta testattiin
alfavirusten, Leishmania-suvun alkueläinten ja keuhkoklamydiabakteerin vastaisina yhdisteinä.
Ensimmäinen ryhmä sisältää melko helposti valmistettavissa olevia johdannaisia, kuten betulii-
nin estereitä ja erilaisia hapetustuotteita. Toinen ryhmä sisältää uusia heterosyklisiä betuliini-
johdannaisia, joissa triatsoli-rengas on fuusioitu betuliinin lupaanirakenteiseen hiilivetyrankaan.
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betuliinijohdannaista osoitti alfavirusten vastaista aktiivisuutta mikromolaarisella konsentraatiol-
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sella oli synergistisiä alfaviruksen vastaisia vaikutuksia muokatun nukleosidijohdannaisen
kanssa. Lisäksi valitut kolme johdannaista olivat aktiivisia myös toista alfavirusta, Sinbis virusta,
vastaan.
Leishmaniaasi-tautia aiheuttavat Leishmania-sukuun kuuluvat alkueläimet. Tauti esiintyy
nisäkkäissä etenkin tropiikissa, ja sitä levittävät perhossääsket. Arvioiden mukaan 12 miljoonaa
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infektioita voidaan hoitaa antibiooteilla, jotka vaikuttavat bakteerin DNA- tai proteiinisynteesiin.
Valitettavasti bakteerin monimutkainen elämänkierto, taudin vaikea diagnosointi ja bakteerille
tyypillinen oireeton, jopa vuosia kestävä piilevänä sairautena pysyminen tekevät taudin hoidos-
ta ongelmallista. Testisarjasta viisi betuliinijohdannaista esti huomattavasti C. pneumoniae
-bakteerin kasvua 1 µM konsentraatiolla. Parhaalla johdannaisella 50 %:n inhibitioarvo saavu-
tettiin nanomolaarisella konsentraatiolla.
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Synthesis of betulin derivatives against intracellular 
pathogens  
 
White birches (Betula spp.) are utilized in huge quantities in the forest 
industry in northern latitudes of the world and low-value side-stream 
birch bark is burnt for energy. Outer birch bark is rich in (up to 30% dry 
weight) triterpene betulin and it can be easily isolated by solvent 
extraction. Betulin could be used as such or as starting material for 
more valuable products, fine chemicals and pharmaceuticals. 
In this work two sets of betulin derivatives were synthesized and 
screened as antiviral, antileishmanial and antibacterial agents. First set 
includes relatively easily synthesizable betulin derivatives, such as esters 
and various oxidation products. Second set includes novel heterocyclic 
betulin derivatives, where triazolo ring is fused by Diels-Alder reaction to 
the lupane skeleton of betulin. 
In the biological assays against human pathogens Semliki Forest virus; 
L. donovani parasites, which cause tropical disease leishmaniasis; and 
Gram-negative bacteria Chlamydia pneumoniae, several betulin 
derivatives displayed low-micromolar 50% growth inhibition values in 
vitro. In addition, most of the derivatives showed low cytotoxicity against 
the host cell lines.
